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General Introduction
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Behavioral toxicity of antidepressants
Adverse effects of antidepressants will be represented in daily life by impaired
cognitive performance and car driving. The use of antidepressants sometimes causes
people  to  get  drowsy  or  slow  down  and  this  may  cause  accidents  on  the  road  or
during work. This reversible pharmacological effect of antidepressants or drugs in
general is called behavioural toxicity and causes disruption of neuropsychological
processes and inhibits or reduces the efficiency of normal behaviour (Ramaekers,
1998). The seriousness, appearance and the type of adverse events differ between
antidepressants, depending on the mechanism of action. In general, antidepressants
with anticholinergic or sedative actions impair cognitive function (Amado-Boccara et
al., 1995). Experimental psychopharmacological research in the present thesis
focuses on the behavioural toxicity of antidepressants. There are two different aims
underlying the various experiments. Firstly, in applied research the side effects of
specific antidepressant treatments on cognition and driving performance are
described. Secondly, the role of the neurotransmitter serotonin in performance is
assessed by experimentally manipulating antidepressant treatment.
A typical experiment described in this thesis, is conducted according to a within
subject design. The behavioural adverse effects of a drug of interest are evaluated by
comparing the drug to a placebo treatment while cognitive and psychomotor tests
are conducted as outcome measures. An active control condition is often included to
compare the effect of the drug of interest quantitatively to another drug of which the
behavioural adverse effects are already established in previous research. Cognition
and  psychomotor  functioning  are  usually  assessed  in  the  laboratory  by  means  of
computerized cognitive tasks. In the present thesis, various computerized tasks are
used covering a  broad range of  cognitive  functions.  Assessing the effects  of  a  drug
on  driving  performance  is  an  important  issue  in  experimental
psychopharmacological research. The knowledge of drug effects on cognitive
functions obtained using abstract computerized laboratory tasks of cognition, is
translated to predict drug effects on car driving and other daily life functions. In
addition to laboratory tasks that measure different aspects of driving related
behaviour as attention, this thesis also contains descriptions of studies of drug effects
on actual driving performance on the road.
In general, both types of psychopharmacological studies can be conducted in
healthy volunteers as well as in mentally ill patients. Examining the possible side
effects on cognition or driving performance of antidepressant medication in healthy
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volunteers will give a clear look at the specific side effects independent of any effect of
mental illness itself. On the other hand, given that depressed patients use these
medications in  daily  life,  it  is  important  to  know what  the net  effect  is  on cognition
and driving performance in patients. Due to symptoms of the psychiatric illness and
the interaction between medication use and the symptoms, cognitive functioning of
patients is possibly different in- and develops differently over time when compared to
healthy volunteers (Lane & O'Hanlon, 1999). In the present thesis, applied research
into over-the-road driving performance in healthy as well as depressed persons is
assessed.
Serotonin and cognition
Serotonin or 5-hydroxytryptamine (5-HT) is an essential monoamine
neurotransmitter involved in behavioural functions including mood, sleep,
aggression, appetite and sex (Aghajanian & Sanders-Bush, 2002).  Serotonin is
released from the raphe nuclei located in the brainstem and it follows 5 major
serotonergic  pathways  projecting  to  the  brain  and  the  body  via  the  central-  and
peripheral nervous system respectively. Only 5% of the total serotonin transmission
is distributed in the brain, the most amount of serotonin (80% of body 5-HT) is found
in the gastrointestinal  tract.  In  the brain,  projections lead to  different  areas  such as
prefrontal cortex, basal ganglia, hippocampus and hypothalamus (Stahl, 1998b).  A
wide  variety  of  serotonergic  receptor  groups  and  subtypes  exist.  For  example  the
group of 5-HT1 receptors includes the 5-HT1A somatodendritic autoreceptor mainly
situated in the hippocampus, amygdala and dorsal raphe nucleus and the group of
5-HT2 receptors includes the 5-HT2A receptor largely available in the cerebral cortex
(Buhot et al., 2000). One mechanism to eliminate serotonin from the brain is reuptake
of serotonin from the synaptic cleft.
Research in animals as well as in humans demonstrated that serotonin is
involved in different aspects of cognition including attention and memory (Buhot et
al., 2000; Matrenza et al., 2004; Meneses, 1999; Riedel et al., 1999). Manipulating or
challenging the serotonergic system in humans is only possible through indirect
mechanisms as serotonin itself does not cross the blood brain barrier. Decreased
serotonin availability can be accomplished experimentally by a method called
tryptophan depletion in which the availability of the precursor of serotonin
(tryptophan) is diminished. This leads to a reduction of serotonin synthesis (Moore
et al., 2000). Increased serotonin levels may be obtained by blocking the reuptake
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mechanisms through oral administration of selective serotonin reuptake inhibitors
(SSRIs).  Acute experimentally decreased serotonin levels has previously been
shown to impair memory consolidation on a verbal memory task (Riedel, Klaassen et
al., 1999; Schmitt et al., 2000) while conversely, another study showed improved
delayed memory recall after intravenous SSRI administration (Harmer et al., 2002).
In addition, SSRIs have been shown to impair sustained attention in several studies,
measured with the Mackworth Clock Test (O'Hanlon et al., 1998; Ramaekers et al.,
1995; Riedel et al., 2005; Schmitt, Ramaekers et al., 2002). Furthermore, acute
tryptophan depletion caused improvement of selective attention (Coull et al., 1995;
Schmitt et al., 2000).  The question arises what pharmacological mechanisms
underlie these effects of serotonin on memory and attention. Consequently, it is
interesting to examine these fundamental mechanisms on the receptor level or on
different brain mechanisms and interacting neurotransmitters.
In  the  present  thesis,  the  role  of  acutely  increased  serotonin  levels  in
memory and attention in humans has been investigated one step further by
exploring different brain and receptor mechanisms (i.e. 5-HT1A and 5-HT2A
receptors) using selective serotonin reuptake inhibition. To increase serotonin, the s-
enantiomer of the SSRI citalopram has been used alone or in combination with
receptor antagonists. Escitalopram is the most selective and most potent
antidepressant among the group of selective serotonin reuptake inhibitors and it
serves as a valuable tool in challenging the serotonergic system.
Depression, antidepressants, cognition and driving performance
Serotonergic  dysfunctioning  is  assumed  to  be  part  of  the  etiology  of  a  variety  of
psychiatric disorders including major depressive disorder (Charney, 1998; Meltzer,
1989). Major depressive disorder is characterized by depressed mood, loss of interest
and serious loss of energy.  Furthermore, patients can experience abnormal sleep
and  psychomotor  agitation  or  slowing.   According  to  the  World  Health
Organization, depression is a common mental disorder with severe consequences for
the patient and for the society. It causes the second highest disease burden in the age
group  15-44  and  by  the  year  2020  it  will  be  the  second  highest  ranking  disease
burden in the developed world (WHO, 2001).
In addition to the more commonly recognised features, depression is often
accompanied by a decline in cognitive and psychomotor functioning. The cognitive
deficits are related to the mental illness itself and not to more general physical
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disease-related factors (e.g. stress or not feeling well) (Den Hartog et al., 2003). An
association between depression and impairment of memory has previously been
demonstrated (Burt et al., 1995). Especially, problems with encoding and retrieval
from episodic memory (Brand et al., 1992; Den Hartog et al., 2003; Zakzanis et al.,
1998) and deficits in attention can be seen in depression (Landro et al., 2001; Purcell
et al., 1997). A review concerning cognitive deficits in depression (Austin et al., 2001)
showed impairment in episodic memory (verbal and visual) and impairment in
executive deficits, for example difficulties on measures of verbal fluency and
attentional set-shifting. Consequently, it is expected that the quality of daily living
functions such as car driving is impaired in depressed patients and moreover, traffic
safety is compromised.
In the Netherlands, around 45% of the depressive population receives
professional care and around 42% of the depressive population is treated with an
antidepressant medication (Spijker et al., 2001). Based on information obtained from
Dutch pharmacies, antidepressants are among the most prescribed drugs and 9 of 10
prescriptions are repeat prescriptions. The number of registered antidepressant
prescriptions was 5,5 million in 2005 accounting for a cost to the society of 162
million euros (Stichting Farmaceutische Kengetallen, 2006). Antidepressants can be
classified by their mechanism of action, for example some inhibit the enzyme
monoamine oxidase and thereby increase the availability of the monoamines (MAO
inhibitors e.g. phenelzine and moclobemide) others block the reuptake of serotonin,
norepinephrine and even dopamine (tricyclic antidepressants, TCAs e.g.
amitriptyline and desipramine) (Stahl, 1998a). Paroxetine and citalopram are the two
most prescribed antidepressants in the Netherlands; these drugs are typically
classified as selective serotonin reuptake inhibitors (SSRIs). The therapeutic effect of
SSRIs  is  thought  to  be  based  on  5-HT1A autoreceptor desensitization.
Somatodendritic 5-HT1A autoreceptors  act  to  reduce serotonin neuronal  firing rates
by  means  of  a  feedback  mechanism.  During  prolonged  SSRI  treatment,  the
autoreceptor will desensitize and thereby neuronal firing will be disinhibited.
Consequently, serotonin neurotransmission is increased (Stahl, 1998b). The third
most commonly used antidepressant is venlafaxine as a serotonergic and
noradrenergic reuptake inhibitor (SNRI) (Stichting Farmaceutische Kengetallen,
2006).
Depending on the mechanism of action, antidepressants exert different side
effects, physically as well as cognitively. MAO inhibitors have serious side effects
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including  elevation  of  blood  pressure.  The  use  of  TCAs  is  accompanied  by  side
effects including constipation, blurred vision, dry mouth and memory impairment
mediated by muscarinic anticholinergic action  and dizziness, drowsiness and
sedation mediated by a high affinity for H1 histaminic receptors or noradrenergic ?1
receptors (Amado-Boccara et al., 1995; Stahl, 1998a). SSRIs are said to be better
tolerated because they are free from negative cognitive and psychomotor effects
compared to TCAs (Hindmarch, 1995). Nevertheless, SSRIs have different
pharmacodynamic profiles compared to each other and therefore SSRIs may have
different, effects on cognition and different adverse effects including nausea, sexual
dysfunction and insomnia (Stahl, 1998b). In their therapeutic action, SSRIs all block
the serotonin reuptake pump,  but  next  to  that  SSRIs  may differ  in  their  binding to
serotonin receptors, in anticholinergic effects, in effects on dopamine
neurotransmission, in affinity for H1 receptors and in affinity for sigma1 binding site
(Lane & O'Hanlon, 1999). Cyclic antidepressants were shown to increase the relative
risk of  depressed patients  to  be  involved in  a  traffic  accident   (Leveille  et  al.,  1994;
Ray et al.,  1992) and to produce driving impairment through the first two weeks of
administration in healthy volunteers (Ramaekers, 2003). Since depression by itself is
associated with cognitive and psychomotor dysfunction, antidepressants with
relatively less negative side effects or even positive effects on cognition are
preferable.
The present thesis explored the side effects of commonly used
antidepressants on cognition and actual driving performance in healthy volunteers
as well as in depressed patients. Central to all chapters is the hypothesis that the core
serotonergic action of antidepressants has specific effects (negative, neutral or
positive) on cognition whereas other pharmacological mechanisms encountered in
antidepressants, such as anicholinergic-, anti-adrenergic and antihistaminergic
mechanisms may have a negative impact on performance.
Aim and outline of the dissertation
The aim of this thesis is on the one hand to give more information on the side effects
of commonly used antidepressants on cognition and driving performance in healthy
persons as well as patients and on the other hand to explore the role of serotonin in
cognition, particularly memory and attention, manipulated at the receptor level by
administering drugs to healthy volunteers and measured at the neuronal network
level by means of fMRI and relating this to drug effects on cognitive performance.
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In Chapter 2 a general overview is given concerning evidence for a role of serotonin
in human cognition discussing studies with healthy volunteers (e.g. using
serotonergic manipulations as SSRIs and ATD) and with selected (clinical)
populations (e.g. depressed patients and patients with Alzheimer’s disease).
Chapter 3 and Chapter 4 are both applied studies investigating driving performance
and side effects of antidepressants. In both studies, actual driving performance was
assessed by two standard on the road driving tests and cognitive and psychomotor
functions were measured by means of  laboratory tasks.  Chapter  3  is  together  with
Chapter 5 derived from a large experiment; both chapters however address a specific
aim.
In Chapter 3 it is specifically examined what the acute and subchronic effects of an
SSRI (escitalopram) and a noradreneric and serotonergic antidepressant
(mirtazapine) on driving performance and psychomotor function in healthy
volunteers, in a randomized within subject design including 18 healthy volunteers.
SSRIs are presumed to have few negative effects on car driving compared to TCA’s.
Citalopram, the parent compound of escitalopram is free from detrimental effects on
psychomotor function (Fairweather et al., 1997; Herberg, 2001; Nathan et al., 2000).
The effect of escitalopram on psychomotor function and actual driving performance
had not yet been examined. Mirtazapine on the other hand was shown to impair
psychomotor function and actual car driving in previous studies (Mattila et al., 1989;
Ramaekers et al., 1998; Ridout et al., 2003).  After evening dosages of escitalopram,
mirtazapine and placebo on separate days for a period of 15 days, performance was
measured the next day (day 2), at day 9 and at day 16. Day 2, 9 and 16 reflect
performance after acute treatment, dose increase and steady state respectively.
It was hypothesized that acute and subchronic treatment with a selective serotonergic
antidepressant would not affect actual driving performance and psychomotor function. In
addition, it was expected that a mixed-action antidepressant, such as mirtazapine, would
impair driving performance and psychomotor function by blocking central H1 receptors in the
brain.
In Chapter 4 the  actual driving performance and cognition in 24 depressed patients
receiving  long-term  antidepressant  (SSRI  and  SNRI)  treatment  compared  to  24
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healthy volunteers in a between subject design is examined. Previous experimental
studies on the effects of antidepressants on driving performance are mainly
conducted in healthy volunteers rather than in depressed patients. In general, it is
expected that  antidepressants  that  are  often prescribed nowadays such as  SSRIs  or
SNRIs have few impairing effects on driving performance. Information on the long-
term effects of antidepressant on driving performance of depressed patients was not
available and had to be investigated. On a single test day, preceded by a training the
day  before,  depressed  patients  receiving  SSRI  or  SNRI  treatment  and  matched
healthy volunteers were tested on memory, attention and driving performance.
It was hypothesized that driving performance and cognition of depressed patients receiving
long-term treatment with with serotonergic/noradrenergic antidepressants was comparable to
that of matched healthy controls, because of alleviation of depressive symptoms caused by the
non-sedating treatment
Chapter  5  to  chapter  8  are  challenge  studies  in  which  the  role  of  serotonin  in
cognition  was  further  explored  by  means  of  a  selective  antidepressant  in  healthy
volunteers. Chapter 6 and 7 are both derived of a large study but these chapters are
designed to address a specific aim. Different laboratory tasks were assessed to cover
a variety of cognitive functions including different aspects of memory and attention,
motor control and motor impulsivity.
Chapter  5 deals with serotonin and verbal memory by assessing the acute and
subchronic effects of different dosages of escitalopram and mirtazapine on verbal
memory measured in a randomized within subject-design with 18 healthy
volunteers.  In  a  previous  study,  the  SSRI  citalopram  was  used  to  manipulate
serotonin and delayed verbal memory was improved in humans after an acute dose
(Harmer et al.,  2002). In the present study escitalopram was used as a selective tool
to  manipulate  serotonin  levels.  No  information  on  the  effects  of  mirtazapine  on
verbal memory was available but by blocking the H1 receptor, mirtazapine has
sedative  properties  (Anttila  &  Leinonen,  2001)  .  From  days  1-7  an  evening  dose  of
escitalopram 10 mg, mirtazapine 30 mg or placebo was administered and from days
8-15 an evening dose of escitalopram 20 mg, mirtazapine 45 mg or placebo was
administered. Verbal memory was assessed at the next day after the first evening of
treatment administration (day 2), at day 9 and at day 16.
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It was hypothesized that an acute and subchronic dose of escitalopram may enhance verbal
memory due to its selective serotonergic action and that acute and subchronic treatment with
mirtazapine would impair verbal memory due to its histaminergic action
In  Chapter  6 it  is  explored  what  the  contribution  of  general  serotonin  levels  and
serotonergic receptor function (i.e. 5-HT1A and 5-HT2A receptors)  on  memory  in  a
fundamental study including 16 healthy volunteers. It has been suggested that
memory function may be mediated by serotonergic receptor activation (Kuypers &
Ramaekers, 2005) and candidate receptors are 5-HT 1A and 5-HT2A receptors (Buhot
et al., 2000; de Quervain et al., 2003; Meneses, 2002; Yasuno et al., 2003). On 4
separate test days, escitalopram 20 mg was administered randomly in combination
with pindolol 10 mg (a very partial 5-HT1A receptor agonist), ketanserin 50 mg (a 5-
HT2A receptor  antagonist)  or  placebo.  Several  memory  tasks  were  conducted
including  a  verbal  memory  task,  a  spatial  working  memory  task  and  a  reversal
learning task.
It was hypothesized that pindolol and ketanserin would augment the effect of escitalopram on
memory by acutely elevating serotonin levels through blockade of the presynaptic 5-HT1A
autoreceptor and by decreasing dopamine function through blockade of the 5-HT2A receptor
respectively
Chapter  7 examines the involvement of general serotonin levels and serotonergic
receptor function (i.e. 5-HT1A and 5-HT2A receptors) in motor control and attention in
a within subject design with 16 healthy volunteers. It was shown before that SSRI
administration has an impairing effect on sustained attention Test (O'Hanlon et al.,
1998; Ramaekers et al., 1995; Riedel et al., 2005; Schmitt, Ramaekers et al., 2002).
Possibly this effect is mediated by specific serotonergic receptor activation. On each
test day (4 in total) tasks concerning attention and motor control were assessed
including a sustained attention task, a selective attention task, a divided attention
task, a critical tracking task and a stop signal task. Treatments on the test days were
escitalopram 20 mg in combination with pindolol 10 mg, ketanserin 50 mg or
placebo, all randomly assigned.
It was hypothesized that the SSRI escitalopram would enhance serotonergic levels and that
blocking the 5-HT1A autoreceptor by pindolol would augment the impairing effect of
CHAPTER 1
16
escitalopram on sustained attention. Furthermore, it was expected that blocking the 5-HT2A
receptor by ketanserin may decrease dopamine release and therefore may also augment the
impairing effect of escitalopram on sustained attention.
Chapter  8 is  a  pharmaco-fMRI  study  in  which  the  impairing  role  of  serotonin  on
brain regions involved in sustained attention is investigated. Previous studies
showed an impairment after SSRI administration on sustained attention measured
with the Mackworth Clock Test (O'Hanlon et al., 1998; Ramaekers et al., 1995; Riedel
et al., 2005; Schmitt, Ramaekers et al., 2002). The purpose of Chapter 8 was to
investigate this impairing effect on the level of brain circuits associated with
sustained attention in a balanced, double blind, 2-way crossover design.
Escitalopram 20 mg and placebo were administered at 2 different test days separated
with a wash-out period for 7 days and participants performed the Mackworth Clock
Test while lying in an fMRI headscanner.
It was hypothesized that increased serotonin levels after escitalopram administration would
impair sustained attention and this was expected to be observed in brain regions involved in
sustained attention
In  the  last  chapter,  Chapter  9,  findings  of  the  previous  chapters  are
integrated and discussed in terms of whether they answered the research questions
outlined above and implications for future studies are given.
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Chapter 2
Serotonin and human cognitive performance
Abstract
In the past decade, experimental studies involving healthy human volunteers have revealed that
manipulations of the central serotonin (5-HT) system can produce quite specific changes in cognitive
functioning, independent of overt mood changes. Reduced serotonin turnover is consistently associated
with impaired long-term memory functioning. Low serotonin function may also impair cognitive flexibility
and improve focused attention. On the other hand, stimulation of central serotonin has repeatedly been
found to impair performance in a true vigilance task. Currently, there is little evidence for mirrored
cognitive changes due to opposite serotonin manipulations in healthy volunteers. Given the mounting
evidence for a role of serotonin in human cognition, reduced serotonin function could be directly linked to
cognitive disturbances in certain conditions, such as in depression and Alzheimer’s Disease (AD). There is
evidence that stimulating (i.e. normalizing) serotonin activity in depression may have specific beneficial
effects on cognition, independent of a general relief of depressive symptoms, but this premise needs to be
confirmed by larger-scale clinical studies. Recently, a potential role of serotonin in the cognitive symptoms
in AD has been identified, but there is insufficient data to evaluate the effects of serotonin stimulation on
cognitive symptoms in AD. It is concluded that serotonin is a potential target for pharmacological
cognition enhancement, particularly for restoration of impaired cognitive performance due to serotonin
dysfunction. Further differentiation of the role of serotonin in normal and disturbed cognition and
evaluation of the effects of serotonin manipulations in various populations is required to establish the full
potential of serotonin drugs as cognition enhancers.
Schmitt, J. A. J., Wingen, M., Ramaekers, J. G., Evers, E. A. T., & Riedel, W. J. (2006).
Serotonin and human cognitive performance. Current Pharmaceutical Design, 12, 2473-
2486.
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Introduction
Serotonin (5-HT) has long been implicated in a wide range of behavioural functions,
specifically in mood regulation, aggression and impulsivity. Serotonergic
disturbances are linked to a variety of psychopathological conditions, the most
prominent being depression, bipolar disorder and obsessive compulsive disorder
(Davis et al., 2002). In the past decade, experimental studies with animals and
humans have revealed that serotonin may also play an important role in normal and
disturbed cognitive functioning. The premise that serotonin is involved in cognitive
functions has important implications. First, it broadens our understanding the origin
of cognitive deficits that are associated with certain conditions. For example, sub-
optimal serotonin activity may be responsible to at least part of the cognitive deficits
seen in depression (Riedel, Klaassen, & Schmitt, 2002) Low serotonin has recently
been related to cognitive deficits seen in Alzheimer’s Disease (Lai et al., 2002;
Newhouse et al., 2002; Porter et al., 2003) and may even contribute to age-related
cognitive decline (Richter-Levin & Segal, 1996). Even in healthy women with
premenstrual complaints, cognitive deficits have been related to serotonergic
disturbances  (Bethea  et  al.,  2002).  Secondly,  such  insights  provide  the  basis  for  the
development of treatment strategies for such conditions. Currently, the serotonergic
system is considered a promising target for cognition enhancement (Allain et al.,
2003; Roth et al., 2004). Thirdly, knowledge of serotonin modulation of cognition
helps predict and possibly avoid cognitive side effects of drugs affecting the serotonin
system (Schmitt, 2001).
Several excellent reviews are available on animal studies on serotonergic
modulation of cognition (Buhot, 1997; Buhot et al., 2000; Meneses, 1999; Robbins et
al., 1998; Steckler & Sahgal, 1995). Despite recent developments and insights,
however,  an  extensive  overview  focusing  on  human  studies  in  this  field  is  not
available. The aim of the current review is to discuss the evidence for a role of
serotonin in human cognitive functions; identify specific human cognitive functions
that  may  be  mediated  by  serotonin;  and  to  explore  the  conditions  under  which
manipulations of central serotonergic activity may enhance cognitive performance in
human  subjects.  For  the  purpose  of  this  review,  we  will  focus  on  the  results  from
psychopharmacological manipulations in either healthy volunteers or selected patient
groups. Although occasionally results from animal studies will be briefly addressed
to provide supplementary information and identify possible neurobiological
mechanisms, an extensive discussion of the animal data on serotonin and cognition is
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beyond the scope of this paper. For this, the reader is referred to the aforementioned
review papers.
In humans, several psychopharmacological approaches can be employed to
study serotonin function in relation to cognition. In recent years, acute tryptophan
depletion (ATD) has gained popularity as a method to temporarily lower serotonin
activity  in  the human brain.  The method is  based on reducing the availability  of  L-
tryptophan (TRP), the only precursor for serotonin, in the brain. In short, ATD
involves oral administration of an amino acid suspension without TRP, which
reduces TRP transport into the brain by increasing competition for active transport
sites  across  the  blood-brain  barrier.  ATD  leads  to  marked  reductions  of  brain  TRP,
serotonin and 5-HIAA (for reviews see (Moore et al., 2000; Reilly et al., 1997)). For
example, five hours after intake of the ATD mixture, the alfa-methyl-[11C]-
tryptophan labeled method of estimating serotonin synthesis rate yielded values
across various regions throughout the brain suggesting that serotonin synthesis rate
was reduced by ~87% and ~97% in healthy men and women, respectively (Nishizawa
et al., 1997). In rats, ATD reduces spontaneous hippocampal serotonin release by
approximately 40% (Fadda, 2000). In a similar fashion, increasing brain TRP
availability through TRP loading can be used to stimulate central serotonin synthesis
(Young, 1986; Young & Leyton, 2002). A maximal increase in brain serotonin
synthesis of  ~100% appears to be achieved after a 3 g oral TRP load (Young, 1996;
Young & Gauthier, 1981).
Quite a number of human studies have assessed cognitive changes after acute
or sub-chronic administration of various medicinal drugs that stimulate serotonin
activity throughout the brain. These are predominantly selective serotonin reuptake
inhibitors (SSRIs) and various tricyclic antidepressants (TCAs), which increase
serotonin neurotransmission by blocking the reuptake of serotonin into the
presynaptic neuron and are widely prescribed as antidepressants. Their cognitive
effects have been investigated in both healthy volunteers as well as various patient
groups, particularly depressed patients. However, these studies are often clinical
trials of antidepressant treatment efficacy in patients in which assessment of cognitive
(side)  effects  is  a  secondary  goal  at  most.  Other  studies  were  designed  as  head-to-
head comparison of cognitive side effects of competing drugs in healthy volunteers.
Because of lack of specificity for the serotonergic system, TCA trials are less suitable
to study serotonin effects on cognition. Their anticholinergic, antithistaminergic,
antidopaminergic and/or antinoradrenergic actions are known to adversely affect
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cognition (Amado-Boccara et al., 1995) and hence obscure any serotonin-related
changes. For this reason, this review will focus on studies involving SSRIs, which lack
significant affinities for non-serotonergic neurotransmitter systems, to evaluate the
cognitive effects of global serotonin stimulation. In addition to the aforementioned
methods to alter whole brain serotonin activity, a number of serotonin receptor
agonists and antagonists with varying selectivity are available for human research.
However, these compounds have only sporadically been used in human cognitive
research.  This  is  unfortunate,  as  they  may  provide  vital  information  regarding
serotonin receptor subtypes that are involved in specific human cognitive domains.
Finally, the prolonged use of MDMA (3,4-methylenedioxymethamphetamine;
ecstasy) is according to some authors associated with quite selective neurotoxic
damage to serotonin neurones in animal experiments (McCann et al., 2000). Hence,
assessment of the cognitive changes in frequent MDMA users may be used to provide
indirect evidence on the role of serotonin in human cognition. Although acute
MDMA intake also invokes potent stimulatory effects on serotonin
neurotransmission, additional pharmacodynamic properties of MDMA, most notably
those pertaining to  the dopamine (DA) system (Green et  al.,  2003),  renders  MDMA
less suitable for examination of specific serotonin mechanisms.
The evidence for a role of serotonin in human cognition will be discussed in
two sections, one dealing with healthy volunteer studies, the other with studies in
selected (clinical) populations. The distinction is based on the premise that the
cognitive effects of various serotonin manipulations may vary according to baseline
central serotonin activity. In several conditions, e.g. depression, and possibly also
Alzheimer’s disease and normal aging, both serotonin hypofunction and cognitive
decline is observed. At this point, the causal relation between a compromised central
serotonin system and the observed cognitive deficits in these and other conditions
has not been clearly established, but there is increasing evidence that low serotonin is
at least partially linked to the cognitive problems. Hence, these populations may
specifically benefit from pro-serotonergic pharmacological therapies that shift central
serotonin neurotransmission towards a more optimal level, thus restoring cognitive
function.  By  contrast,  in  healthy  volunteers,  no  performance  deficits  due  to  a
compromised serotonin system are to be expected. As they already operate close to
their optimal cognitive performance level, cognition enhancement is generally
difficult to achieve, by any means. Possibly, stimulation of the serotonin system in
this group may even result in diminished performance, if optimal serotonin
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modulation is disrupted. As such, assessing the cognitive sequelae of altered central
serotonin levels in healthy volunteers is a valuable method to identify the
fundamental role of serotonin in cognition, providing leads for investigating possible
serotonergic mechanisms underlying impaired cognition in specific clinical
populations, and ultimately providing the rationale for serotonergic treatment
options.
Serotonin and human cognition: evidence from healthy volunteers studies
Recent findings from psychopharmacological studies with healthy volunteers have
identified  a  number  of  cognitive  domains  that  appear  to  be  sensitive  to  changes  in
serotonin neurotransmission in the brain. The most consistent effects relate to long-
term memory functions, certain attentional functions, notably focused and sustained
attention, and specific executive functions that mediate behavioural adaptations to
changing environmental demands: a function referred to as cognitive flexibility. In
the following section, the evidence for serotonin involvement in these functions from
experiments with healthy human volunteers is reviewed.
Serotonin and human memory functions
Memory is a multifaceted cognitive function relating to the acquisition, storage and
preservation of information for short and longer time periods, and the subsequent
retrieval of this information. Numerous memory tests are available, varying in terms
of  the  types  of  information,  temporal  characteristics  and  specific  processes  that  are
targeted. List learning paradigms are often used to test various aspects of declarative
memory  (memory  for  facts).  Such  tests  typically  consist  of  one  or  more  acquisition
trials in which information is presented, followed by recall and recognition trials to
assess retrieval and storage, respectively. Varying the time interval between
presentation and assessment allows for a differentiation between short- and long-
term memory functioning.
The serotonergic system appears to be involved in specific human memory
processes. The perhaps most compelling evidence for this was obtained in a number
of experiments in which ATD was used to lower central serotonergic activity in
healthy volunteers. These studies demonstrated that lowering of serotonergic activity
is associated with a quite specific impairment of long-term memory performance
(Riedel, Klaassen, & Schmitt, 2002). In one of the initial experiments, Riedel et al
(1999) showed that ATD reduced the ability to actively recall, as well as recognize,
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words from a previously presented word list. The effect was only apparent after a 30
minutes delay between presentation and assessment, but not when word recall was
assessed immediately after presentation. This pattern lead the investigators to the
conclusion that consolidation of new information into long-term memory was
compromised by a reduction of central serotonin activity, but that short-term
memory functions appear to be spared. Several studies have subsequently confirmed
the notion that serotonin is specifically involved in long-term memory functioning.
ATD was found to specifically reduce delayed recall and/or delayed recognition of
visually presented words (Harrison et al., 2004; Kilkens et al., 2004; Rowley et al.,
1998; Schmitt et al., 2000; Sobczak et al., 2002), spoken words (McAllister-Williams et
al., 2002), pictures (Sobczak et al., 2002) and even abstract figures (Rubinsztein et al.,
2001), whereas two studies failed to detect ATD-induced changes in memory for
words (Hughes, Gallagher et al., 2003; Shansis et al., 2000). The authors of the latter
study suggest that the results may have been hampered by modest levels of
tryptophan depletion. Overall, results seem to indicate that ATD-induced memory
impairment  occurs  independent  of  the  nature  of  the  stimuli  and  suggest  that
serotonin modulates long-term memory processes at a fundamental level. The
specificity of this effect for the depletion of tryptophan was demonstrated in two
studies where the memory consolidation deficit was found in the ATD condition but
not when other amino acids, lysine (Klaassen et al., 1999) and tyrosine/phenylalanine
(Harrison  et  al.,  2004)  respectively,  were  depleted  within  the  same  group  of
volunteers.  Furthermore,  it  was  demonstrated  that  ATD  does  not  affect  long-term
memory retrieval or recognition when the depletion is induced after learning and
consolidation of a word list (Schmitt et al., 2000). Event related potential (ERP)
recordings further showed that impaired long-term memory recall for words after
ATD occurred without changes in the magnitude or topography of the neural
correlates of retrieval functions (McAllister-Williams et al., 2002). These results
suggest that impaired storage and/or consolidation of new information, rather than
the  ability  to  access  and  retrieve  information,  underlies  poor  long-term  memory
performance after serotonin depletion.
The results emerging from ATD studies indicate that reduced long-term
memory performance is not likely to be attributable to consistent changes in
perceptual functions, information processing, attention or executive functions
(Gallagher et al., 2003; Harrison et al., 2004; Park et al., 1994; Riedel, Klaassen et al.,
1999;  Schmitt  et  al.,  2000).  In  fact,  there  is  some  indication  that  some  attentional
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functions, i.e. selective attention (see below), and memory related executive functions,
i.e. strategy driven retrieval from semantic memory (word fluency), may benefit from
a reduction of serotonin neurotransmission (Schmitt et al., 2000). Also, the absence of
evident changes in self-reported mood ratings of healthy volunteers following ATD
(Booij et al., 2003; Riedel, Klaassen, & Schmitt, 2002; Young & Leyton, 2002) suggests
that diminished memory function is not mediated by mood changes. A detailed
analysis of the long-term memory impairment following ATD, however, revealed
that recall of words with a positive and neutral affective valence was specifically
impaired, whereas recall of negative words was unaffected (Klaassen et al., 2002). The
authors conclude that serotonin depletion shifts affective memory bias towards
words with a negative affective valence. Supporting this notion, recent data show
that ATD was associated with a specific decrement in memory for positively loaded
words (Kilkens et al., 2004). The results are indicative of a mood congruent memory
bias caused by a lowering of mood and suggest an interaction between subtle mood
effects and memory effects induced by low serotonin activity.
In contrast with the quite consistent findings on serotonin depletion and
memory impairment, the studies on the effects of serotonin stimulation on memory
functions in healthy volunteers are scarce and have yielded rather inconsistent
results. No changes in long or short-term memory performance were seen after 50 mg
acute (Coffey et al., 1994) or 50-100 mg subchronic (Schmitt et al., 2001; Siepmann et
al., 2003) administration of the SSRI sertraline in healthy volunteers. Citalopram
administration has been associated with decreased long-term memory performance
in healthy middle-aged subjects. After 14 days of treatment with citalopram: 20mg on
days 1-7; 40 mg on days 8-14), subjects reproduced 1.5 words less (5%) at delayed
recall (Riedel et al., 2005) Impairment of delayed word recall was also found after
sub-chronic administration of 20-40 mg paroxetine in healthy middle-aged subjects
(Schmitt et al., 2001). Memory function, particularly long-term memory retrieval and
storage,  was impaired following intravenous administration of  7  g  TRP (Sobczak et
al., 2003). However, the relatively high dose of TRP had marked sedative effects,
probably due to the conversion of TRP to melatonin, as was apparent from subjective
rating scales and spontaneous reported side effects. Moreover, sedation was
positively correlated with memory performance, suggesting that the observed
memory effect was primarily mediated by melatonin accumulation and possibly, to
some extent, by sedative effects of serotonin stimulation itself. Finally, memory-
enhancing effects of SSRIs have also been reported. An acute intravenous
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administration of 10 mg of the selective serotonin reuptake inhibitor (SSRI)
citalopram in healthy volunteers was shown to facilitate verbal memory
consolidation (Harmer et al., 2002). After subchronic administration of the SSRI
sertraline in healthy elderly subjects, sertraline plasma levels were correlated
positively with short-term memory scores on day 7 (low dose: 50 mg) and long-term
memory scores on day 21 (high dose: 150 mg), while no correlation with memory was
found on day 14 (intermediate dose: 100 mg) (Furlan et al., 2001). A study of the acute
effects of 10 mg ipsapirone, a 5-HT1A agonist, and 0.5 mg/kg m-CPP
(metachlorophenylpiperazine), a 5-HT2C agonist, showed that ipsapirone impaired
immediate recall in healthy volunteers (Riedel, Klaassen, Griez et al., 2002).
Data  from serotonin depletion studies  provide ample evidence for  a  role  of
the central serotonergic system in long-term memory functioning. It seems that
increasing serotonin activity in healthy volunteers, however, does not necessarily
lead to memory improvement. In fact, some findings suggest that overstimulation of
the serotonin system actually induces memory impairment. The absence of consistent
beneficial effects of serotonin stimulation may indicate that in healthy volunteers,
under normal conditions, the level of central serotonin activity is not a limiting factor
for optimal memory functioning. From the current data, serotonin manipulations do
not seem a particular viable method to enhance memory in healthy subjects, although
reports of improved memory following serotonin stimulation certainly merit further
investigation.
Serotonin and human attention functions
Focused attention
Focused attention refers to the ability to attend a relevant stimulus or stimulus
attribute while ignoring irrelevant information. In focussed attention tasks a
predefined informational cue, indicating the required response, is accompanied by
distracting  information,  which  causes  interference.  A  classic  and  often  used  test  of
focused  attention  is  the  Stroop  Colour  Word  Test  (Stroop,  1935),  in  which  subjects
have  to  ignore  the  content  of  a  series  of  printed  colour  names  and  name  the
incongruent  ink colours  (e.g.  “yellow” printed in  blue ink).  Interference can also be
introduced in flanker task (Eriksen & Eriksen, 1974) by simultaneous presentation of
distracting information in  proximity of  the target  stimulus,  e.g.  a  central  arrow that
indicates the required response is flanked by arrows that point in the opposite
direction. Another example of a focused attention task is the shadowing condition of
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the  dichotic  listening  task  (Kimura  &  D'Amico,  1989),  in  which  series  of  numbers
spoken in one ear have to be processed while ignoring simultaneously spoken
numbers in the other ear.
Data  from several  ATD experiments  indicate  a  putative role  of  serotonin in
the modulation of focused attention. In a healthy volunteer study, ATD was found to
reduce  interference  in  a  Stroop  Colour  Word  Test  and  increase  performance  on  the
focussed attention component of the dichotic listening task (Schmitt et al., 2000).
These  findings  are  in  line  with  previous  ATD  studies  reporting  decreased
interference in the Stroop test (Rowley et al., 1998) and speeded responses to
incompatible stimuli (e.g. the word “left” presented at the right side of the screen)
after  ATD  (Coull  et  al.,  1995).  The  positive  effects  of  ATD  on  Stroop  and  dichotic
listening performance could not be replicated in a subsequent study, although the
data tended to show a similar pattern(Sobczak et al., 2002). The authors argued that
the heterogeneity of their study population, in terms of age and psychiatric family
loading,  may  have  lead  to  reduced  sensitivity.  Lack  of  ATD  effects  on  Stroop
performance  have  also  been  reported  in  two  other  studies  (Danjou  et  al.,  1990;
Gallagher et al., 2003). A recent finding, however, of a dose-related increase in
performance on the Stroop test in a study comparing the effects of two levels of ATD
in depressed patients provides strong evidence for serotonin involvement in focused
attention (Booij et al., 2005). The role of serotonin in focused attention is further
substantiated by EEG (electroencephalography) and MEG (magnetoencepha-
lography) measures in healthy volunteers after ATD. Both EEG and MEG correlates
of auditory attention (mismatch negativity, N2b and N2 wave) suggested that ATD
decreased involuntary attention shifting to task-irrelevant sound changes and thus
modulated resource allocation to the task-relevant activity (Ahveninen et al., 2002).
In healthy volunteers, there is no clear evidence that serotonin stimulation
influences measures of focused attention, although it must be noted that only a few
studies have addressed this issue. Performance on the Stroop test was unaffected by
14-15 days of administration of 20-40 mg paroxetine (Hindmarch & Harrison, 1988;
Kerr et al., 1992; Schmitt, Ramaekers et al., 2002) and 50-100 mg sertraline (Schmitt,
Ramaekers et al., 2002). No changes in performance on a dichotic listening task, in an
identical version that was shown to be sensitive to ATD, were found following sub-
chronic administration of 50-100 mg sertraline and 20-40 mg paroxetine (Schmitt,
Ramaekers et al., 2002). A 7g intravenous TRP challenge to stimulate serotonin
neurotransmission resulted in diminished speed of responding to incompatible
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stimuli in a left-right task TRP (Sobczak et al., 2003), in line with the effects of ATD on
focused  attention.   However,  the  effect  was  only  observed  in  those  subjects  with  a
first degree relative with bipolar disorder. Furthermore, the effect did not extend to
other tests of focused attention in the study, i.e. the Stroop test and dichotic listening.
Sustained attention (vigilance)
Sustained attention is the ability to direct and focus cognitive activity or alertness on
specific stimuli over a prolonged period of time. In tests of sustained attention or
vigilance stimuli are usually intermittent, unpredictable and infrequent. The
prototypical vigilance task is the Mackworth Clock task (Mackworth, 1950). This task
was  developed  during  World  War  II  to  simulate  radar  monitoring  operations.  A
computer screen displays a circular arrangement of dots simulating the second marks
on a clock. Dots are briefly illuminated in clockwise rotation. At irregular intervals a
“double jump” occurs by skipping one of the dots in the normal sequence. These are
the signals that an observer has to detect and respond to. It has been shown that
vigilance performance declines steeply as a function of time on task (Mackworth,
1950).
Augmentation of serotonin neurotransmission has been shown to impair
human vigilance performance, i.e. the ability to remain alert for prolonged periods of
time. Ramaekers et al. compared the acute and subchronic effects of fluoxetine 20mg
on  sustained  attention  to  those  of  placebo  in  a  double-blind,  cross-over  study
involving 18 healthy volunteers. Sustained attention was assessed using the
Mackworth Clock paradigm (Mackworth, 1950) on days 1, 8 and 22 of treatment. A
reduction in sustained attention was observed throughout the fluoxetine treatment
period. The selective impairing effects on vigilance and sustained attention have also
been observed following two weeks of administration of incremental dose regimens
of venlafaxine (75-150mg) to healthy volunteers. Little effect of venlafaxine on
sustained attention was seen on the first day of treatment but the effect increased to
become significant after one week of treatment. Subjects seemed to notice
venlafaxine’s  effect  on  vigilance  as  they  subjectively  rated  their  alertness  less  as
compared  to  placebo.  Single  and  repeated  doses  of  paroxetine  30mg  did  not  affect
vigilance performance as compared to placebo in healthy volunteers (Deijen et al.,
1989). However in this study maprotiline 100mg failed to affect vigilance
performance also, even though this drug is known to produce drowsiness. Deyen et
al (Deijen et al., 1989) did not reveal any task parameters relevant to an operational
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Mackworth clock paradigm but their vigilance data suggests that their version may
not have been sensitive enough to assess drug-induced changes. Schmitt et al (2002)
on the other hand did report a paroxetine induced vigilance decrement. They
compared the effects of subchronic treatment with sertraline (50-100mg) and
paroxetine (20-40mg) on sustained attention in a placebo controlled study in 21
healthy volunteers. Paroxetine significantly reduced performance on the Mackworth
Clock task, i.e. it decreased the number of correct detections and increased mean
reaction time for correct detections. In contrast, sertraline did not reduce the number
of correct detections and decreased mean reaction time. Similar results were reported
in a placebo controlled study by Riedel et al (2005). They found that citalopram
impaired vigilance performance in healthy volunteers during the first week of
treatment with 20 mg and during the second week of treatment with 40 mg daily. In
contrast, no vigilance impairment was found during sertraline (50-100mg) treatment.
The magnitude of citalopram induced impairment in the Mackworth Clock task was
comparable to that previously observed for fluoxetine, venlafaxine and paroxetine
(O'Hanlon et al., 1998; Ramaekers et al., 1995; Schmitt, Ramaekers et al., 2002). Edgar
et al (Edgar et al., 2004) assessed vigilance performance in 2 groups of healthy
volunteers  who  received  16  days  of  treatment  with  escitalopram  or  sertraline.  The
Mackworth Clock Test was administered at baseline and on day 16 at 2 and 4 hrs post
dosing. Relative to baseline escitalopram decreased vigilance accuracy, but only at 2
hrs post dosing. Harmer et al (2002) failed to measure any affect of citalopram on
sustained attention while using another vigilance paradigm: i.e. Rapid Digit
Information  Processing.  It  is  unclear  however  whether  this  paradigm  measures  the
same aspects of vigilance as the Mackworth Clock Test.
 Thus, sertraline is the only SSRI studied so far with no detrimental effects on
vigilance. It has been suggested that the latter may be due to the fact that sertraline
also possesses an ancillary mechanism that facilitates cortical arousal; i.e. blockade of
DA reuptake. In such case vigilance impairment following serotonin stimulation may
be counteracted by the vigilance promoting effects of DA stimulation (Schmitt,
Ramaekers et al., 2002).
Studies employing the Mackworth Clock paradigm thus all seem to point out
that enhancing serotonin in normal individuals consistently impairs vigilance. The
mechanism underlying this effect however has not been fully elucidated. A reduction
in  noradrenergic  (NA)  activity  does  not  seem  to  play  a  major  role  as  simultaneous
enhancement of NA with serotonin by venlafaxine was previously shown not to
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counteract the vigilance decrement (O'Hanlon et al., 1998). Similarly, decreased
catecholamine availability after tyrosine/phenylalaline depletion did not affect
performance of healthy volunteers in a digit-vigilance task (Harrison et al., 2004).
Animal  studies  have  also  indicated  that  NA  is  not  specifically  associated  with  the
maintenance of vigilance (Delagrange et al., 1993; McGaughy et al., 1997), but is more
likely  to  control  phasic  arousal  and  hence  may  be  related  only  when  a  sensory
pathway habituation type of  vigilance decrement  is  at  stake.  DA on the other  hand
has  been  associated  with  tonic  arousal  and  readiness  to  respond  (Pribram  &
McGuinness, 1975; Robbins, 1997). Stimulation of DA transmission by amphetamine
and methylphenidate has been shown to improve vigilance performance (Koelega,
1993). Vigilance impairment produced by SSRIs may involve both serotonin and DA
neural circuits. It is interesting in this context that simultaneous depletion of
serotonin and catecholamines did impair sustained attention of healthy volunteers in
a digit-vigilance task (Hughes, Matrenza et al., 2003), whereas selective depletion of
serotonin and catecholamines did not (Harrison et al., 2004). It has been shown that
serotonin projections from the raphe nucleus exert a tonic inhibitory influence over
the mesocortical, nigrostriatal and mesolimbic DA systems. Thus augmentation of
serotonin can be predicted to further inhibit DA transmission in DA pathways
(Schmitt, Ramaekers et al., 2002).
Several researchers have claimed that SSRIs can increase general CNS
(Central Nervous System) arousal and attention (Kerr et al., 1991). This claim was
generally based on the notion that SSRIs are capable of increasing the critical flicker
fusion (CFF)  threshold in  healthy volunteers.  CFF is  a  task that  requires  subjects  to
discriminate  flicker  from  fusion  in  a  set  of  light  emitting  diodes  held  in  foveal
fixation. The psychological functions that are being measured with CFF however
have never been truly established. In general, drug induced decrements in CFF
threshold  are  believed  to  reflect  sedative  aspects  from  a  particular  compound,
whereas elevation of CFF threshold might indicate the opposite: i.e. activation. If true,
data demonstrating elevated CFF thresholds after SSRIs administration could be
taken to support the notion that these drugs improve (sustained) attention. However
it has also been argued that a rise in CFF threshold may also result from mydriasis
produced by SSRIs rather than a change in arousal (Ramaekers et al., 1995). Pupil
diameter  is  an  important  determinant  of  CFF  threshold  and  several  studies  have
shown that serotonergic drugs may alter pupil size. More in particular it has been
shown that  SSRIs  may cause a  2mm increase in  pupil  size  after  single  and repeated
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doses (Deijen et al., 1989; McGuirk & Silverstone, 1990; Raptopoulos et al., 1989;
Saletu & Grunberger, 1988; Schmitt, Riedel et al., 2002). It is noteworthy in this
respect that all of the studies reporting SSRI induced elevation of CFF threshold failed
to control pupil size as a possible confounder, and that investigators that did control
pupil diameter while measuring the effects of SSRIs on CFF did not report any
significant elevations in CFF threshold (Ramaekers et al., 1995 ; Schmitt, Riedel et al.,
2002). Only Mattilla et al (Mattila et al., 1988) reported a slight CFF threshold
elevation from baseline following the administration of an SSRI (sertraline 50mg) in
an CFF paradigm controlling for pupil size. However, the authors believed that this
finding was invalid as it was confounded by irregular baseline deviations. When
compared directly to placebo, no significant change in CFF was reported following
administration of sertraline.  Thus, studies showing SSRI induced elevations in CFF
threshold do not necessarily contradict with studies showing that SSRIs decrease
vigilance or sustained attention. CFF data should always be interpreted with caution,
particularly when confounding factors such pupil size are uncontrolled for.
Serotonin and cognitive flexibility
Cognitive flexibility refers to the ability to adapt ongoing behaviour to changes in
reinforcement. It is a multi component process, involving several cognitive sub-
processes such as feedback processing, behavioural adaptation, learning of new
stimulus-reward associations and inhibition of the previously stimulus-reward
associations (response inhibition). Tasks measuring cognitive flexibility include
reversal learning tasks, decision making tasks or gambling tasks, the intra
dimensional/ extra dimensional shift (ID/ED) task, and the Wisconsin Card Sorting
Task (WCST). Typically, these tasks require the subjects to choose the appropriate
response, and adjust their response strategy based on the feedback or cues they
receive (correct/incorrect, reward/punishment, probabilities). Especially the
orbitofrontal and cingulate cortices have been associated with cognitive flexibility
(Catafau et al., 1998; Cools et al., 2002; Krawczyk, 2002; Kringelbach & Rolls, 2003;
Rezai et al., 1993; Rogers, Owen et al., 1999; Volz et al., 1997). Neuroimaging studies
have implicated these brain regions in various cognitive processes that are important
for flexible behaviour, including cognitive processing of affective meaning and
reward, and inhibitory control (see (Murphy et al., 2003; Rogers, Owen et al., 1999;
Rogers et al., 2003)).
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In a typical reversal learning task the subject has to choose between two stimuli that
are presented simultaneously. The assignment is to identify the correct or most
profitable stimulus based on the feedback that is given after each response. Once the
correct association is learned, the reinforcement rules are reversed the subject has to
adjust its responding to the new stimulus reward association (reversal shift). Several
animal studies have implicated serotonin in reversal learning (see (Clark et al., 2004;
Clarke et al., 2004). In healthy human volunteers, ATD impaired the ability to
perform a reversal shift in an ID/ED task, as was apparent from an increase in
erroneous responses after a reversal shift (Park et al., 1994; Rogers, Blackhaw et al.,
1999). Impaired performance after ATD was also observed in a probabilistic reversal
learning task, although deficits were observed for speed, rather than accuracy
(Murphy et al., 2002). In a recent fMRI study (Evers, Cools et al., 2005), ATD did not
affect behavioural indices of reversal learning, increased activation in the
dorsomedial PFC after ATD was found when subject adapted their behaviour after a
reversal.  There  was  a  trend  that  the  increased  activation  in  the  dorsomedial  PFC
extended to all the events where negative feedback was received. It was suggested
that decreased serotonin may impair cognitive flexibility by increasing the sensitivity
for negative feedback. Lack of effects of ATD on reversal learning, as measured by an
ID/ED task (Hughes, Gallagher et al., 2003), WCST (Gallagher et al., 2003; Hughes,
Gallagher et al., 2003) and a probabilistic reversal learning task involving multiple
reversal shifts (Evers, Tillie et al., 2005), have also been reported. While the apparent
inconsistencies may be attributed to methodological issues, i.e. small sample size
(Murphy et al., 2002), timing of the post-treatment assessments (Evers, Tillie et al.,
2005) and modest levels of tryptophan depletion (Hughes, Gallagher et al., 2003), it is
clear that further research is required to confirm and specify the role of serotonin in
reversal learning.
The ability to make decisions that are most favourable in term of reward, and
to adjust choices to varying conditions of potential reward and punishment, has also
been associated with serotonin. Decision making tasks assess the quality and speed of
choices that a subject makes under various conditions of potential gains or losses and
associated chances of winning or losing. ATD tended to increase deliberation times,
i.e. reduced the speed of decision making, particularly when probabilities of making
the correct choice were higher. Furthermore, quality of decision making, i.e. choosing
the  most  likely  of  the  two  response  options,  was  reduced.  ATD  did  not  affect  risk-
taking,  i.e.  the  size  of  the  bets  that  subjects  placed  on  a  particular  response,  or
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impulsivity  in  the  selection  of  the  bets  (Rogers,  Everitt  et  al.,  1999).  In  subsequent
study (Rogers et al., 2003) it was shown altered decision making after ATD may be
mediated  by  changes  in  reward  processing.  More  specifically,  ATD  was  found  to
attenuate the subjects’ ability to discriminate between different magnitudes of
expected gains. Processing of punishment cues (discrimination between small and
large losses) or probability cues (discrimination between low and high probability of
winning) was not affected by ATD. The authors propose that complex interactions
between serotonin and mesolimbic DA system may underlie the observed changes in
affective processing that is associated with the orbitofrontal cortex. In contrast,
Anderson et  al  (Anderson et  al.,  2003)  failed to  detect  any ATD-induced changes in
decision making in a gambling task in which probabilities of winning and potential
gain were manipulated. As was also noted by the authors, the parallel group design
and modest sample sizes (15 ATD versus 13 placebo subjects) probably limited the
study’s statistical power.
Currently,  there  are  no  reports  on  the  effects  of  serotonin  stimulation  on
cognitive flexibility in healthy volunteers.
Clinical aspects
Depression, serotonin and cognition
Impaired cognitive function is one of the key features of a depressive disorder. The
cognitive deficits that are associated with a depressive episode were initially thought
to be secondary symptoms, mediated by lowered mood, abnormal sleep, loss of
interest or motivational deficits. These factors may certainly contribute to abnormal
cognitive functioning in depression, however, it has now become clear that cognitive
impairment is one of the core symptoms of depression and may occur independent of
mood changes.
A depressive episode is often accompanied by extensive cognitive
impairment across a wide range of cognitive domains. Impairment of long-term
memory functioning, particularly impairment of encoding and retrieval, is frequently
and quite consistently observed in depression (Austin et al.,  2001; Brand et al.,  1992;
Burt et al., 1995; Den Hartog et al., 2003; Zakzanis et al., 1998). In addition, attention
deficits (Landro et al., 2001; Purcell et al., 1997) and impairment of executive
functions, for example difficulties on measures of verbal fluency, attentional set-
shifting and cognitive flexibility, are reported (Austin et al., 2001; Austin et al., 1992;
Elliott, Baker et al., 1997; Elliott, Sahakian, Herrod et al., 1997; Elliott et al., 1996;
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Elliott, Sahakian, Michael et al., 1997; Fossati et al., 2002; Murphy et al., 2001; Murphy
et al., 2003; Stordal et al., 2004). Given that central serotonergic dysfunction is
considered to be one of the neuronal substrates of depression(Maes & Meltzer, 1995),
one could speculate at least part of the observed cognitive deficits are directly
attributable to diminished brain serotonin neurotransmission. It is particularly
noteworthy that the observed deficiencies in memory encoding and/or consolidation
during depression are highly comparable to the memory effects that are seen
following ATD in healthy volunteers (Riedel, Klaassen, & Schmitt, 2002). Similarly,
reduced cognitive flexibility in depression seems to be in line with ATD-induced
impairment of cognitive flexibility in healthy volunteers. It must be noted, however,
that  depression is  also associated with deficits  in  central  catecholaminergic  (i.e.  NA
and DA) activity (Anand & Charney, 2000; Ordway et al., 2002) neuroendocrine
abnormalities, (e.g. cortisol hypersecretion) (Porter et al., 2004; Schatzberg et al., 2002)
and immunological changes(Kronfol, 2002; O'Brien et al., 2004). It is therefore likely
that the pattern of depressive symptoms, including the cognitive changes, is the
result of a complex interplay between various neurobiological, neuroendocrine and
immunological factors.
Many antidepressant drugs stimulate serotonergic neurotransmission by
either blocking the reuptake of serotonin into the presynaptic neuron or inhibiting the
enzyme responsible for the degradation of serotonin (monoamine oxidase). The most
obvious and straightforward approach to gain insight in the role of serotonin in
cognitive deficits in depression is to evaluate the cognitive effects of treatment of
depressed patients with pro-serotonergic antidepressants. Successful antidepressant
treatment alleviates depressive symptoms and is generally associated with
improvement of cognitive performance. Clinical improvement and enhanced
memory performance was observed after six weeks of treatment with fluoxetine in
depressed patients (Richardson et al., 1994). In elderly depressed patients,
improvement of short- and long-term memory functions, visuospatial capabilities,
arousal measures, and psychomotor speed was observed after 6 weeks
administration of fluoxetine (Fairweather et al., 1993; La Pia et al., 2001). Similarly, in
elderly depressed patients, twelve weeks of treatment with sertraline reduced
depression symptoms and improved short- and long-term memory function
(Bondareff  et  al.,  2000;  Finkel,  Richter,  &  Clary,  1999).  Also  in  elderly  depressed
patients, 12 weeks treatment with fluoxetine or sertraline improved clinical ratings,
short- and long-term memory function and performance on the digit symbol
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substitution test (Doraiswamy et al., 2003; Finkel, Richter, Clary et al., 1999;
Newhouse et al., 2000). It is worth mentioning that in those studies in which the
effects of non-selective antidepressants were also assessed, notably mianserin (La Pia
et al., 2001), nortriptyline (Bondareff et al., 2000; Doraiswamy et al., 2003; Finkel,
Richter, & Clary, 1999), imipramine (Koetsier et al., 2002) or amitriptyline
(Richardson et al., 1994), these drugs generally had comparable efficacy in terms of
the therapeutic effect, but produced significantly less cognitive improvement or in
some cases cognitive deterioration. These findings highlight the unfavourable
cognitive side effects produced by anti-cholinergic, anti-noradrenergic and anti-
histaminergic drug actions.
A major methodological caveat in the aforementioned clinical trials is the
absence of a control condition. Cognitive performance is known to improve with
repeated assessments due to practice effects, procedural learning and familiarity with
the testing protocols, leading to reduced anxiety. The importance of a control group is
illustrated by a study by Nebes et al. (Nebes et al., 2003). In this study, improvement
of cognitive performance was observed following 12 weeks of treatment with
paroxetine and nortriptyline in elderly depressed patients. However, a similar
improvement  of  cognitive  performance  was  observed  in  a  healthy  matched  control
group that underwent an identical study procedure (except for drug administration).
The results could not be explained by treatment response, benzodiazepine co-
medication, age of depression onset, or by co-existence of early dementia.
Consequently, it was concluded that there was also no evidence for nortriptyline or
paroxetine having an effect on cognition in elderly depressed patients. Others did
find that nortriptyline and paroxetine treatment improved cognitive performance in
elderly depressed patients compared to a healthy control group, although the effect
was  modest  and  limited  to  those  subjects  that  were  modestly  to  severely  cognitive
impaired at baseline (Butters et al., 2000). Sertraline or desipramine treatment did not
significantly alter cognitive performance (reaction time, DSST, trail making) in
depressed elderly patients, when compared to placebo treatment. However, clinical
efficacy also did not  differ  between treatment  groups and placebo,  according to  the
authors, due to modest sample sizes, mild to moderate severity of depression, and a
high placebo response. In another study, depressed patients, when compared to a
healthy control group, showed improved performance on a continuous performance
task, along with clinical improvement, following 4 weeks of fluvoxamine
administration (Koetsier et al., 2002). In a group of depressed inpatients receiving
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fluoxetine, performance on a series of tests assessing fine motor skills was markedly
improved  after  5  weeks  of  treatment,  compared  to  healthy  controls  undergoing  the
same assessments (Sabbe et al., 1996). Overall, these findings suggest that cognition
does tend to improve with successful antidepressant therapy, but without ample
control for spontaneous changes in performance there is a risk of overestimating the
actual cognitive effect of antidepressant treatment.
A second important issue is whether or not cognitive improvement after
serotonergic antidepressant treatment is a direct effect of enhanced serotonin
neurotransmission or the secondary result of alleviation of the depressive illness in
general, e.g. removal of mood, motivational and sleep abnormalities. Mixed results
were obtained when clinical improvement was correlated with improvement of
overall cognitive performance (combined changes in memory and DSST scores)
following 3 months of nortriptyline, sertraline, or fluoxetine treatment. While
significant correlations were found for patients treated with sertraline and, albeit
weaker, for nortriptyline, no correlation was found in patients treated with
fluoxetine. Thus, although cognitive improvement may be linked to clinical efficacy,
this  does  not  seem  to  be  a  prerequisite.  The  authors  suggested  that  both  a  direct
pharmacological effect, i.e. serotonin stimulation, as well as improvement of
depression may affect cognition in depressed patients (Doraiswamy et al., 2003).
Also, no correlation between improvement of clinical depression scales and improved
performance on a continuous performance test could be found following 4 weeks of
imipramine or fluvoxamine treatment (Koetsier et al., 2002). There is some evidence
that serotonin stimulation may indeed improve cognition directly, independent of
relieve of other depressive symptoms. After 6 weeks of trazodone treatment, clinical
remission and improved verbal long-term memory function (in spite of trazodone’s
sedating effects) was observed in a group of middle-aged depressed patients. In the
ensuing placebo washout period of one week, memory performance reverted to
baseline levels while depression ratings remained below depression threshold. Thus,
memory function appeared to fluctuate mainly as a function of serotonin activity,
rather than depressive symptomatology (Riedel, Schoenmakers et al., 1999). In
another study, the noradrenergic antidepressant desipramine and the SSRI fluoxetine
were found to be equally effective in terms of their clinical effects. Improvement of
memory, however, was only apparent with the serotonergic antidepressant
fluoxetine. This does not only suggests a dissociation between clinical response and
memory improvement, but is also in keeping with the specific role of serotonin in
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memory processes (Levkovitz et al., 2002). One study has investigated the acute
effects of 10 mg ipsapirone, a 5-HT1A agonist, and 0.5 mg/kg m-CPP
(metachlorophenylpiperazine), a 5-HT2C agonist, on cognition and mood in
medication-free, young and middle-aged, depressed patients and healthy controls
(Riedel, Klaassen, Griez et al., 2002). Ipsapirone tended to improve short-term
memory in patients, but impaired short-term memory in controls, whereas neither
group showed any ipsapirone–induced changes in mood. M-CPP, on the other hand,
impaired performance on reaction time tests in all subjects, and visual search
efficiency in patients only. After m-CPP, depression and tenseness ratings were
increased  in  patients,  and  increased  fatigue  was  seen  in  all  subjects.  The  pattern  of
results seem to indicate that certain transient mood changes may affect certain aspects
of performance: increased fatigue was accompanied by increased reaction times, and
depression and tenseness were associated with visual search deficiencies. Altered
memory functioning, however, appeared to occur without any overt changes in mood
states. Moreover, while 5-HT1A agonism impaired memory in healthy subjects,
facilitating effects were found in patients. The authors speculate that the latter finding
may be related to hippocampal 5-HT1A desensitation in patients (Riedel, Klaassen,
Griez et al., 2002). As such, it may be tentatively hypothesized that the differential
memory effects may reflect normalization versus overstimulation of hippocampal 5-
HT1A-mediated serotonergic neurotransmission in patients and healthy subjects,
respectively.
Serotonin in neurodegeneration: ageing and dementia
Improved  understanding  of  the  nature  of  alterations  in  the  serotonin  system
occurring in aging, late-life depression, and dementia has important implications for
testing hypotheses of neurochemical mechanisms underlying the aging process and
age-related neuropsychiatric disease. Cognitive performance enhancing effects of
serotonin manipulations could be useful in various clinical populations in whom
serotonin function is thought to be compromised. Given the specific involvement of
serotonin in memory consolidation, neurodegenerative diseases may involve the
serotonergic system. To consider are ageing, Alzheimer's Disease (AD) and
frontotemporal dementia. The working hypothesis is that therapies that stimulate the
serotonergic system in these populations might be beneficial.
There is increasing evidence for alterations in the function of the serotonin
system in AD, which may be responsible for many of the behavioural aspects of the
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disease including the frequent coexistence of depression. The literature implicating
serotonin dysfunction in depression, aging and AD is based largely on the results of
indirect measures, including animal models, post mortem human studies, and
peripheral  measurements  of  serotonin binding (Meltzer  et  al.,  1998).  In  aging,  it  has
recently been shown that 5-HT2A receptor binding decreases dramatically in a variety
of brain regions up through midlife (Sheline et al., 2001). In AD, serotonin
dysregulation is reported separately or in conjunction with that of the cholinergic
system, due to interactions at the receptor level, in particular in septo-hippocampal
cholinergic neurones as well as in cholinergic neurones from the nucleus basalis to
the cortex and the amygdala  (Buhot  et  al.,  2000).  In  a  study by Porter  (Porter  et  al.,
2003) AD patients were administered ATD and their cognitive responses were
compared to those of age-matched controls. No specific differences were found with
respect to cognitive responses to ATD between the AD and control groups. However,
the observed effects of ATD both in the normal aged and in the AD groups seemed to
differ from those seen in healthy young volunteers. An impairment of performance
on the backward digit span was observed after ATD in both groups. Such impairment
may  well  underlie  other  memory  deficits  induced  by  ATD,  such  as  the  observed
ATD-induced impairment in the Paired Associates Learning test (Porter et al., 2003).
However, no ATD-induced impairments were found on the Rey auditory verbal
learning task and neither on the Rey Visual Design Learning Test. Ultimately, this
could  mean  that  memory  consolidation  impairment,  acts  as  a  marker  of  cognitive
aging and although it  is  a  sensitive  indicator  of  ATD,  might  not  be  a  relevant  state
marker of serotonin in AD. Previously, the same group (Porter et al.,  2000) reported
on the basis of differences between AD patients and healthy controls in their response
to  ATD,  that  using  the  3MSE,  an  extended  version  of  the  Mini  Mental  State
Examination  scored  on  a  scale  of  1-100,  AD  patients  responded  to  ATD  by  an
impairment of performance on that scale whereas elderly controls did not. Porter et
al. (2003) noted that this may reflect a ceiling effect on this scale in the elderly control
group. We therefore remain with the fact that this was hitherto the first and only
study to investigate the specific role of serotonin in aging and AD.
There are almost no reports of attempts to use SSRIs in AD and ageing
specifically aimed at enhancing cognition. Partly, this is due to the fact that studies of
SSRIs in ageing subjects are usually focused on alleviating low mood in late-life
depression. In AD, studies of SSRIs have been reported to improve the non-cognitive
symptoms rather than cognitive performance (Gottfries, 2001). Furthermore, a trial
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has been reported in which treatment of AD patients with cholinesterase inhibitors
was  compared  to  the  same  in  addition  with  the  SSRI  citalopram.  The  outcome
focused on attributing additional mood and behavioural symptoms improvement in
the cholinesterase inhibitor + SSRI group (Moretti et al., 2002).
Rahman et al. (Rahman et al., 1999) have recently suggested that some of the
symptoms associated with the frontal variant of frontotemporal dementia (fvFTD) are
related to serotonergic dysfunction. This concerns marked deficits on tests sensitive to
ventromedial prefrontal or orbitofrontal function (i.e. risk-taking, reversal learning),
in the relative absence of impairments on tests sensitive to dorsolateral prefrontal
function (i.e. spatial working memory and planning) (Rahman et al., 1999). Many of
the  symptoms  of  fvFTD  are  indeed  currently  treated  using  serotonin-boosting
compounds, which are presumably aimed at the aforementioned brain regions and
their associated behaviours such as impulsiveness, depression, alterations in eating
habits and obsessions and compulsions (Rahman et al., 1999). Swartz et al. (Swartz et
al., 1997) have demonstrated in preliminary studies that it is possible to ameliorate
many of these specific symptoms, including impulsivity, depression, carbohydrate
craving and compulsions, in fvFTD patients by using serotonin-boosting compounds
(Swartz et al., 1997).  Recently, however, administration of the SSRI paroxetine was
found  to  impair  the  ability  to  perform  reversal  shifts  in  the  ID/ED  shift  task  in
patients with frontotemporal dementia (Deakin JB, 2004).
Acquired neurodegeneration: serotonergic vulnerability associated with MDMA-use
Other evidence for cognitive dysfunction associated with putative serotonergic
neurodegeneration may come from studies in former users of MDMA. Longlasting
degeneration of long serotonergic fibres is seen after MDMA-use in animal studies
(Ricaurte et al., 2000) and may also occur in human users (McCann et al., 2000;
McCann et al., 1998; Reneman, 2001). These indirect observations of potential
neurotoxicity are thought to underlie the overtly observed impairments of memory
and mood in abstinent MDMA-users. More specifically it has been hypothesised that
MDMA-users ‘display cognitive deficits in tasks predominantly sensitive to temporal
lobe dysfunction,’ but no deficits in most tasks sensitive to prefrontal functioning
(Fox et al., 2002). This dissociation might be related to a predominant physiological
role of the serotonin system for mnemonic processes, as has been suggested by
neuroanatomy (Buhot et al., 2000) and by ATD studies (Riedel, Klaassen, & Schmitt,
2002). However, it may also be related to a particular vulnerability of the
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hippocampal complex to neurotoxic effects of MDMA (Gouzoulis-Mayfrank et al.,
2003).  Hence,  ATD  may  be  a  model  of  the  serotonergic  depletion  observed  after
MDMA use. A recent report comparing the metabolic and cognitive responses to
ATD of former MDMA users showed that altered serotonin levels (as manifested by
tryptophan levels) as well as impaired memory were the most sensitive markers of
ATD's effects in ex-users of MDMA(Curran & Verheyden, 2003). Furthermore, these
measures  were  related  in  such  a  way  that  altered  metabolism  of  tryptophan  in  ex-
users may reflect serotonergic vulnerabilty, either due to pre-morbid differences in
their serotonin function or due to acquired drug-induced vulnerability (Curran &
Verheyden, 2003).
Treatment options for this group are predominantly antidepressants such as
the reuptake inhibitors of serotonin, as they have been shown to not only elevate
serotonin function, but have also been hypothesised to promote neurogenesis
(Duman et al., 2001; Jacobs et al., 2000). Besides, estrogen, lithium and rolipram
(phosphodiesterase inhibitor) have also been suggested (Duman et al., 2001).
Cognitive dysfunction as a marker of low serotonin in diseases associated with peripheral
serotonergic dysfunction
A high proportion of cancer and hepatitis C patients receiving immune-based therapy
with the cytokine interferon-alpha, develop symptoms of depression and co-morbid
cognitive symptoms such as memory impairment that are indistinguishable from
those found in major  depressive disorders  (Capuron et  al.,  2002).  The mechanism is
poorly understood and could either lead to low serotonin via reduced appetite due to
cytokine treatment or ATD by the cytokine-mediated induction of indoleamine 2,3-
dioxygenase (IDO), the enzyme that accelerates the catabolism of tryptophan, or
both(Capuron et al., 2002). Antidepressant treatment could improve these patients'
conditions of interleukin-induced depression and memory impairment, by
preventing these symptoms to occur and improving compliance with interleukin
therapy. The results of a recent placebo-controlled study of preventive SSRI treatment
seemed to be largely consistent with this hypothesis (Capuron et al., 2003).
In a different group of cancer patients suffering from carcinoid tumors in the
gastrointestinal tract which are known to probably cause a prolonged state of low
serotonin  by  means  of  endogenous  tryptophan  depletion  (Russo  et  al.,  2003),  a
pattern of cognitive performance was observed that did not resemble that observed in
depression, but rather consisted of improved measures of focused attention, similar
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to  the effects  of  ATD previously described in  healthy volunteers  (Coull  et  al.,  1995;
Schmitt et al., 2000).
The sensory function of the intestine is highly serotonergically innervated
(Camilleri, 2001). In patients with irritable bowel syndrome (IBS), serotonin may play
a regulatory role in both gastrointestinal motility and sensitivity, as well as in
affective dysregulation (Kilkens et al., 2003). In IBS there is also a hypothesis of
endogenous tryptophan depletion and clinical benefits of several serotonergic agents
have been shown (Lembo, 2000). Furthermore, it has been reported that greater brain
serotonin synthesis in female IBS patients may be related to the pathological visceral
pain processing of the IBS patients, a larger female predominance of the disorder, and
the sex difference of the efficacy of the 5-HT3 antagonist in treatment (Nakai et al.,
2003). A recent attempt to show the association of peripheral and central serotonergic
dysregulation, has shown that acute lowering of 5-HT synthesis enhances visceral
urge and pain perception, while at the same time inducing memory impairment
manifested  as  affective  memory  bias  (i.e.  preferential  loss  of  memory  for  positive
emotions), presumably through serotonergic modulation of the 'brain-gut axis'
(Kilkens et al., 2004). Treatment of IBS with 5-HT3 antagonists is aimed at improving
peripheral serotonergic function. 5-HT3 antagonists have been studied for cognition
enhancement, but clinical trials in AD and mild cognitive impairment have failed.
Concluding remarks
Healthy volunteer  studies  have provided support,  of  varying strength,  for  a  role  of
serotonin in a number of human cognitive functions. The most robust evidence is
available for human episodic memory functions and particularly the detrimental
effects  of  low  brain  serotonin  on  long-term  memory  consolidation  are  quite
consistently found. At the same time, it must be noted that the experimental data on
serotonin inhibition and human memory are only available from studies using one
specific method to lower central serotonin neurotransmission, namely ATD. The
memory deficits that are associated with prolonged MDMA use, presumably caused
by  MDMA’s  neurotoxic  effects  on  the  serotonin  system,  provides  indirect
corroborating evidence, but currently there are no data on the memory effects of, for
example, 5-HT antagonists. Furthermore, it appears to be difficult to ascertain any
consistent effects of increased central serotonin on memory in healthy volunteers. A
similar pattern is seen for the notion that serotonin is involved in focused attention
and cognitive flexibility, which is largely based on results of ATD studies, and
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serotonin’s  effect  on  vigilance,  which  is  solely  based  on  SSRI  studies.  Overall,  the
findings of serotonin modulation of cognition in healthy volunteers are characterized
by quite consistent and selective effects of cognitive changes, predominantly
performance decrements, following serotonin manipulations in one direction
(inhibition or stimulation), without clear evidence of mirrored behavioral effects of
opposite serotonin manipulations. This may be due to several factors. As mentioned
earlier, it may easier to induce performance decrements than to enhance cognitive
performance in healthy volunteers who have a close to optimal performance level.
Secondly, relatively few serotonin challenge studies have been performed, using
varying pharmacological manipulations, dosages, methods of administration, and
treatment regimes, which all can affect the actual level of central serotonin effects that
are achieved, and hence the behavioral outcome of the manipulation. In addition, it is
unclear if the relationship between serotonin activity and cognitive function is a
linear  one,  or  instead follows an inverted U-curve,  as  has  been proposed for  frontal
DA activity and working memory functions (Lidow et al., 2003). In latter case, the
behavioral effect would be the combined result of baseline serotonin activity and the
level of pharmacological stimulation, with the possibility of performance decrements
through overstimulation. At this point, however, there is insufficient data to either
support or dismiss an inverted-U curve hypothesis.
While the potential for cognition enhancement by serotonin drugs in healthy
volunteers remains to be established, restoration of impaired cognitive performance
due to serotonin dysfunction is more viable potential target for serotonin drugs. The
observed long-term memory deficits in depression are consistent with the ascribed
role  of  serotonin  in  memory  formation,  and  evidence  suggest  that  serotonin
stimulation may have particular beneficial effects on memory in these patients. Yet, a
clear evaluation of the cognitive effects of 5-HT antidepressants in most clinical trials
is  hampered by a  lack of  control  groups.  Furthermore,  5-HT drug effects  have been
almost exclusively assessed in a limited subpopulation, namely elderly depressed
patients. Also, from the existing data, it is difficult to dissociate the direct effects of
serotonin augmentation on cognition from those that are mediated by alleviation of
other symptoms of depression. Comparative studies, assessing the additional value,
with regard to cognition, of 5-HT drugs over other effective antidepressant therapies,
i.e. non-serotonergic antidepressants and non-pharmacological interventions, would
provide further insight into this matter. Low serotonin has also been implicated in
aging, AD and fvFTD, but it is unclear to what extent these serotonergic changes are
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responsible for the observed cognitive problems. Little work has been done in this
area,  but  evaluation  of  the  cognitive  effects  of  pro-serotonergic  drugs  in  these
populations could lead to new fundamental insights in the neurobiology of these
conditions, and, if successful, lead to new (co-) treatment strategies and drug
development targets for these conditions.
Generally, impaired cognitive function is likely to be the resultant of a set of
interacting neurobiological changes, rather than a single factor. Serotonergic
dysfunction is unlikely to be the sole cause of cognitive impairment in any condition
of  illness,  but  given  the  mounting  evidence  of  serotonin  involvement  in  variety  of
cognitive functions, loss of integrity of the central serotonergic system may certainly
contribute, in various degrees, to cognitive deterioration. As such, the serotonergic
system has become a target for pharmacological cognitive enhancement. The
challenge for  future  research is  to  seek out  those conditions in  which low serotonin
significantly contributes to cognitive decline. Furthermore, future research aimed at
clarifying the nature of the relationship serotonin and human cognition, identification
of the role of 5-HT receptor subtypes, and the potential functional interactions
between serotonin and other neurotransmitter systems that may underlie serotonin
modulation of cognition, would be essential for understanding the full potential of 5-
HT drugs as cognition enhancers, even in healthy individuals.
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Chapter 3
Actual driving performance and psychomotor
function in healthy subjects after acute and
subchronic treatment with escitalopram,
mirtazapine and placebo
Abstract
Objective: The effects of escitalopram 10-20 mg/day and mirtazapine 30-45 mg/day on actual driving and
psychomotor performance of 18 healthy subjects were determined in a randomized, double-blind, placebo-
controlled, multiple-dose, 3-way crossover trial. Method: Each treatment period lasted for 15 days and was
separated from the next period by a washout period of at least 13 days. Subjects received an evening dose
of escitalopram 10mg, mirtazapine 30mg, or placebo from Days 1-7 and an evening dose of escitalopram
20mg, mirtazapine 45mg, or placebo from Days 8-15. On Days 2, 9, and 16, reflecting acute period, dose
increase, and steady state respectively, the Road Tracking test was performed. The main parameter was
Standard Deviation of Lateral Position. Psychomotor performance was also assessed on Days 2, 9, and 16
by laboratory computer tasks. Subjective sleep quality was measured and mood was measured by visual
analogue scales. Results: Treatment differences were apparent during the acute treatment period, in which
subjects treated with mirtazapine 30mg performed less well in the driving test as compared to placebo. The
Divided Attention Task results also revealed a significant increase in tracking error after a single dose of
mirtazapine 30mg as compared to placebo. Mirtazapine decreased feelings of alertness and contentedness.
Mirtazapine did not affect performance on days 9 and 16 of treatment. Escitalopram did not affect driving,
psychomotor performance or subjective mood throughout treatment. Conclusion: In conclusion, driving
performance, as well as psychomotor functioning, was not affected by escitalopram treatment in healthy
subjects. Driving performance was significantly impaired after ingestion of mirtazapine 30 mg during the
acute treatment period.
Wingen,  M.,  Bothmer,  J.,  Langer,  S.,  &  Ramaekers,  J.  G.  (2005).  Actual  driving
performance  and  psychomotor  function  in  healthy  subjects  after  acute  and
subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.
Journal of clinical psychiatry, 66(4), 436-443.
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Introduction
Escitalopram is the S-enantiomer of citalopram and it is the most selective serotonin
reuptake inhibitor (SSRI). Escitalopram treats major depressive disorder effectively
(Lepola et al., 2003) and has been shown to be superior to citalopram (Auquier et al.,
2003). The standard dose is 10 or 20 mg daily and the most common side-effect is
nausea (Aronson & Delgado, 2004). Mirtazapine is a noradrenergic and specific
serotonergic antidepressant (NaSSA) and its therapeutic effect is derived by blockade
of  the  ?2-adrenoceptors  and  by  indirect  stimulation  of  the  5-HT1 receptors, via
blockade of 5-HT2 and 5-HT3 receptors (De Boer & Ruigt, 1995). Mirtazapine has
shown antidepressant efficacy in placebo-controlled trials (Anttila & Leinonen, 2001).
The  most  prominent  side-effects  of  mirtazapine  are  drowsiness  or  sedation,  dry
mouth, increased appetite, and weight gain (Kasper et al., 1997; Montgomery, 1995).
Sedation is attributed to mirtazapine’s high affinity for blocking the histaminergic H1
receptor (Anttila & Leinonen, 2001). The sedative effects of mirtazapine may
potentially last for a prolonged period, as the drug possesses an elimination half-life
of 20-40 hours.
Antidepressants can have an impairing effect on psychomotor function and car
driving due to  side-effects,  such as  sedation,  blurred vision or  dizziness.  These side
effects  may  reduce  the  driving  ability  of  depressed  patients.  However,  not  all
antidepressants influence driving ability to the same extent. In cases of severe major
depression, an effective antidepressant with few side effects, may even improve
driving performance when alleviating the depression (Grappe et al., 1998;
Hindmarch, 1995, 1997). Selective antidepressants, such as selective serotonin
reuptake inhibitors (SSRIs) are known to have less impairing effects on car driving
than tricyclic antidepressants (TCAs) in depressed patients (Brunnauer & Laux, 2003).
In addition, driving should be contraindicated during the starting phase of treatment
with TCAs, because of the sedating effects that appear immediately after acute doses
(Ramaekers, 2003). A few studies have determined the effects of citalopram or
escitalopram on psychomotor performance and tasks related to driving performance
in healthy volunteers. An acute dose of citalopram 10 mg showed comparable effects
to  placebo  on  a  number  of  psychomotor  tests  and  on  a  driving  simulator  test
(Wilkinson et al., 2003). Herberg (2001) (Herberg, 2001) found that citalopram 20 and
40 mg daily did not impair psychomotor performance in healthy subjects. In another
placebo-controlled study, an improvement in choice reaction time and critical flicker
fusion threshold was shown, 1 to 4 hours after citalopram 20 mg administration
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(Nathan et al., 2000). Other psychomotor tests showed no improvement, i.e. the digit
symbol substitution test and the trailmaking B test (Nathan et al., 2000). After 1 and 8
days administration of 10, 20 and 40 mg citalopram, there were no detrimental effects
on psychomotor functioning, including the choice reaction time test and
compensatory tracking, compared to placebo (Fairweather et al., 1997). In general, it
can be said that citalopram is free of impairing psychomotor effects. There are some
indications that citalopram as well as escitalopram in some degree decreases
vigilance (Edgar et al., 2004; Riedel et al., 2005; Schmitt, Riedel et al., 2002). The
relevance of this finding for actual driving performance is however presently unclear.
No  previous  studies  have  been  carried  out  to  assess  the  effects  of  citalopram  or
escitalopram on actual driving performance.
The  aim  of  the  present  study  was  to  compare  the  influence  of  acute  and
subchronic treatment with escitalopram and mirtazapine on actual driving
performance and psychomotor functioning in healthy subjects.
Materials and methods
Subjects
Eighteen healthy subjects, 9 men and 9 women, mean age (sd): 31,4 (5,8), were
recruited by advertisement in local newspapers. Subjects were screened by a
telephone interview and a health questionnaire and all underwent a medical
examination (including a standard 12- lead electrocardiogram, blood haematology
and chemistry, urinalysis and drug and pregnancy screening). Selection was based on
the following inclusion criteria: possession of a valid driving license for more than 3
years,  driving experience of  >5000 km per  year  in  average,  normal  binocular  visual
acuity  corrected  or  uncorrected  and  body  mass  index  between  19  to  29  kg/m2.
Subjects who met one or more of the following criteria were excluded from the study:
history or present evidence of a serious illness such as renal, hepatic, cardiovascular,
pulmonary, endocrine, neurological or psychiatric, haematological, gastrointestinal
diseases,  medical  history  of  glaucoma,  pregnancy  (as  determined  at  screening)  or
breastfeeding,  known  hypersensitivity  to  medicinal  drugs,  treatment  with  an
investigational drug within 3 months prior to screening, use of medicines (except oral
contraceptives and paracetamol), excessive smoking (more than 10 cigarettes a day),
overconsumption of alcohol (more than 35g ethanol a day, comparable to 3,5
standard drinks) or caffeine (more than 6 cups of regular coffee a day), positive result
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of urine drug screening at the screening visit for alcohol and/or drug of abuse, positive
result of HCV antibody or HBs antigen testing or blood donation.
The  study  was  approved  by  the  standing  medical  ethics  committee  of  Maastricht
University and it was carried out in accordance with the World Medical Association’s
Declaration of Helsinki (Edinburgh, 2000). Written informed consent was obtained
from each subject prior to participation.
Design and treatments
The study was a randomized, double-blind, placebo-controlled, 3-way crossover
design. Treatments were administered in separate 15-day series and treatment orders
were balanced and assigned by a pre-determined randomization schedule. Subjects
received 10 mg/day escitalopram on Days 1 to 7 followed by 20 mg/day
escitalopram on Days 8 to 15, 30 mg/day mirtazapine on Days 1 to 7 followed by 45
mg/day mirtazapine on Days 8 to 15 or placebo. Drugs and placebo were always
ingested at fixed times in the evening. Dosing started the evening before (Day 1) the
first test day (Day 2).The treatment sessions were separated by washout periods of at
least 13 days.
Testing Procedure
Subjects were trained in two sessions, one week prior to their first treatment
condition in driving and psychometric tests to minimize learning effects. Training in
the Critical Tracking Task and the Divided Attention task (see detailed descriptions
below)  continued  until  the  subject  had  performed  each  test  with  less  than  5%
variance from the average over the final three trials. The assessments were done on
Days 2 (referred to as acute), Day 9 (dose increase) and Day 16 (steady state) of each
treatment series, 12 to16 hours after drug administration. Subjects were not allowed
to  consume  alcohol  48  hours  prior  to  testing  and  caffeine-containing  beverages  4
hours  prior  to  testing.  On  each  test  day,  subjects  were  screened  for  alcohol  use  in
breath and for recent drug use in urine for opiates, methadone, cocaine,
amphetamines, ecstasy and cannabinoids. During testing, subjects were not allowed
to smoke. Subjects arrived at 9.00 a.m. and psychometric tests started at 9.30 a.m. The
driving test started at 10.30 a.m.
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Actual Driving Performance (Road Tracking Test)
In the Road Tracking Test (O'Hanlon, 1984), subjects operated a specially
instrumented vehicle over a 100 km primary highway circuit while maintaining a
constant speed (95 km or 58 miles per hour) and a steady lateral position between the
delineated boundaries of the right (slower) traffic lane. The vehicle was dual-
controlled and the subject was accompanied by a driving instructor. An electro-
optical device mounted at the rear of the car continuously measured lateral distance
separating the vehicle and the left lane-line. This signal was digitised at a rate of 4 Hz
and  stored  on  an  onboard  computer  disk  file  for  later  editing  analysis.  The  off  line
editing routine involved removal of all data segments that revealed signal loss,
disturbance or occurrence of passing manoeuvres. The remaining data were then
used to calculate means and variances for lateral position and speed (SP). Standard
deviation of lateral position (SDLP in cm) was taken as a variable. SDLP is a measure
of road tracking error; in practical terms, a composite index of allowed weaving,
swerving and overcorrecting. The standard deviation of the speed (SDSP) was also
taken as a performance measure. The test duration was to be about 1 hour; the actual
test duration varied between 45 and 120 minutes.
Critical Tracking Task
Critical Tracking Task (CTT) (Jex et al., 1966) measures the subject’s ability to control
a  displayed  error  signal  in  a  first-order  compensatory  tracking  task.  Error  was
displayed  as  an  increasing  horizontal  deviation  of  a  cursor  from  the  midpoint  on  a
horizontal, linear scale. Compensatory joystick movements nulled the error by
returning the cursor to the midpoint. The frequency, at which the subject lost control,
was the critical frequency or lambda c (lc ) in rad/s. The test included 5 trials of which
the lowest and the highest scores were discarded; the average of the remaining scores
was taken as the final score.
Divided Attention Task
Divided Attention Task (DAT) (Moskowitz, 1973) measures the ability to divide
attention between two tasks performed simultaneously. Firstly, the subject performed
the same tracking task as  described above but  at  a  constant  level  of  difficulty  set  at
50% of his/her maximum capacity for 12 minutes. Tracking error is measured as the
difference in millimetre between the position of the cursor and the midpoint of the
scale. Secondly, the subject monitored 24 peripheral displays upon which single
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digits change asynchronously at 5 seconds intervals. The occurrence of the digit “2”
was a  signal  for  the subject  to  remove the foot  from a pedal  as  rapidly as  possible.
Signals  occurred  twice  at  every  location,  in  random  order,  at  intervals  of  5  to  25
seconds.  Mean  absolute  tracking  error  (DATte  in  mm)  and  average  reaction  time
(DATrt in ms) were taken as variables.
Syntactical Reasoning Task
A series of 32 sentences were presented to the subject. Each described the order of the
two letters; e.g. “B follows A”. Each sentence is followed immediately by the same
letters, printed on the computer screen; e.g. “AB”. In half of the trials the order was
the same as described by the preceding sentence and in the other half of the trials the
order was opposite. Sentence difficulty varies within the series, from simple active
sentences as given above to more complicated sentences involving passives,
negatives or both; e.g., “B is not followed by A”. The required response was to
indicate as quickly as possible using appropriate push buttons whether or not the
pair  of  letters  was  in  the  same  order  as  given  in  the  preceding  sentence.  This  task
measures working memory (Baddeley, 1968). Correct number of responses (SRTcr)
and mean reaction time (SRTrt) were the measurements.
Digit-Symbol Substitution Task
The Digit-Symbol Substitution Task (DSST) is a computerised version of the original
paper and pencil test taken from the Wechsler Adult Intelligence Scale (Wechsler,
1981) and is a measurement of psychomotor speed, concentration and attention. The
subject was briefly shown an encoding scheme consisting of a row of squares at the
top  of  the  screen,  in  which  9  digits  were  randomly  associated  with  particular
symbols. The same symbols were presented in a fixed sequence at the bottom of the
screen as a row of separate response buttons. The randomization procedures were
chosen such that symbols never appeared at the same ordinal position within both
rows. The encoding scheme and the response buttons remained visible while the
subject was shown successive presentations of a single digit at the centre of the
screen.  The task was to  match each digit  with a  symbol  from the encoding list  and
click  the  corresponding  response  button.  The  number  of  digits  correctly  encoded
within 3 minutes was the performance measure (DSSTcr).
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Subjective measurements
Different visual analogue scales were used to assess subjective measurements of
mood and drug effects  on driving,.  In  addition,  each test  day subjects  filled out  the
Groninger Sleep Quality Scale (Mulder-Hajonides van der Meulen, 1981) to assess
sleep quality during the preceding night. The measurements were a total score of 14
yes/no questions to score the number of sleep complaints (ranging from good sleep
(score 0) to worst possible sleep (score 14)) and specific questions about time needed
to fall  asleep,  number of  awakenings during the night  and sleep duration in  hours.
Adverse  events,  observed,  spontaneous  reported  by  the  subject  or  elicited  upon  a
non-leading question were recorded. After the psychometric tests, subjects were
asked to assess their mood by filling in a 16-item mood scale from which the factors
Alertness, Contentedness and Calmness were derived (Bond & Lader, 1974). Subjects
were  asked  to  rate  their  driving  performance  after  the  road  tracking  test  and  the
driving  instructor  was  asked  to  rate  the  driving  performance  and  the  degree  of
sedation of the subject after the road tracking test.
Pharmacokinetics
Blood samples for serum drug level analysis were collected on day 2, 9 and 16 of each
treatment period using the following procedure: peripheral venous access was
established and the required blood sample of 7 ml whole blood was taken. The blood
samples were analysed for serum concentration of escitalopram, the S-enantiomer
and R-enantiomer of the metabolites demethylcitalopram (DCT) and
didemethylcitalopram (DDCT), and for mirtazapine by means of a validated analysis
method according to the principles of Good Laboratory Practice.
Statistical analyses
Sample size was based on a power calculation for detecting a treatment difference of
2.0  cm or  more on the primary measure,  i.e.  Standard Deviation of  Lateral  Position
(SDLP). A treatment difference of 2.4 cm was found to be clinically relevant which
corresponds with a blood alcohol concentration (BAC) of 0.5 mg/ml in a study with
social drinkers performing the same Road Tracking Test (Louwerens et al., 1987) The
power of detecting a mean difference of 2.0 cm was calculated to be greater than 90%
using the non-central T- distribution, with the within subject standard deviation
being 2.1 cm as estimated in previous studies carried out by the Maastricht University
research group.
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Parameters  of  the road tracking test,  psychometric  tests  and subjective mood scales
were subject to ANOVA analyses with Subject, Treatment and Period as factors.
Driving and psychomotor data were analyzed for each test day separately. In case of
a main treatment effect, drug-placebo effects were determined using simple contrasts.
The  results  of  the  Groninger  Sleep  Quality  scale  were  not  normally  distributed.  To
examine the main treatment effects, the variables were analyzed by the Friedman Test
(nonparametric). In case of a significant treatment effect, drug-placebo comparisons
were defined through the Wilcoxon signed-rank test (nonparametric). All statistical
tests were conducted using SPSS (version 11.5 for Windows).
Results
Missing data
A total of 18 subjects completed the study. The road tracking test was interrupted by
the driving instructor in one subject after treatment with mirtazapine 30 mg/day
(Day 2) because he fell asleep while driving. In this case, the remaining data (64%
complete) were used to calculate driving measurements. There were no missing data
concerning the psychometric test. One subject did not complete the Groninger Sleep
Quality scale Questionnaire during the second day of placebo treatment. These
incomplete data were treated as missing values.
Driving and psychometric tests
Summary  of  the  results  of  the  driving  test  and  the  psychometric  tests  is  shown  in
Table 1. Standard deviation of lateral position (SDLP) showed a significant effect of
Treatment  and  Period  (F2,32=5.59, p<0.05) on Day 2. Drug-placebo comparisons
revealed an impairing effect of mirtazapine (30 mg), but not of escitalopram (10 mg).
No interaction was found between Treatment  and Period.  Treatments  did not  affect
SDLP  on  Days  9  and  16.  Results  of  the  SDLP  are  presented  in  Figure  1.  Mean  (se)
tracking error in the divided attention task is presented in Figure 2 for each treatment
condition. Significant effects of Treatment and Period (F2,32=3.46, p<0.05) were found
on  tracking  error  in  the  divided  attention  task  on  Day  2.  Mirtazapine  (30  mg)
significantly increased tracking error, as demonstrated by drug-placebo contrasts.
Escitalopram (10 mg) had no effect on tracking error on Day 2 compared to placebo.
No interaction was found between Treatment and Period. There were no significant
Treatment  effects  demonstrated  on  Days  9  and  16.  For  the  remaining  performance
measurements, no statistically significant effects of Treatment were established.
ESCITALOPRAM AND MIRTAZAPINE IN PSYCHOMOTOR FUNCTION
51
Figure 1 Mean (SE) standard deviation of lateral position (SDLP) after 2, 9 and 16
days of treatment with escitalopram, mirtazapine and placebo
* p<0.001
Figure 2 Mean (SE) tracking error of the divided attention task after 2, 9 and 16 days
of treatment with escitalopram, mirtazapine and placebo.
* p<0.05
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Subjective measurements
Summary of the results of subjective mood measurements are shown in Table 1.
Alertness and Contentedness were significantly affected by Treatment on day 2.
Drug-placebo comparisons revealed that mirtazapine (30 mg) reduced alertness and
contentedness. No significant Treatment effects were demonstrated on day 2 for the
factor calmness or on day 9 and 16 for the three factors.
Summary of the results of Groninger Sleep Quality Scale and subjective driving
measurements are shown in Table 2. Friedman Test revealed effects of Treatment on
sleep duration on nights 1 and 15. Drug-placebo comparisons showed that
escitalopram significantly reduces sleep duration by 67 minutes, whereas mirtazapine
increased sleep duration by 58 minutes during the first night of treatment. Other
drug-placebo comparisons did not reveal significant differences.
Effects of Treatment on day 2 were significant for the ratings of driving performance
by the driving instructor and by the subjects. Drug-placebo comparisons however
revealed no significant treatment effects on driving performance rated by the driving
instructor. Subjects rated their driving performance worse after mirtazapine (30 mg)
treatment, demonstrated by placebo-drug comparisons. There was also a significant
Treatment  effect  on day 9  on driving performance as  rated by the subjects,  but  this
could not be attributed to any of the drugs as compared to placebo.
 Adverse events
The adverse events with the highest incidence in the escitalopram group were
fatigue, insomnia and headache, followed by nausea (Table 3). In the mirtazapine
group,  the  adverse  event  with  the  highest  incidence  was  fatigue,  followed  by
insomnia and headache. In the placebo group, fatigue, insomnia and headache
occurred most frequently.
Pharmacokinetics
Mean (SD) plasma concentrations for escitalopram were 20.17 (4.60) nmol/L at Day 2,
71.44 (27.89) nmol/L on Day 9 and 97.78 (41.46) nmol/L on Day 16. Mean (SD)
plasma concentrations for mirtazapine were 67.67 (16.52) nmol/L on Day 2, 166.07
(52.64) nmol/L on Day 9 and 203.67 (98.48) nmol/L on Day 16. The values were
within the expected therapeutic range.
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Table 1. Summary of the results of the driving test, psychometric tests and subjective
mood measurements
Mean (standard error of mean) Treatment effect Contrast analyses
Overall ESC vs PLA MIR vs PLA
Day PLA ESC MIR F df p p p
SDLP 2 17.9 (0.72) 18.1 (0.87) 21.8 (1.36) 13.1 2,32 <.001 ns <.001
(cm) 9 18.2 (0.87) 19.2 (0.97) 19.5 (1.03) 2.34 2,32 ns
16 18.6 (1.01) 19.4 (0.94) 19.2 (0.94) .503 2,23 ns
SDSP 2 1.68 (0.09) 1.61 (0.08) 1.68 (0.09) .470 2,32 ns
(km/h) 9 1.71 (0.11) 1.72 (0.11) 1.66 (0.08) .108 2,32 ns
16 1.68 (0.82) 1.76 (0.08) 1.68 (0.07) .578 2,32 ns
CTT 2 4.17 (0.18) 4.20 (0.18) 3.96 (0.17) 2.60 2,32 ns
(rad/s) 9 4.08 (0.17) 4.20 (0.16) 4.02 (0.16) 1.62 2,32 ns
16 4.28 (0.16) 4.21 (0.15) 4.19 (0.14) .516 2,32 ns
DATte 2 17.0 (0.96) 15.5 (0.91) 19.1 (1.14) 7.65 2,32 .002 ns .032
(mm) 9 17.2 (1.26) 16.0 (0.81) 18.0 (1.13) 1.96 2,32 ns
16 16.2 (1.03) 16.0 (1.07) 17.0 (1.01) .749 2,32 ns
DATrt 2 1683 (79) 1633 (56) 1717 (60) 1.12 2,32 ns
(ms) 9 1727 (80) 1659 (67) 1671 (63) .687 2,32 ns
16 1646 (59) 1616 (65) 1612 (53) .233 2,32 ns
SRTcr 2 22.7 (1.53) 23.4 (1.48) 23.7 (1.60) .516 2,32 ns
(#) 9 24.0 (1.63) 24.3 (1.32) 23.6 (1.50) .348 2,32 ns
16 23.4 (1.69) 25.3 (1.19) 23.3 (1.44) 1.17 2,32 ns
SRTrt 2 1489 (94) 1530 (88) 1613 (85) 2.27 2,32 ns
(ms) 9 1417 (93) 1474 (98) 1483 (88) .603 2,32 ns
16 1430 (92) 1463 (81) 1406 (85) 2.79 2,32 ns
DSSTcr 2 76.1 (2.76) 77.2 (2.35) 75.1 (2.16) .945 2,32 ns
(#) 9 78.1 (2.88) 78.9 (2.45) 77.0 (1.92) .629 2,32 ns
16 79.6 (2.07) 78.8 (2.02) 78.4 (2.11) .279 2,32 ns
Alertness 2 79.2 (3.88) 74.6 (4.65) 60.3 (5.10) 11.9 2,32 <.001 ns <.001
(mm) 9 71.5(5.15) 73.6 (3.68) 68.9 (5.52) .812 2,32 ns
16 76.9 (5.78) 76.0 (4.28) 71.3 (4.53) 1.70 2,32 ns
Conten- 2 85.3 (3.42) 82.7 (3.55) 80.5 (3.51) 4.24 2,32 0.023 ns .007
tedness 9 81.5 (3.72) 83.9 (3.51) 80.8 (4.35) 1.35 2,32 ns
(mm) 16 84.9 (3.54) 84.8 (3.94) 83.6 (3.80) .235 2,32 ns
Calmness 2 83.7 (4.06) 80.1 (4.68) 83.1 (4.14) 3.05 2,32 ns
(mm) 9 83.6 (3.38) 81.9 (4.72) 85.2 (3.21) .502 2,32 ns
16 87.8 (2.54) 81.9 (4.58) 82.3 (3.68) 1.74 2,32 ns
Treatments are placebo (PLA), escitalopram 10-20 mg (ESC) and mirtazapine 30-45 mg (MIR), df = degrees
of freedom, ns = not significant
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Table 2. Summary of the results of the Groninger Sleep Quality Scale and subjective
driving measurement
Mean (standard error of mean) Treatment effect Contrast analyses
Overall ESC vs PLA MIR vs PLA
Night PLA ESC MIR F df p p p
Sleep 1 2.29 (0.87) 4.83 (0.96) 3.33 (0.70) 3.23 2,32 ns
complaints 8 3.28 (1.00) 4.72 (0.81) 3.61 (0.52) 2.49 2,32 ns
15 3.56 (0.88) 4.61 (0.99) 2.72 (0.49) 2.27 2,23 ns
Time needed 1 16.4 (4.15) 36.1 (14.5) 17.5 (7.00) 4.13 2,32 ns
to fall asleep 8 17.6 (4.23) 15.4 (3.09) 25.0 (7.62) 0.13 2,32 ns
 (min) 15 22.1 (4.85) 21.4 (4.41) 21.8 (4.52) 0.98 2,32 ns
# Awakenings 1 0.94 (0.38) 2.11 (0.54) 1.29 (0.34) 4.33 2,32 ns
8 1.44 (0.33) 1.44 (0.35) 1.17 (0.39) 2.72 2,32 ns
15 1.14 (0.33) 1.83 (0.48) 0.61 (0.22) 5.77 2,32 ns
Sleep duration1 7.24 (0.23) 6.12 (0.39) 7.82 (0.28) 13.7 2,32 .001 .007 .05
(hours) 8 7.11 (0.34) 7.10 (0.22) 7.56 (0.32) 2.86 2,32 ns
15 7.28 (0.32) 6.76 (0.24) 7.78 (0.22) 12.76 2,32 .002 ns ns
Day
Driving rated 2 77.4 (4.62) 71.3 (4.79) 12.3 (53.7) 6.37 2,32 0.041 ns 0.025
by subject 9 75.4(5.15) 65.4 (5.02) 67.7 (5.50) 6.68 2,32 0.036 ns ns
(mm) 16 71.9 (5.6) 63.0 (3.89) 66.3 (5.09) 3.44 2,32 ns
Driving rated 2 81.1 (2.23) 79.2 (2.69) 74.8 (3.27) 6.96 2,32 0.031 ns ns
by instructor 9 76.6 (3.82) 75.0 (3.58) 78.3 (4.35) 1.94 2,32 ns
(mm) 16 77.1 (3.06) 71.3 (4.75) 74.4 (3.47) 1.53 2,32 ns
Sedation rated 2 19.5 (6.01) 20.9 (6.70) 28.2 (7.16) 1.34 2,32 ns
by instructor 9 18.3 (5.94) 20.0 (5.15) 18.2 (5.83) 0.76 2,32 ns
(mm) 16 20.2 (5.78) 26.0 (5.58) 18.4 (4.30) 2.66 2,32 ns
Treatments are placebo (PLA), escitalopram 10-20 mg (ESC) and mirtazapine 30-45 mg (MIR), df = degrees
of freedom, ns = not significant
Table3. Number and percentages of most common adverse events
Preferred Term PLA (n=18) ESC (n=18) MIR (n=18)
Fatigue 3 (16.7%) 6 (33.3%) 11 (61.1%)
Insomnia 3 (16.7%) 4 (22.2%) 2 (11.1%)
Somnolence 1 (5.56%) 4 (22.2%) 7 (38.9%)
Headache 3 (16.7%) 4 (22.2%) 2 (11.1%)
Dizziness 1 (5.56%) 3 (16.7%) 5 (27.8%)
Dry mouth 1 (5.56%) 3 (16.7%) 1 (5.56%)
Nausea 2 (11.1%) 3 (16.7%) 1 (5.56%)
Agitation 0 (0) 1 (5.56%) 0 (0)
Treatments are placebo (PLA), escitalopram 10-20 mg (ESC) and mirtazapine 30-45 mg
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Discussion
The main goal of the present study was to compare the effect of different evening
doses of escitalopram and mirtazapine on actual driving performance as measured by
the  subjects’  mean  standard  deviation  of  lateral  position  (SDLP)  during  the  Road
Tracking Test. Results from the present study showed that escitalopram did not affect
driving performance in the acute (10 mg), dose increase (20 mg) or steady state
treatment phase. Mirtazapine, on the other hand, produced driving impairment after
the initial dose as indicated by a significant rise in mean SDLP compared to placebo.
In  the  case  of  one  subject  the  driving  test  could  not  be  completed  due  to  excessive
sleepiness after a single dose of mirtazapine 30 mg. Mirtazapine’s detrimental effect
on driving decreased over time and was no longer of clinical relevance after repeated
dosing. Escitalopram (10-20 mg) did also not affect psychomotor function after single
and repeated doses. Mirtazapine impaired tracking in a divided attention task. This
effect  however  was  only  apparent  after  a  single  dose  and  not  after  repeated  drug
administration. On the first night of treatment, subjective measurements of sleep
showed a reduction of sleep duration after escitalopram administration and an
increase of sleep duration after mirtazapine administration. In addition, subjective
measurements of driving performance showed that subjects rated their driving
performance much worse after mirtazapine 30 mg treatment.
Results of the present study are fully in line with current notions regarding
the effects of escitalopram and mirtazapine on psychomotor and/or driving
performance.  Escitalopram  is  a  SSRI  and  SSRIs  have  generally  been  shown  to
produce no or little effect on psychomotor function and cognition. Mild psychomotor
or cognitive impairment is most likely to occur for SSRIs possessing some affinity for
muscarinic receptors such as paroxetine and fluvoxamine, or for ?1 receptors such as
nefazadone (see review: (Ramaekers, 2003)). Escitalopram, however, is the most
selective SSRI available and possesses no affinity for additional receptors systems (see
review: (Aronson & Delgado, 2004)). The absence of any driving and psychomotor
impairment in the present study provides further evidence that therapeutic doses of
escitalopram do not affect driving performance.
Mirtazapine is an ?2 antagonist that is known to possess strong, antagonistic
binding affinities for postsynaptic serotonergic and histaminergic receptors. The
antagonistic effect on histaminergic H1 receptors is not thought to mediate
therapeutic effects. Rather H1 blockade causes somnolence and sedation that may
result in performance impairment on a range of activities. The sedative effects of
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mirtazapine may potentially last for a prolonged period, as the drug possesses an
elimination half-life of 20 to 40 hours. Consequently, mirtazapine is generally given at
night to promote sleep and reduce daytime drowsiness.
Several  investigations  about  the  effects  of  mirtazapine  on  psychomotor
function and driving in healthy volunteers have been reported. Ramaekers et al
(1998) assessed the effect of evening doses of mirtazapine for 15 days. Actual driving
and psychomotor assessments were conducted on days 2, 8, 9 and 16 of each period.
Subjects received mirtazapine in doses of 15mg and 30mg nocte during the first and
second week of dosing respectively. Mirtazapine 15mg nocte increased Standard
Deviation  of  Lateral  Position  (the  main  driving  parameter)  by  2,2cm  after  the  first
dose  which  was  less  than  shown  by  social  drinkers  performing  the  same  Road
Tracking Test with a blood alcohol concentration (BAC) of 0.5 mg/ml (Louwerens et
al., 1987). The magnitude of mirtazapine induced impairment was much less than
those reported in other studies. Mattila et al (1989)  (Mattila et al., 1989) for example,
reported that single doses of mirtazapine 15mg and amitriptilyne 50mg produced
severe and comparable psychomotor impairment after administration in the morning.
The main difference with the study design of Ramaekers et al (1998) lies in the time of
drug  administration,  namely  at  the  test  day  or  at  the  evening  before  the  test  day.
Consequently, Ramaekers et al (1998) has suggested that the sedative effect of
mirtazapine on daytime performance might be much alleviated by nocturnal
administration. This notion has recently been confirmed by Ridout et al (Ridout et al.,
2003) who assessed the psychomotor effects after evening and daytime doses of
mirtazapine (15-30 mg) in a single, comparative placebo-controlled study over a 5
day period. Day time doses of mirtazapine 15mg significantly impaired performance
in a Brake Reaction Time test on the first day of treatment. A single nocturnal dose of
mirtazapine 15 mg however did not affect brake reaction time after single and
repeated doses. In addition, both drug regimens did not affect driving performance
after 5 days of dosing. These studies thus seem to suggest that the impairing potential
of mirtazapine in whole or in part is mitigated by nocturnal dosing or sleep. In
addition, the degree of daytime performance impairment during mirtazapine
treatment may also depend on the starting dose. The three studies above have
assessed mirtazapine 15mg doses during treatment initiation, whereas in medical
practice mirtazapine treatment is often started at higher doses, i.e. 30mg. Data from
the present study thus may provide complementary information on the impairing
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effects of mirtazapine treatment on daytime performance, complementary during
treatment initiation.
As it turned out in the present study study, an evening dose of mirtazapine
30 mg significantly impaired actual driving performance and psychomotor function
after the first night of treatment. The drug increased SDLP by 3.9 cm as compared to
placebo  in  the  Road  Tracking  Test.  The  effect  of  mirtazapine  30  mg  in  the  evening
would  be  the  equivalent  of  driving  with  a  blood  alcohol  concentration  (BAC)  of
above 0.5 mg/ml (Louwerens et al., 1987), i.e. the BAC above which drivers have an
elevated risk of becoming involved in a traffic accident (Borkenstein et al., 1974). The
rise in SDLP after the 30mg dose of mirtazapine was also bigger as compared to the
effect of the noctural 15mg dose, i.e. 2,2, cm in the previous driving study (Ramaekers
et al., 1998). The latter elevation in SDLP was associated with a BAC below 0.5 mg/ml
and was generally considered of insufficient magnitude to reduce driver safety. The
present data however demonstrate that the acute, sedative effect of mirtazapine on
driving will become clinically relevant when treatment is started at higher doses,
such as 30mg nocte.
The detrimental effect of mirtazapine on driving performance was primarily
limited to the acute phase of treatment. There was some indication of a rise in SDLP
after mirtazapine dose escalation, but this effect was relatively small in magnitude
and not significantly different from mean SDLP in the escitalopram condition.
Overall, driving performance did not differ during the dose escalation and steady
state compared to placebo. Other measures also demonstrated that mirtazapine
impairment was limited to the acute phase of treatment. Mirtazapine 30mg in the
evening decreased tracking performance in a Divided Attention Task and decreased
feelings of alertness and contentedness. The Critical Tracking task did not show
impairment after mirtazapine 30 mg. Apparently, when the cognitive load
performance is increased by adding a visual search task as in the Divided Attention
Task,  tracking  performance  becomes  more  vulnerable  to  the  impairing  effects  of  a
drug.  None  of  the  effects  were  present  after  1  or  2  weeks  of  repeated  dosing.  The
absence of mirtazapine impairment after repeated dosing is probably related to the
development  of  tolerance.  Many  studies  have  shown  that  tolerance  to  the  acutely
impairing effects of sedative antidepressants on driving performance develops within
a few days of dosing (see review: (Ramaekers et al., 1998)). The implication is that
driving under the influence of a sedative antidepressant such as mirtazapine should
only be contraindicated during the acute phase of treatment.
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A potential limitation of the present study is the restricted age range of the subjects
(21-40 years of age). It is generally believed that elderly people are more vulnerable to
pharmacologic treatment. Generalisation of results from experimental driving studies
in younger volunteers to the elderly population has to be done with caution
(Ramaekers, 2003). The magnitude of driving impairment observed in adult
volunteers  might  only  be  a  conservative  estimate  of  a  drug’s  activity  in  elderly
individuals who appear extra sensitive to pharmacologic treatment, particularly in
case of sedating antidepressants.
In conclusion, escitalopram 10 to20 mg did not affect actual driving,
psychomotor performance and cognitive function in healthy subjects. Mirtazapine
30mg nocte produced significant and clinically relevant impairment of driving and
psychomotor  performance  during  the  acute  treatment  phase.  The  findings  on
psychomotor and driving performance are supported by subjective evaluations.
Mirtazapine decreased feelings of alertness and contentedness; no subjective mood
changes were present during escitalopram treatment. It is recommended to avoid
high doses of mirtazapine during treatment initiation in order to promote safety over
the day. The results from this study show that antidepressants can affect driving
performance differently because of differences in their pharmacodynamic profiles.
Importantly,  broad  class  warnings  about  antidepressants  and  driving  may  not  be
informative enough and should be specified to individual substances.
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Chapter 4
Driving impairment in depressed patients receiving
long-term antidepressant treatment
Abstract
Background: Depression is a common mental disorder with cognitive deficits, but little information is
available on the effects of antidepressant treatment on driving performance in depressed patients.
Aims: Assessing actual driving performance and cognition of depressed patients receiving long-term
antidepressant treatment. Method: Performance was assessed in depressed patients receiving SSRI
(Selective Serotonin Reuptake inhibitor) or SNRI (Serotonin and Noradrenalin Reuptake Inhibitor)
treatment for 6-52 weeks and in matched, healthy controls by means of two standardized on-the-road
driving tests and laboratory tests of cognition. Results: Data  showed  poorer  driving  performance  as
indicated  by  a  higher  Standard  Deviation  of  Lateral  Position  (SDLP)  or  ‘weaving  motion’  in  medicated
patients relative to controls. Time to speed adaptation and Critical Flicker Fusion Threshold were also
impaired in medicated patients. Hamilton Depression Rating Scale scores in medicated patients were
significantly higher as compared to controls. No other significant results between the two groups were
demonstrated on the variables of the driving tests and laboratory tests of cognition. Conclusions: Depressed
patients receiving long-term treatment with SSRI and SNRI type antidepressants show impaired driving
performance. This impairment in driving performance can probably be attributed to residual depressive
symptoms instead the of antidepressant treatment.
Wingen, M., Ramaekers, J. G., & Schmitt, J. A. (2006). Driving impairment in
depressed patients receiving long-term antidepressant treatment. Psychopharmacology,
188(1), 84-91.
CHAPTER 4
60
Introduction
Depression is a common mental disorder that, in addition to affective disturbances, is
characterized by loss of energy and cognitive decline (Austin et al.,  2001; Burt et al.,
1995; Zakzanis et al., 1998). This pattern of symptoms is likely to affect daily
functions, including driving ability. However, despite concerns of both patients and
clinicians regarding driving ability during depression, driving performance of treated
or untreated depressed patients remains poorly investigated.
Epidemiological data show that depression itself and the use of sedative
antidepressants increase the relative risk of depressed patients of becoming involved
in traffic accidents (Leveille et al., 1994; Ray et al., 1992; Vaa, 2003). On the other
hand, selective serotonin reuptake inhibitors and related antidepressants did not
increase crash risk in patients (Barbone et al., 1998). Experimental driving studies
have shown that sedative antidepressants such as TCAs and alpha-2-antagonists
produce driving impairment through 1-2 weeks after treatment initiation (Ramaekers,
2003). However, these experimental driving studies have mainly focused on
measuring antidepressant effects in healthy volunteers rather than in depressed
patients. Only one study assessed the effects of antidepressant treatment with
fluoxetine  and  moclobemide  on  actual  on  actual  road  driving  performance  in  a
depressed patient population (Ramaekers et al., 1997). That study showed that
driving performance did not improve over a 6 week course of treatment with any of
these antidepressants and that driving was not correlated to changes in HAMD
ratings.
Information  on  the  long  term  effects  of  antidepressant  drugs  on  driving  in
depressed patients is presently not available.  In general, it can be expected that non-
sedating antidepressants that are prescribed nowadays produce few side effects and
will produce little or no driving impairment and possibly may even improve driving
performance in depressed patients by alleviating the depressive symptoms. However,
this has never been investigated.
In the present study, the effect of long-term antidepressant treatment in
depressed patients on actual driving performance and cognition was examined.
Driving performance of depressed patients receiving chronic antidepressant
treatment  and  healthy  controls  was  assessed  in  two  on-the-road  driving  tests  in
normal traffic. Cognition was measured by tasks that are related to driving skills and
tasks that are shown to be sensitive to impaired performance associated with
depression i.e. memory and attention measurements. It was expected that driving
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performance and cognition of depressed patients receiving long-term treatment with
non-sedating antidepressants was comparable to that of matched healthy controls.
Materials and Methods
Subjects
Twenty-four depressed patients who received antidepressant treatment with a SSRI
or venlafaxine for 6-52 weeks, referred to as treated patients, were recruited through
regional psychiatric centers in the South-Limburg area and by advertisement in local
newspapers. In addition, twenty-four healthy volunteers were recruited by
advertisement in local newspapers. Participants were screened by a telephone
interview and health questionnaire including questions about the individual’s
medical condition and medical history, lifestyle and demographical characteristics.
All participants were free from neurological, cardiovascular, respiratory,
metabolic, hepatic or renal disorders or a history of these illnesses, did not use illicit
drugs,  were  not  pregnant  or  lactating  and  were  devoid  of  any  sensory  or  motor
deficits that could reasonably be expected to affect test performance. All participants
had a valid driving license for at least three years and driving experience of at least
5000 km/years during each of the preceding three years.
Healthy participants were free from psychiatric illnesses at present or in the
past  and  had  no  first  degree  relative  with  a  history  of  a  psychiatric  illness.  Treated
patients had a primary diagnosis of unipolar disorder with an active depressive
episode by a psychiatrist or physician according to DSM-IV criteria with scores on the
Hamilton Depression Rating Scale above 17. In addition, the diagnosis prior to start
of treatment was confirmed by a retrospective Structured Clinical Interview for DSM-
IV (SCID) at the laboratory. None of the participants had a present or past diagnosis
of psychotic depression.
 Healthy participants did not take any medication, except for oral
contraceptives. Depressed patients received treatment with citalopram (n=4, average
dose: 25 mg (SD 10), range: 20-40 mg), sertraline (n=4, average dose: 87,5 mg (SD 25 ),
range: 50-100  mg), paroxetine (n=8, average dose: 28,8 mg (SD 9.9), range: 20-40  mg)
or venlafaxine (n=8, average dose: 134,4 mg (SD 75.5), range:  75-300mg), but no other
psychoactive medication. Two patients used concomitant antihypertensive
medication, i.e irbesartan 150 mg and lisinopil 20 mg. Demographical characteristics
of  the  two  groups  are  shown  in  table  1.  The  study  was  approved  by  the  standing
medical ethics committee of Maastricht University and the Maastricht Academic
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Hospital’s  Board  of  Directors.  It  was  carried  out  in  accordance  with  the  World
Medical Association’s Declaration of Helsinki (Edinburgh, 2000). Written informed
consent was obtained from each volunteer prior to participation to the study.
Table 1: Subject characteristics for the group of patients receiving antidepressant
treatment for 6-52 weeks, their matched healthy controls.
Characteristics Depressed patients with
treatment for 6-52 weeks
Healthy Volunteers
N 24 24
Sex
     Male
     Female
12 (50%)
12 (50%)
12 (50%)
12 (50%)
Age
     Mean
     Minimum
     Maximum
42.2
21
63
41.8
22
61
Hamilton Depression rating Scale
     Mean
     Minimum
     Maximum
8.8 (SE 1.37)
0
26
0.5 (SE 0.19)
0
3
Precipitating factor
     None
     Somatic illness
     Psychosomatic stressors
     Both
19 (79%)
0
5 (21%)
0
-
-
-
-
Characterization
     Depression with anxiety
     Depression with mainly
          somatic symptoms
     Retarded depression
     Neurotic depression
3 (13%)
21 (87%)
0
0
0
-
-
-
-
-
Design
The study was conducted according to a parallel group design, comparing a group of
treated depressed patients with healthy controls. Each patient was matched to a
healthy control subject comparable for age, gender and years of driving experience.
Testing Procedure
On a separate training day, participants practiced the driving and cognitive tests to
familiarize with the procedure and test instructions. On the test day, participants
arrived at the university laboratory at 13.15h and subsequently filled out the self-
rating  questionnaires.  At  13.30h  the  cognitive  test  battery  was  administered,  which
took approximately 35 minutes. Next, the Hamilton Depression Rating Scale was
completed. At 14.30h participants were driven to the starting point of the driving
circuit. During the subsequent 105 minutes the driving assessments were conducted,
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allowing for a 10-minute break between the tests. The participants arrived back at the
university at 17.15h. In total, the test day lasted 4 hours.
Assessments
Actual driving performance
Road Tracking Test
In the Road Tracking Test (O'Hanlon, 1984), participants operated a specially
instrumented vehicle over a 100 km primary highway circuit while maintaining a
constant speed (95 km/58 miles per hour) and a steady lateral position between the
delineated boundaries of the right (slower) traffic lane. The vehicle was dual-
controlled and the participant was accompanied by a driving instructor. An electro-
optical device mounted at the rear back of the car continuously measured lateral
distance separating the vehicle and the left lane-line. This signal was stored on an
onboard computer disk file for later editing analysis. The remaining data were used
to calculate means and variances for lateral position and speed. Standard deviation of
lateral  position  (SDLP  in  cm)  was  taken  as  a  performance  measure.  SDLP  is  a
measure  of  road  tracking  error;  in  practical  terms,  a  composite  index  of  weaving,
swerving and overcorrecting. The standard deviation of the speed was also taken as a
performance measure.
Car-following Test
The car following test, adapted from a previous study (Brookhuis et al., 1994),
involved two cars driving on a secondary highway (Ramaekers et al., 2002). The
participant controlled the following car accompanied by a driving instructor. The
participant  was requested to  attempt to  drive at  15-30 meters  behind the preceding
car which was controlled by a second driving instructor. The test began with the two
vehicles traveling one after the other at speeds of 70 km/h. The speed of the leading car
was automatically controlled by a modified cruise-control system and could be
changed  within  amplitude  of  10  kilometers  per  hour.  The  main  parameter  was  the
time to speed adaptation (TSA in msec); this is the reaction time of the participant to
speed and deceleration of the leading car. Between speed maneuvers, the investigator
in the leading car randomly activated the brake lights. The participant was instructed
to react to the brake lights by removing his/her foot from the speed pedal as fast as
possible; this parameter was called brake reaction time. Headway was continuously
recorded.
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Cognition
The cognitive test battery consisted of various tasks measuring psychomotor and
cognitive  function.  The  visual  verbal  learning  task,  an  adapted  version  of  the
Auditory  Verbal  Learning  Task,  was  used  to  assess  short  and  long  term  memory
function (Rey, 1964). The Change Blindness Task measured visual scene analysis and
memory. Participants were shown a series of 100 photographs from various traffic
situations on a computer screen. Subjects were required to report changes in each of
these traffic scenes that occurred during an occlusion period of 1 sec (Dornhoefer et
al., 2002). The Left-Right test was used as a parametric version of the well-known
color-word response conflict task. This test measures simple reaction time and
selective attention (Stroop, 1935). The Continuous Performance Test (CPT) was used
to study vigilance (attention) (Conners, 1992)and also provided a measure of the
ability to inhibit or suppress a habit response. In the present study a computerized
version of the original CPT was used. The Critical Flicker Fusion Threshold was
determined using the Leeds Psychomotor Tester (Leeds Psychomotor Services, York).
This  is  a  measure  of  CNS  arousal  and  activation  (Curran  &  Wattis,  1998;  Schmitt,
Riedel et al., 2002). The mean of six measurements was taken as dependent variable.
Finally, a computerized version of the Digit-Symbol Substitution Task (DSST)
(Wechsler, 1981)was administered.
Subjective measurements
The Hamilton Depression Rating Scale (Hamilton, 1967) and Beck’s Depression
Inventory (Beck et al., 1961) were used to rate vegetative and cognitive symptoms of
depression, including co morbid anxiety symptoms. In addition, participants rated
feelings  of  depression,  tension,  fatigue,  vigor  and  anger  by  means  of  the  Profile  Of
Mood States (McNair et al., 1992). Participants filled out the Groninger Sleep Quality
Scale on the evenings prior to testing in order to assess subjective sleep quality and
sleep duration (Mulder-Hajonides van der Meulen, 1981). Participants as well as the
driving instructor were asked to rate their driving performance after completion of
the driving tests.
Statistical analyses
The  outcome  variables  of  the  driving  tests,  cognitive  tests  and  questionnaires  were
subject to analysis of variance (ANOVA) comparing two groups: patients treated
with antidepressants and matched healthy controls. Subsequent analysis on type of
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antidepressant (i.e. SSRI vs SNRI) was conducted on outcome variables that showed a
significant difference between patients and controls. Differences in performance
between SSRI treated patients and their matched healthy controls were compared to
differences in performance between venlafaxine treated patients and their matched
healthy  controls,  also  by  ANOVA  to  examine  if  type  of  antidepressant  has  an
influence  on  the  results.   A  correlational  analysis  of  HDRS  scores  and  SDLP  was
conducted over difference scores of treated patients and their matched healthy
controls. All statistical tests were conducted using SPSS (version 11.5 for Windows).
Results
Actual Driving Performance
Road Tracking Test
ANOVA revealed a statistically significant difference in SDLP between patients and
controls.  SDLP  was  higher  for  treated  patients  compared  to  healthy  controls
(F1,46=8.29, p<0.01). Results of SDLP for patients and controls are presented in Figure
1.
Car-following Test
Time to speed adaptation in the car following test was statistically significant
impaired in treated patients compared to healthy controls (F1,46=5.73, p<0.05)
presented in Figure 2. Other outcome measures of this test, i.e. brake reaction time,
speed and headway did not differ significantly between groups. Means (SE) of these
measures are shown in table 2.  Means (SE) of these measures are shown in table 2.
Cognition
Average Critical Flicker Fusion threshold frequency was statistically significantly
reduced in treated patients compared to healthy controls (F1,46=11.16, p<0.01). For
the remaining cognitive performance measurements, no statistically significant effects
were established. Means (SE) of all cognitive assessments are shown in table 2.
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Figure 1. Mean (SE) Standard Deviation of Lateral Position (SDLP)
* p<0.01
Figure 2. Mean (SE) Time to Speed Adaptation (TSA) of the car following test
* p<0.05
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Table 2: Cognitive and driving assessments (means, SE) for the group of depressed
patients receiving antidepressant treatment for 6 to 52 weeks and healthy controls.
Assessments/outcome measures Depressed patients with
treatment for 6-52 weeks
Healthy Volunteers
Driving Assessments
Road Tracking Test
    Standard Deviation of Lateral Position
(cm)
    Speed
    SD Speed
Car Following Test
    Brake reaction time (msec)
    Time To Speed Association (sec)
Driving Instructor Rating
     Driving quality
     ‘Sedation’
Volunteer Rating
     Driving quality
20.5 (0.65)
96.2 (0.22)
2.2 (0.30)
588 (21.7)
3.1 (0.33)
6.6 (0.31)
1.1 (0.41)
3.9 (0.37)
18.0 (0.58)
95.8 (0.24)
1.9 (0.36)
548 (28.1)
2.1 (0.19)
7.4 (0.28)
0.49 (0.19)
2.8 (0.25)
Cognitive Tests
30 Word Learning Test
     Immediate recall (# words)
     Delayed recall (# words)
     Delayed recognition (% correct)
     Delayed recognition speed (msec)
35.0 (2.1)
11.8 (0.90)
80.3
800 (34.8)
35.2 (1.9)
10.9 (0.91)
80.7
828 (24.0)
Left-Right Task
     Compatible RT (msec)
     Incompatible RT (msec)
     Incompatible correct responses
     Compatible correct responses
604 (16.6)
628 (11.6)
15.9 (0.06)
15.6 (0.10)
614 (13.2)
635 (13.1)
15.8 (0.12)
15.7 (0.12)
Critical Flicker Fusion
     Threshold frequency (Hz) 19.8 (0.42) 22.0 (0.50)
Digit Symbol Substitution Task
     Correct substitutions 70.8 (2.78) 76.3 (2.22)
Continuous Performance Test
     Reaction time hits (msec)
     Correct detections (#)
384 (11.6)
46.0 (0.73)
385 (9.94)
47.0 (0.27)
Change Blindness Task
     Overall correct detections
     Relevant correct detections
     Irrelevant correct detections
     RT overall correct detections (msec)
     RT relevant correct detections (msec)
     RT irrelevant correct detections (msec)
43.1 (1.36)
29.8 (0.72)
14.2 (1.00)
884 (31.3)
780 (46.8)
1032 (43.6)
44.7 (1.24)
31.1 (0.63)
13.6 (0.77)
871 (28.4)
807 (28.8)
1018 (42.3)
Subjective measurements
A  summary  of  the  results  of  subjective  mood  measurements  is  shown  in  Table  3.
There was a statistically significant difference in scores on the Hamilton Depression
Rating  Scale  between  the  two  groups.  Patients  treated  with  antidepressants  had  a
higher HDRS score (F1,46=35,49, p<0.001).
Treated patients had statistically significant higher scores on the Beck
Depression Inventory as compared to healthy controls (F1,46=27.2, p<0.001).
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Furthermore, treated patients had statistically significant higher scores on the
‘depression’ (F1,46=11.2, p<0.05), ‘tension’ (F1,46=10.1, p<0.05) and ‘fatigue’
(F1,46=14.6, p<0.001) subscales of the POMS, and significantly lower scores on the
‘vigour’ subscale (F1,46=21.4, p<0.001). No effects were seen on the ‘anger’ subscale.
Sleep quality was statistically significant reduced in treated patients. The average
number of sleep complaints in these patients was more than 3 times as high as those
reported by healthy volunteers (F1,46=11.3, p<0.01) . The level of alertness and
driving quality, as rated by the accompanying driving instructor, of treated patients
was not statistically significant different than that of healthy controls. However,
treated patients’ rating of their own driving ability was statistically significant worse
than that of healthy controls (F1,46=6.81, p<0.05).
Table 3: Subjective assessments of mood and sleep quality (means, SE) for the group
of depressed patients receiving antidepressant treatment for 6 to 52 weeks and
healthy controls.
Questionnaire/ subscale Depressed patients with
treatment for 6-52 weeks
Healthy Volunteers
Beck Depression Inventory (BDI) 11.8 (1.8) 3.0 (0.5)
Profile of Mood States (POMS)
     Depression
     Tension
     Fatigue
     Vigour
     Anger
51.9 (2.9)
34.2 (2.5)
34.23 (2.8)
79.4 (1.9)
51.60 (2.7)
63.7 (2.0)
47.1 (1.3)
41.0 (1.8)
90.6 (1.5)
54.27 (1.5)
Sleep Quality
     Number of sleep complaints
(Groninger sleep questionnaire)
5.2 (0.9) 1.6 (0.6)
Type of antidepressant
Given  the  different  types  antidepressants  i.e.  SSRI  and  venlafaxine,  it  was
investigated whether these subtypes affected outcomes variables differently.
Outcome variables including SDLP, TSA, average Critical Flicker Fusion threshold
frequency, HDRS, POMS and average number of sleep complaints revealed no
statistically significant differences on type of antidepressant. The only statistically
significant difference was shown on the Beck Depression Inventory (F1,22=6,19,
p<0.05) with higher difference scores between venlafaxine treated patients and their
matched healthy controls compared to SSRI treated patients.
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Correlation analysis
There was no statistically significant correlation between difference scores of HDRS
and difference scores of SDLP. No statistically significant differences were revealed
by dividing treated patients in 2 groups of ‘low’ (HDRS<8) and ‘high’ HDRS scores
on SDLP. The mean SDLP for these groups were 20,14 (n=13) and 20,86 (n=11)
respectively.
Discussion
This is the first study that examined the effects of long-term treatment with SSRI and
SNRI antidepressants on actual driving performance in depressed patients. Results
revealed a statistically significant impairment of driving performance in depressed
patients receiving long-term antidepressant treatment as compared to healthy
controls.  Driving  impairment  was  evident  from  increments  in  weaving  (SDLP)  and
time  to  speed  adaptation  (TSA)  on  the  on-the-road  driving  tests.  Objective
impairment in the driving test was corroborated by subjective ratings of driving
performance. Patients receiving long-term antidepressant treatment rated their own
driving ability significantly worse as compared to healthy controls. No significant
differences between depressed patients receiving antidepressant treatment as
compared to healthy controls were found on cognition such as memory and attention.
Driving performance was comparable in patients receiving SSRIs or venlafaxine.
Previous studies also suggest that successful antidepressant treatment may
not normalize driving ability of depressed patients. In depressed patients receiving
amitriptyline, little improvement was seen on a series of laboratory tasks aimed at
assessing fitness for driving in the first six weeks of treatment, although depression
ratings fell significantly (Gerhard & Hobi, 1984). Even after treatment with novel
antidepressants depressed patients showed an impairing effect on a ‘act and react’
test system assessing driving skills, although these novel antidepressants have been
shown to produce less performance impairment than tricyclic antidepressants
(Brunnauer  &  Laux,  2003).  In  another  study,  89%  of  depressed  patients  receiving
polypharmacological antidepressant treatment assessed with the same ‘act and react’
test system, were considered unfit to drive (Grabe et al.,  1998). The validity of these
laboratory tasks in terms of real life driving performance remains uncertain but the
results  are  confirmed  by  one  study  using  an  actual  on  the  road  driving  test  in
depressed patients. Here an improvement of depressive symptoms but no
improvement  of  SDLP  in  depressed  patients  treated  with  fluoxetine  and
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moclobemide during 6 weeks of treatment was demonstrated (Ramaekers et al.,
1997).
It is very difficult to validate the results of the driving tests against the
criterion of actual accident involvement, but it is possible to quantify the test results
against  a  secondary  criterion  that  itself  is  highly  correlated  with  accident  risk,  i.e.
blood  alcohol  concentration  (BAC).  The  association  between  SDLP  and  BACs
between 0.00 and 0.15 mg/mL has been established in a series of controlled studies
with healthy social drinkers (Louwerens et al., 1987). Against these data, the increase
in SDLP in the treated patients receiving SSRI treatment would compare to a BAC of
0.50 mg/ml, which is the legal BAC limit for driving in many countries. It is
important to note that the comparisons with alcohol merely illustrate the magnitude
of the SDLP effects; they do not necessarily translate into comparable accident risks. It
is unclear to which extend the factors that determine SDLP performance also
contribute to the increased accident risk with alcohol.
The  absence  of  deficits  in  memory,  psychomotor  and  attention  functions  in
the  medicated  depressed  patient  group  in  the  present  study  is  consistent  with  the
notion that successful SSRI therapy is generally associated with an alleviation of the
cognitive deficits that are seen during a depressive episode (Amado-Boccara et al.,
1995).  However,  driving  performance  appears  to  be  much  less  susceptible  to
antidepressant treatment. Our observation of a decreased CFF threshold – an indirect
measure  of  central  arousal  (Curran,  1990)  –  in  the  medicated  patients  in  our  study
suggests that impaired driving performance in this group may be related to sub-
optimal energetic resources, perhaps due to the mild reduction in sleep quality that
was found in this  group.  One may argue that  the prolonged driving tests  are  more
sensitive to arousal-mediated effects on performance than short-lasting laboratory
tests. Correlational analysis has shown that conventional psychomotor and cognitive
tests do not strongly predict antidepressant effects on actual driving performance
(Ramaekers, 2003). Residual depressive symptoms were present in the treated
depressed  patients  group  (average  HDRS  of  8.8  versus  0.5  in  healthy  controls)  and
these  may  possibly  be  associated  to  impaired  driving  performance.  However,  no
correlation  was  found  between  driving  performance  and  HDRS,  suggesting  that
depressive  symptomology  is  not  a  primary  factor  in  the  observed  effects.  Further,
although citalopram  (Riedel et al., 2005), paroxetine (Schmitt, Ramaekers et al., 2002),
and venlafaxine (O'Hanlon et al., 1998) have been shown to induce mild reductions of
vigilance in healthy volunteer studies, these drugs generally do not affect SDLP after
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acute or repeated doses in healthy volunteers (Ramaekers, 2003).  It is therefore
unlikely that behavioral side-effects of the SSRIs influenced driving performance in a
meaningful way. Rather driving impairment in depressed patients seems most likely
caused by the residual depression itself.
While antidepressant treatment apparently did not normalize driving
performance of depressed patients, it may still have attenuated driving impairment
relative to untreated depression. We did not test untreated depressed patients, but in
order  to  gain insight  into this  issue,  we compared our data  to  historical  SDLP data
obtained  from  baseline  assessments  of  a  study  on  the  effects  of  fluoxetine  and
moclobemide on driving  performance (Ramaekers et al., 1997). The SDLP
methodology was identical except for the type of vehicle used. To control for this, we
calculated a correction factor based on the difference between mean (placebo) values
obtained in 8 studies with the previous car and 8 studies with the current car.  Also,
we were able to match a sub-sample of the untreated patients to our patients, based
on age, gender and driving experience. The corrected SDLP in untreated depressed
patients was 21.9 (SE 1.1) compared to 20.5 (SE 0.7) in the present treated patient
group. There was no statistically significant difference between both groups.
Nevertheless, the average increase in SDLP seen in the untreated patients was
reduced by 35% in the SSRI and venlafaxine treated patients, suggesting there may be
a small beneficial effect of treatment on driving performance. It is clear that the use of
historical controls may have many pitfalls and that changes in driving performance
over the course of antidepressant treatment need to be studied directly in order to
obtain a reliable picture.
In conclusion, it was shown that depressed patients receiving long-term SSRI
or SNRI treatment exhibit statistically significant inferior driving skills, as assessed
with standardized on the road driving tests, compared to matched healthy controls.
Based on the fact that there are generally no detrimental effects of SSRIs on driving
performance and despite no correlation between HDRS scores and SDLP, the
impairment in driving performance can probably be attributed to residual depressive
symptoms but this remains to be investigated. Whether the observed impairment
translates into increased accident risk remains to be established, but it seems prudent
that patients are advised of potentially compromised driving ability, even when
clinical remission by antidepressant treatment is achieved. Further research,
specifically longitudinal studies addressing the time course of the effects of various
antidepressant treatments on driving performance in depressed patients, is needed to
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elucidate the relation between depression, antidepressant treatment and driving
ability.
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Chapter 5
Verbal Memory performance during subchronic
challenge with a selective serotonergic and a mixed
action antidepressant
Abstract
Objectives: Effects of escitalopram 10-20 mg/day and mirtazapine 30-45 mg/day on verbal
memory of 18 healthy participants were assessed in a randomized, double-blind, placebo-
controlled, 3-way crossover trial.
Method: Each treatment period lasted for 15 days and was separated from the next period by a
washout period of at least 13 days. Participants received an evening dose of escitalopram
10mg, mirtazapine 30mg, or placebo from days 1-7 and an evening dose of escitalopram 20mg,
mirtazapine 45mg, or placebo from days 8-15. On days 2, 9, and 16 a visual verbal memory task
was performed measusing drug effects during the acute phase, after dose increase and at
steady state.
Results: Escitalopram did not affect immediate or delayed verbal memory score throughout
treatment. During mirtazapine treatment, participants performed less well in the overall
immediate recall score compared to placebo. This impairment was most pronounced in the
final trial of the visual verbal learning task.
Conclusion: Verbal memory was not affected by acute and subchronic escitalopram treatment in
healthy participants. Overall immediate verbal memory was slightly but significantly impaired
throughout mirtazapine treatment, probably due to a general reduction in overall arousal
caused by H1 blockade.
Wingen M, Langer S, Ramaekers JG (2006): Verbal memory performance during
subchronic challenge with a selective serotonergic and a mixed action antidepressant.
Human psychopharmacology 21:473-9.
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Introduction
The role of serotonin in cognition and specifically in memory is an issue of present
interest. Recent studies have given new insights in serotonergic manipulations and
memory. Animal research shows that serotonin receptors are situated in brain areas
involved in memory and different 5-HT-agonist or 5-HT-antagonists show memory
improvement or impairment (Buhot et al., 2000; Meneses, 1999). There are a number
of  ways  to  examine  the  role  of  serotonin  in  memory  in  healthy  volunteers.  A
convincing  way  to  study  the  effect  of  decreased  serotonin  levels  is  tryptophan
depletion. Several studies show an impairment of memory consolidation after acute
tryptophan depletion in healthy volunteers (Riedel et al., 2002) which implicates that
lowered serotonin levels are associated with memory impairment. Conversely, one
could expect that serotonin augmentation would improve verbal memory.
 Increased serotonin levels  in  healthy volunteers  can be obtained by the use
of antidepressants, particularly by the use of selective serotonin reuptake inhibitors
(SSRIs).    A  few  studies  in  healthy  volunteers  have  been  conducted  to  assess  the
effects  of  SSRIs  on  memory  specifically  but  these  studies  have  shown  controversial
results.  Subchronic  administration  of  sertraline  produced  no  effects  on  memory
compared to placebo (Schmitt et al., 2001; Siepmann et al., 2003) but subchronic
administration of paroxetine did impair delayed recall on a memory task (Schmitt et
al., 2001). An acute dose of the SSRI fluvoxamine, 50 and 100 mg, produced no effect
on memory compared to placebo (Fairweather et al., 1996). Different doses of
citalopram had comparable effects to placebo on the Sternberg Memory Scanning
task after acute and subchronic (8 days) administration in healthy volunteers
(Fairweather et al., 1997). Administration of 40 mg/day citalopram for 15 days
impaired delayed recall compared to placebo, whereas 100 mg/day sertraline did not
(Riedel  et  al.,  2005).  There  was just  one study showing an improvement  of  delayed
verbal memory after increased serotonin levels caused by SSRI administration
(Harmer et al., 2002). In the latter study, citalopram 10 mg was administered
intravenously which probably resulted in higher brain serotonin levels as compared
to oral dosing studies. The controversial results of the above-mentioned studies could
be due to differences between specific SSRIs. For instance, the impairing effect of
paroxetine is probably attributional to additional muscarinic receptor blockade, next
to paroxetines’ serotonergic mechanism (Schmitt et al., 2001). Other differences
between the results may have resulted from methodological differences such as a
variety in memory tasks, in SSRI dosages or in time of treatment administration.
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The present study tried to take these differences into account and assessed
the effect of different dosages of escitalopram and mirtazapine on short term and
long term verbal memory. Escitalopram is the S-enantiomer of citalopram.
Escitalopram is currently the most selective serotonin reuptake inhibitor (Owens et
al., 2001; Sanchez et al., 2004). It therefore may serve as a valuable tool in challenge
studies of the serotonergic system. It was hypothesized that an acute and subchronic
dose of escitalopram may enhance verbal memory. In this study, the noradrenergic
and specific serotonergic antidepressant (NaSSA) mirtazapine was used as an active
control. Due to its high affinity for blocking the histaminergic H1 receptor (Anttila &
Leinonen, 2001; Biswas et al., 2003) mirtazapine shows sedative properties. Acute and
subchronic treatment with mirtazapine was hypothesized to impair memory.
Materials and Methods
Subjects
Eighteen healthy participants (9 women and 9 men) with a mean age (SD) of 31,4 (5,8)
were recruited by advertisement in local newspapers. All participants underwent a
medical examination by a medical doctor, including a standard 12- lead
electrocardiogram, blood haematology and chemistry, urinalysis, drug and
pregnancy screening. In addition, participants filled out an extensive medical
questionnaire, which was reviewed by the medical doctor. Exclusion criteria were
history or present evidence of renal, hepatic, cardiovascular, pulmonary, endocrine,
neurological or psychiatric illness, haematological, gastrointestinal diseases and
medical history of glaucoma. Other exclusion criteria were body mass index below 19
or above 29 kg/m2, pregnancy (as determined at screening) or breastfeeding, known
hypersensitivity  to  medicinal  drugs,  treatment  with  an  investigational  drug  within  3
months  prior  to  screening,  use  of  medicines  (except  oral  contraceptives  and
paracetamol), excessive smoking (more than 10 cigarettes a day), overconsumption of
alcohol (more than 35mg ethanol a day) or overconsumption of caffeine (more than 6
cups of  regular  coffee  a  day),  positive  result  of  urine drug screening at  the screening
visit for alcohol and/or drug of abuse, and any sensory or motor deficits which would
reasonably be expected to affect test performance. All participants gave their written
informed consent prior to participation. The study was approved by the standing
medical  ethics  committee  of  Maastricht  University  and  it  was  carried  out  in
accordance with the World Medical Association’s Declaration of Helsinki
(Edinburgh, 2000).
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Design and treatments
The study was conducted according to a randomized, double-blind, placebo-
controlled, 3-way crossover design. Treatments were administered in separate 15-day
series  and  treatment  orders  were  balanced  and  assigned  by  a  Latin  square  design
resulting in 6 treatment orders over 18 participants. Participants received 10 mg/day
escitalopram at days 1 to 7 followed by 20 mg/day escitalopram at days 8 to 15, 30
mg/day mirtazapine at days 1 to 7 followed by 45 mg/day mirtazapine at days 8 to
15 or placebo. Drugs and placebo were always ingested in a given time-frame in the
evening (between 8.00 and 10.00 p.m.). Dosing (day 1) started in the evening prior to
the first test day (day 2). The treatment sessions were separated by washout periods
of at least 13 days.
Testing Procedure
Participants were trained prior to the study to practice the memory test. The
assessments were done at days 2, 9 and 16 of each treatment series, 12-14 hours after
drug administration. Participants were not allowed to consume alcohol 48 hours
prior to testing and caffeine-containing beverages 4 hours prior to testing. During
testing, participants were not allowed to smoke. Participants completed the Visual
Verbal learning task (see below) at the training session and at every test day. There
were ten assessments  (1  training session and 3  testdays per  each of  the 3  treatment
periods). Therefore ten versions of the visual verbal learning task, with different but
comparable  words,  were  used.   This  study  was  a  part  of  a  larger  study  previously
published (Wingen et al., 2005) in which participants were subjected to an extensive
testing battery.
Visual verbal learning task
The visual verbal learning task is an adapted version of the Auditory Verbal Learning
Task and assesses short and long term memory function (Rey, 1964). The test consists
of a list of 15 monosyllabic words. Each word is shown on the computer display for 2
seconds  and  the  participant  is  requested  to  read  it  aloud  and  to  remember  it.  The
participant is asked to freely recall as many words as possible when the series ends.
The  number  of  words  remembered  is  the  first  trial  score.  In  total,  the  same  list  is
presented in the same manner for five successive occasions. The words correctly
recalled in all five trials are summed to the total immediate recall score, a measure for
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short-term memory. After 30 minutes delay with distracting tasks to prevent the
participant from rehearsing the learned words, the participant is asked to recall as
many  words  as  possible.  The  number  of  words  correctly  recalled  is  taken  as  the
delayed  recall  score,  a  measure  for  long-term  memory.   This  is  followed  by  a
recognition  test,  where  15  words  from  the  list  previously  shown  and  15  other
monosyllabic words are presented. The participant has to respond as quickly as
possible by pressing the “YES” or “NO” button to indicate recognition of the word.
The number of correctly recognized words counts for the delayed recognition score.
Statistical analyses
All statistical tests were conducted using SPSS (version 11.5 for Windows).
Parameters of the visual verbal learning task were subject to univariat ANOVA
analyses. Memory data were analyzed overall with Subject, Treatment, Day and
Period as factors and for each test day separately with Subject, Treatment and Period
as factors. In case of a Treatment effect, drug-placebo effects were determined using
simple contrasts. The alpha criterion significance level was set at p=0.05.
Pharmacokinetics
Blood samples for drug serum level analysis were collected on day 2, 9 and 16 of each
treatment period using the following procedure: peripheral venous access was
established and the required blood sample of 7 ml whole blood was taken. The blood
samples were analysed for serum concentration of escitalopram, the S-enantiomer
and R-enantiomer of the metabolites demethylcitalopram (DCT) and
didemethylcitalopram (DDCT), and for mirtazapine by means of a validated analysis
method according to the principles of Good Laboratory Practice.
Results
All 18 participants completed the study. Mean (SD) plasma concentrations for
escitalopram were 20.17 (4.60) nmol/L at Day 2, 71.44 (27.89) nmol/L at Day 9 and
97.78 (41.46) nmol/L at Day 16. Mean (SD) plasma concentrations for mirtazapine
were 67.67 (16.52) nmol/L at Day 2, 166.07 (52.64) nmol/L at Day 9 and 203.67 (98.48)
nmol/L at Day 16. The values were within the expected therapeutic range.
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Immediate recall
Overall analysis revealed a significant effect on the total immediate recall score on the
factors Treatment (F2,138=3,03, p=0.05), Day (F2,138=6,10, p<0.01) and Period (F2,138=4,24,
p<0.05). Further analyses showed no significant Treatment by Day or Treatment by
Period  interaction.  This  indicates  that  the  treatment  effect  stands  for  its  own.
According to drug-placebo comparisons, mirtazapine had an impairing effect on total
immediate recall. Escitalopram did not impair total immediate recall (see Figure 1).
Subsequently, the overall analysis revealed a significant Treatment effect (F2,138=3,41,
p<0.05) on the fifth trial score. Drug-placebo comparisons showed an impairing effect
of mirtazapine (p=0.017). A significant Period effect was found on the third trial score
(F2,138=4,48, p<0.05) but there was no Drug by Period interaction. A summary of the
results  of  the  Visual  Verbal  Learning  task  is  shown  in  table  1.  Analyzing  each  day
separately, there were no Treatment effects on Day 2, 9 or 16 shown in table 2.
Figure 1. Means (SE) of theVisual Verbal Learning Task – overall total immediate
recall score.
*p=.017 mirtazapine compared to placebo
Delayed recall
No significant effects on the delayed recall score or on the delayed recognition score
were detected, overall and for each day separately.
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Table 1. Summary of the overall average results for each trial of the Visual Verbal
Learning Task
Mean (SE) of number of words
Measurement Escitalopram Mirtazapine Placebo F df p
Immediate recall
Trial 1 7,7 (0,30) 7,9 (0,31) 8,0 (0,32) 0,7 2,138 ns
Trial 2 10,7 (0,29) 10,6 (0,31) 11,1 (0,31) 2,0 2,138 ns
Trial 3 12,1 (0,25) 12,1 (0,26) 12,6 (0,28) 2,3 2,138 ns
Trial 4 13,0 (0,25) 12,7 (0,23) 13,0 (0,24) 0,7 2,138 ns
Trial 5 13,4 (0,24) 13,0 (0,24) 13,6 (0,21) 3,4 2,138 .036
Delayed recall 12,1 (0,35) 11,7 (0,37) 12,1 (0,39) 1,2 2,138 ns
Word recognition
Correct 28,7 (0,19) 28,5 (0,24) 28,8 (0,20) 0,5 2,138 ns
Reaction time 650 (6,61) 648 (7,4) 651 (7,5) 0,1 2,138 ns
ns= not significant
Table 2. Summary of the results for each test day of the Visual Verbal Learning Task
Mean (SE) of number of words
Measurement Escitalopram Mirtazapine Placebo F df p
Immediate recall
Day 2 55,3 (2,0) 55,1 (1,94) 56,7 (2,31) 0,9 2,32 ns
Day 9 56,2 (2,08) 56,7 (2,25) 58,6 (2,04) 1,9 2,32 ns
Day 16 59,1 (1,68) 57,1 (2,00) 59,1 (1,84) 2,1 2,32 ns
Delayed recall
Day 2 12,2 (0,53) 11,5 (0,60) 12,4 (0,69) 1,7 2,32 ns
Day 9 11,6 (0,65) 11,4 (0,70) 12,2 (0,68) 1,0 2,32 ns
Day 16 12,3 (0,62) 12,1 (0,65) 11,8 (0,67) 0,5 2,32 ns
Word recognition
Correct              Day 2 28,9 (0,34) 28,6 (0,37) 28,7 (0,39) 0,3 2,32 ns
Day 9 28,7 (0,29) 28,4 (0,50) 28,9 (0,32) 0,6 2,32 ns
Day 16 28,6 (0,37) 28,6 (0,38) 28,7 (0,32) 0,01 2,32 ns
RT (msec)         Day 2 660 (11,90) 658 (12,39) 663 (16,30) 0,1 2,32 ns
Day 9 640 (9,59) 642 (11,58) 639 (10,62) 0,03 2,32 ns
Day 16 649 (12,77) 645 (14,71) 652 (11,29) 0,2 2,32 ns
ns= not significant
Discussion
The results of this study suggest that different dosages (10mg and 20mg) of
escitalopram have no effect on short-term and long-term verbal memory whereas
mirtazapine (30mg increased up to 45mg after 8 days) slightly impaired immediate
recall, during 16 days of treatment compared to placebo. The impairing effect was
particularly evident in the fifth and final learning trial. The impairing effect of
mirtazapine on memory was rather small and only reached statistical significance
when combined over all treatment days.
It was hypothesized that escitalopram would enhance memory by increasing
central serotonin levels. For citalopram an improving effect on verbal memory,
specifically delayed recall and recognition, had been shown (Harmer et al., 2002).
There are several reasons that can account for acute escitalopram administration not
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having enhancing effects in the present study. Harmer et al. (2002) administered
citalopram  10  mg  intravenously,  however  in  the  present  study  escitalopram  10  mg
was administered orally. The estimate of bioavailability for escitalopram (oral
administration) appears to be around 80% (Sogaard et al., 2005). Although limited,
first-pass metabolism of the hepatic circulation may decrease the blood plasma levels
for escitalopram. As a result, the serotonin levels in the brain may be lower after oral
administration compared to intravenous administration. Furthermore, the time of
drug administration differed between both studies. Harmer et al (2002) used daily
dosing and the memory task was carried out 45 min after the end of the infusion. In
the present study, escitalopram was administered in the evening and verbal memory
was tested the next day. Consequently, there was no measurement of the earliest
action of escitalopram. Still, the results of the present study are in line with the results
of  a  previous  study  on  escitalopram  (10  mg)  in  which  no  effect  on  verbal  memory
was found after acute treatment (Wilkinson et al., 2003). Future studies on serotonin
and  memory  should  emphasize  the  use  of  intravenous  administration  of  SSRI’s  for
manipulating the serotonergic system although this may move away from the clinical
understanding of the cognitive and behavioural toxicity of oral medication.
  The  present  study  found  no  effects  on  verbal  memory  after  subchronic
administration of escitalopram. Previous studies showed that subchronic
administration of citalopram did not affect memory (Fairweather et al., 1997), but 15
days of administration of citalopram 40 mg impaired delayed recall (Riedel et al.,
2005). Time of drug administration can be a possible explanation for the rather
deviant results in the present study. Daytime testing after daytime administration (4-
6 hours after citalopram intake) may substantially differ from daytime testing after
evening administration (12-14 hours after escitalopram intake). The possibility exist
that overnight sleep after nocturnal administration may have mitigated any
detrimental effects of escitalopram on memory performance. For example, previous
studies have show that daytime driving impairment after treatment with sedating
antidepressant was much less after nocturnal dosing as compared to daytime dosing
even though drug-blood concentration were the same  after both dosing regimes
(Ramaekers, 2003).
The  role  of  serotonin  in  memory  is  still  unknown.  Only  one  study  showed
memory improving effects after increasing serotonin by means of a SSRI (Harmer et
al., 2002). Probably, the serotonergic system is a very complex system including many
different serotonergic receptors. As animal studies showed, stimulation of different 5-
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HT  receptors  can  have  opposing  effects  on  memory  (Buhot  et  al.,  2000;  Meneses,
1999). The serotonin level in the brain increases after administration of an SSRI and
this affects various post- and presynaptic 5-HT receptors. Decreasing the serotonin
level by tryptophan depletion also affects the 5-HT receptors although differently.
Increasing or decreasing the serotonin level in the brain does not have to have
opposite effects on memory. One study investigated the effect of serotonin increase
by means of 3,4-methylenedioxymetamphetamine (MDMA) administration in human
volunteers on verbal memory and showed a memory impairing effect on immediate
and delayed verbal recall (Kuypers & Ramaekers, 2005). In contrast to tryptophan
depletion and SSRI administration which are involved in memory consolidation,
MDMA administration apparently also impairs immediate recall, possibly mediated
through 5-HT1A receptor or 5-HT2A receptor agonism (Kuypers & Ramaekers, 2005).
This also supports the assumption of that the association between serotonin and
memory is complex involving specific serotonin receptor subtypes.
In the present study, it was expected that mirtazapine would impair memory
performance and, essentially, a significant overall impairment was found. In other
words, mirtazapine impaired immediate verbal recall during 16 days. Analyzing for
each test day separately, it was not possible to assign this effect to an initial dose,
dose increase or steady state effect. Impairment of psychomotor and cognitive
performance is common after single and repeated doses of alpha2-antagonists such as
mirtazapine  (Ramaekers et al., 1998; Wingen et al., 2005). Detrimental effects of
mirtazapine on cognition are generally believed to result from the drugs’ high affinity
for the H1 receptor. Blockade of the brain H1 receptors is well known to cause
drowsiness and sedation and result in acute psychomotor and cognitive impairment
(Hindmarch & Shamsi, 1999; O'Hanlon & Ramaekers, 1995; Theunissen et al., 2006).
Importantly, although it is said that mirtazapine is a well tolerated antidepressant
that improves sleep in depressed patients (Nutt, 2002), it can still reduce daytime
alertness the day after the initial dose (Radhakishun et al., 2000). Notably, the results
of the present study are not completely generalizable to older medication users
because of the relative limited age range of the study. In addition, different memory
tasks or paradigms might show more pronounced treatment effects.
In summary, escitalopram 10 and 20 mg had no effect on a visual verbal
memory task that measured immediate and delayed recall and recognition. A role of
serotonin in memory could not be further established. Mirtazapine 30 mg and 45 mg
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revealed a slightly impairing overall effect on immediate recall, probably due to its
sedative effects caused by H1 receptor blockade.
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Chapter 6
Selective verbal and spatial memory impairment
after 5-HT1A and 5-HT2A receptor blockade in
healthy volunteers pre-treated with an SSRI
Abstract
Introduction: Serotonergic neurotransmission has been implicated in memory impairment. It is unclear
however if memory performance is mediated through general serotonin availability, through specific 5-HT
receptors or both. The aim of the present study was to assess the contribution of serotonin reuptake
inhibition and specific blockade of 5-HT1A and 5-HT2A receptors to memory impairment. Methods: The study
was conducted according to a randomized, double-blind, placebo controlled, 4-way crossover design
including 16  healthy volunteers.  The  treatment  consisted of  oral  administration of  escitalopram 20  mg +
placebo, escitalopram 20 mg + ketanserin 50 mg, escitalopram 20 mg + pindolol 10 mg and placebo on 4
separate days with a wash-out period of minimum 7 days. Different memory tasks were performed
including verbal memory, spatial working memory and reversal learning. Results: Escitalopram showed an
impairing effect on immediate verbal recall which nearly reached statistical significance. No effects of
escitalopram were found on other types of memory. In combination with pindolol, immediate verbal recall
was significantly impaired. Escitalopram in combination with ketanserin impaired spatial working
memory significantly. No effects were found on reversal learning. Conclusion: Selective impairment of
immediate verbal recall after a 5-HT1A partial agonist and selective impairment of spatial working memory
performance after 5-HT2A receptor antagonist, both in combination with a selective serotonergic reuptake
inhibitor (escitalopram), suggests that 5-HT1A and 5-HT2A receptors  are  distinctly  involved in  verbal  and
spatial memory.
Wingen M, Kuypers KPC, Ramaekers JG (2006): Selective verbal and spatial memory
impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-
treated with an SSRI. Journal of Psychopharmacology DOI:10.1177/0269881106072506.
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Introduction
In humans, the association between memory function and serotonin has mostly been
studied in tryptophan depletion studies and in serotonergic challenge studies. Acute
trypthophan depletion studies have consistently shown to reduce memory
consolidation (Harrison et al., 2004; Riedel, Klaassen et al., 1999; Schmitt et al., 2000)
which implicates that lowered serotonin levels are associated with memory
impairment. Challenge studies with acute and chronic administration of selective
serotonin reuptake inhibitors (SSRIs) that enhance serotonin levels (Anderson et al.,
2005) have provided inconsistent results by showing  negative (Riedel et al., 2005),
neutral (Riedel et al., 2005; Wilkinson et al., 2003; Wingen et al., 2006) as well as
positive (Harmer et al., 2002) effects on memory consolidation. Likewise, other
serotonergic drugs such as MDMA have been shown to impair verbal and spatial
memory performance during intoxication when serotonin levels are high (Kuypers &
Ramaekers, 2005; Kuypers & Ramaekers, 2006) but also during abstinence when
serotonin levels are low (Curran & Travill, 1997; Parrott et al., 1998). Consequently, it
has been proposed that memory function may be mediated through some alternative
mechanism such as serotonergic receptor activation rather than through synaptic
serotonin availability alone (Kuypers & Ramaekers, 2005).
Studies in animals as well as humans have provided strong evidence for an
involvement of 5-HT1A and 5-HT2 receptors  in  different  aspects  of  memory.  The  5-
HT1A receptor can be found pre- and post-synaptically and is highly concentrated in
the hippocampus and in the raphe nucleus. In animals, 5-HT1A-agonist or 5-HT1A-
antagonists have been shown to respectively produce memory improvement or
impairment (Buhot et al., 2000). In humans, administration of a 5-HT1A agonist
impaired immediate and delayed verbal recall presumably by stimulating the
postsynaptic 5-HT1A receptor  in  the  hippocampus  (Yasuno  et  al.,  2003).  The  5-HT1A
agonist ipsapirone also impaired immediate verbal memory in healthy volunteers but
improved immediate verbal memory in depressed patients (Riedel, Klaassen, Griez et
al., 2002). Post-synaptic 5-HT2A receptors can be found in high levels in cerebral
cortical areas and at intermediate levels in the hippocampus, nucleus accumbens and
the hypothalamus (Dwivedi & Pandey, 1998). A role for 5-HT2 receptors in memory
seems present, although the exact mechanism is not clear (Meneses, 2002). In healthy
humans the 5-HT2A receptor was shown to be involved in memory by the fact that a
polymorphism of the gene encoding the 5-HT2A receptor affected delayed memory
recall negatively. Carriers of heterozygous variant, which indicates a blunted receptor
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response,  had  a  poorer  episodic  memory  performance  compared  to  carriers  of  the
common variant (de Quervain et al., 2003).
The  aim  of  this  study  was  to  further  assess  the  contribution  of  general
serotonin levels and serotonergic receptor function to memory performance. General
elevation of synaptic serotonin levels was achieved by pretreating healthy volunteers
with an SSRI, i.e. escitalopram. Escitalopram is the most selective SSRI available in
dosages of 10 and 20 mg (Aronson & Delgado, 2004). Additional blockade of 5-HT1A
and 5-HT2A receptors, was achieved by subsequent administration of pindolol and
ketanserin respectively. Pindolol is a very partial 5-HT1A agonist that blocks 5-HT1A
receptors preferentially presynaptically (Rabiner et al., 2004; Rabiner et al., 2000). The
indirect inhibiting effect of the SSRI on serotonin via the 5-HT1A autoreceptor is
attenuated by pindolol which leads to increased serotonin levels (Rasmussen et al.,
2004). Consequently, it was expected that pindolol would augment the effect of
escitalopram on memory. SSRIs in combination with pindolol have also been used in
preclinical studies to augment or accelerate the antidepressant effect of SSRIs (Blier et
al., 1998). To obtain a 37 % occupancy of the 5-HT1A autoreceptor a 10 mg single dose
of pindolol was necessary in healthy volunteers (Rabiner et al., 2001). Ketanserin has
previously shown to be a valuable drug for studying the role of 5-HT2A receptors in
human performance (Liechti et al., 2000; Vollenweider et al., 1998). It was suggested
that the agonistic effect of MDMA on the dopaminergic system through 5-HT2
stimulation  was  blocked  by  ketanserin  50  mg  (Liechti  et  al.,  2000).  In  the  present
study,  it  was  expected  that  blocking  the  5-HT2A receptor by ketanserin would
decrease dopamine release (Bortolozzi et al., 2005; Lucas & Spampinato, 2000) which
in theory would also augment the effects of the SSRI on memory.
Methods
Subjects
Sixteen healthy volunteers (8?, 8?) mean age (se) 25,9 (1,73) were recruited.
All participants underwent a screening procedure consisting of a telephone
interview, health questionnaire, 12-lead electrocardiogram, laboratory test
(haematology and blood chemistry, urinalysis, drug-and pregnancy screening) and a
routine medical examination. Volunteers were included when they were 21 to 45
years of age, healthy (i.e. absence of all exclusion criteria), had a normal static
binocular acuity (corrected or uncorrected), a body mass index between 19 and 30,
and were willing to sign an informed consent. Excluded were those volunteers who
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suffered from, or had a history of cardiac, hepatic, renal, pulmonary, neurological,
gastrointestinal, haematological or psychiatric illness. Other exclusion criteria were
excessive drinking (>20 glasses of alcohol containing beverages a week), pregnancy
or lactation, menstrual disorder, use of medication other than oral contraceptives,
smoking tobacco or use of illicit drugs, and any sensory or motor deficits which could
reasonably be expected to affect test performance. Those volunteers who had a first-
degree relative with a psychiatric disorder or a history of a psychiatric disorder were
also excluded. The study was approved by the standing medical ethics committee of
Maastricht University and the Maastricht Academic Hospital’s Board of Directors. It
was carried out in accordance with the World Medical Association’s Declaration of
Helsinki (Edinburgh, 2000). Written informed consent was obtained from each
volunteer prior to participation to the study.
Design and treatment
The study was conducted according to a double-blind, placebo controlled, 4-way
crossover design. Complete balancing of the treatment orders yielded sixteen
treatment orders randomly assigned to 16 healthy human volunteers. Balancing the
treatments to prevent order effects, results in every treatment being administered for
a  given  period  in  the  same  number.  Treatments  consisted  of  escitalopram  20  mg  +
placebo,  escitalopram 20 mg + ketanserin 50 mg,  escitalopram 20 mg + pindolol  10
mg and placebo + placebo administered at 4 different test days separated by a wash-
out period of at least 7 days (mean (se), range: 8,5 (0,48), 7-23) to prevent carryover
effects. Escitalopram oral dose has a Cmax around 4 hours and a half-life of 27-32
hours (Aronson & Delgado, 2004). Ketanserin and pindolol also oral dosages have a
Cmax of 2 hours and 1 hour and a half-life of 3-4 hours and 13-18 hours respectively
(Aellig et al., 1981; Hedner et al., 1983).
Testing procedure
Participants were trained prior to their first treatment condition on cognitive
assessments to minimize learning effects. Participants arrived at 9.00 a.m. at the test
laboratory; received a standard breakfast and completed a sleep quality
questionnaire. They received the first treatment capsule, containing either
escitalopram or placebo at 9.30 a.m. Participants were then seated for the next 4 hrs in
a  secluded  waiting  room  in  order  to  wait  for  escitalopram  to  reach  Cmax.   At  12
hours participants received a standard lunch, followed by the second treatment
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capsule at 12.30 p.m. containing pindolol, ketanserin or placebo. Mood assessment
and cognitive assessments were conducted at 13.30 p.m., i.e. at 1 hr after the second
drug treatment. Participants were not allowed to consume alcohol 24 hours prior to
testing and caffeine-containing beverages 4 hours prior to testing.
Cognitive assessments
The Visual Verbal Learning task (VVLT)
The VVLT, a modified version of the Rey Auditory Verbal Learning Test (Rey, 1964)
consisted of a list of 30 monosyllabic words in Dutch, which were presented in three
trials on a computer screen (Riedel, Klaassen et al., 1999). Immediately after each
presentation (immediate recall) and 20 minutes after the last presentation (delayed
recall) participants were asked to verbally reproduce as many of the presented words
as possible. Twenty-five minutes after the last presentation a delayed recognition test
was administered. A series of thirty words were shown (fifteen new and fifteen old
words  from  the  original  wordlist)  and  the  participant  was  asked  to  press  ‘yes’  for
‘familiar’ and ‘no’ for ‘new’, as quickly as possible. According to the theory of signal
detection (Pollack et al., 1964), the proportion of correct recognized words (cr) and the
proportion of falsely recognized (fr) constitute the nonparametric sensitivity measure:
A’ = 1 – 1/4(fr/cr + (1-cr)/(1-fr)). A’ is in fact the proportion of correctly recognized
words corrected for  the participant’s response tendency.  A’ was arcsin transformed
before statistical analyses.
The outcome measurements were the number of correct words recalled during the
three immediate recall trials as a measure of short term memory, the number of
correct  words  produced  on  delayed  free  recall  as  a  measure  of  retrieval  from  long
term memory, A’ as a measure of storage in long term memory, and the mean
reaction  times  of  correctly  recognized  words  as  a  measure  of  speed  of  long  term
memory.
Spatial Memory Task (SMT)
 The spatial memory task assessed short-term memory for spatial information
(Vermeeren et al., 1995). The spatial memory task was based on spatial localization.
The  participant  was  briefly  shown  a  fixation  point  in  the  centre  of  the  computer
display. Shortly thereafter, a target appeared at a random location for 500msec. The
participants’ task was to memorize the position of the target and, using a trackball, to
relocate the cursor as accurately as possible over that position. The cursor appeared
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either  immediately  upon  target  offset  or  after  a  delay  of  2  or  4  sec.  The  participant
depressed a button to indicate that the cursor was at the recalled position of the
target. The test consisted of 75 trials, divided equally among 3 response delays. The
sequence of delays was random. Regression lines were calculated to describe
localization error (in mm) as a function of response delay. The slope reflects memory
decay, and the intercept the participant’s localization error.
Probabilistic Reversal Learning task (RVL)
In the reversal-learning task (Cools et al., 2002) two abstract stimuli, composed of two
bars  of  different  colour,  were  randomly  presented  to  the  left  or  right  side  of  a
computer screen (Evers, Tillie et al., 2005). One stimulus was advantageous (S+) and
was usually (70%) associated with large reward (addition of 80 – 250 points) and
occasionally (30%) with a small punishment (subtraction of 10 – 60 points), based on a
pseudo-random sequence. The other stimulus was disadvantageous (S-) and was
usually (60%) associated with a large punishment (250 – 600 points) and occasionally
(40%) with a small reward (30 – 60 points).  Volunteers had to determine which
stimulus was advantageous based on the feedback; the number of points won or lost.
Once this  was learned,  i.e.  the  advantageous stimulus was chosen four  times out  of
five responses, the stimulus-reward contingencies were reversed (S+ became S-, and
S-  became  S+).  The  participant’s  task  was  to  keep  track  of  the  most  profitable
stimulus and to collect as many points as possible. The task duration was 10 minutes
or 121 trials. Outcome measurements were total number of reversals, total number of
perseverations in proportion to the reversals, total number of points collected, overall
mean reaction time and mean reaction time of the first correct response after a
reversal switch.
Subjective measurement
Participants rated feelings of depression, tension, fatigue, vigour and anger by means
of the Profile Of Mood States (McNair et al., 1992).
Statistical analyses
Data were analyzed by means of a GLM repeated measures analysis (SPSS 11.5) with
Treatment (4 levels) as main factor. In case of a significant overall effect of Treatment,
follow-up contrast tests were used to test for differences between drugs and placebo
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and between combination treatments and escitalopram. The alpha criterion
significance level was set at p=0.05.
Results
Missing data
All 16 subjects completed the study, there were no missing values. Drugs were
tolerated well by all participants during the test days. For spontaneously reported side
effects see Table 1.
Table 1. Spontaneously reported side effects
Escitalopram Esitalopram
+ ketanserin
Escitalopram
+ pindolol
Placebo
Drowsiness during test day 6% 25% 12,5% -
Nausea during test day 6% 6% 6% -
Drowsiness started the next evening - - 12,5% -
Nausea startedthe next evening - 12,5% - -
Cognitive assessments
A summary of mean (se) performance scores on all cognitive and subjective measures
in each treatment condition is given in Table 2. Mean differences (confidence
intervals), estimates of effect sizes and observed power are given in Table 3.
The Visual Verbal Learning task (VVLT)
Overall, Treatment significantly affected total immediate recall (F3,45=3.96, p<.05).
Drug-placebo contrasts showed a slight impairing effect of escitalopram that
approached statistical significance (F1,15=3.54,  p=.08).  Furthermore,  escitalopram  +
pindolol impaired total immediate recall significantly (F1,15=8.19, p<.05). Drug-drug
comparison showed that total immediate recall after escitalopram + pindolol was
worse compared to escitalopram alone (F1,15=5.525, p<.05). No interaction effects were
found between Treatment and learning trials. No effects were found on delayed recall
and delayed recognition. Mean (se) immediate recall scores in every treatment
condition for the separate learning trials are shown in Figure 1.
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Table 2. Mean (se) outcome variables of memory tasks and subjective measurement
Mean (standard error of mean)
Overall Treatment Escitalopram Escitalopram
+ ketanserin
Escitalopram
+ pindolol
Placebo
F, df=3,45 p
 VVLT
Total immediate recall 41,9 (2,28) 42,1 (2,39) 37,8 (2,82)A,C 44,1 (1,23) 3.96 <.05
Delayed recall 13,1 (1,23) 13,2 (1,35) 12,4 (1,57) 14,2 (1,44) 0.88 ns
Delayed recognition
# Correct recalled words 13,6 (0,29) 13,6 (0,34) 13,2 (0,38) 12,8 (0,48) 1.53 ns
Mean RT (msec) 787 (37,67) 787 (40,44) 774 (31,77) 787 (29,66) 0.12 ns
A’ 0,94 (0,01) 0,96 (0,01) 0,95 (0,01) 0,96 (0,02) 0.95 ns
SMT
Localization error delay 0 (mm) 8,4 (0,44) 11,1 (1,05)B,C 8,1 (0,59) 7,8 (0,41) 5.99 <.01
Localization error delay 2 (mm) 11,3 (0,77) 14,3 (1,26)A,C 11,5 (0,79) 11,1 (0,84) 3.03 <.05
Localization error delay 4 (mm) 13,7 (1,06) 16,3 (1,19)A 13,8 (0,79) 12,6 (0,94) 2.78 =.05
Mean RT delay 0 (msec) 2240 (181,59) 2403 (269,55) 2126 (146,24) 2026 (110,55) 1.85 ns
Mean RT delay 2 (msec) 2128 (151,84) 2243 (219,55) 1930 (123,11) 2055 (151,86) 2.53 ns
Mean RT delay 4 (msec) 2289 (198,37) 2302 (267,06) 2013 (151,64) 2048 (143,44) 1.72 ns
Intercept 8,5 (0,44) 11,3 (1,08)A,C 8,4 (0,55) 8,2 (0,44) 5.18 <.05
Slope 1,3 (0,23) 1,3 (0,15) 1,4 (0,10) 1,2 (0,18) 0.44 ns
RVL
# reversals 14,8 (0,90) 13,9 (0,70) 14,0 (1,00) 14,4 (1,05) 0.37 ns
# perseverations 3,86 (0,88) 5,06 (2,30) 1,81 (0,53) 1,07 (0,33) 1.80 ns
# points 9082 (782,95) 9505 (935,08) 10201 (826,31) 9248 (785,13) 1.16 ns
Mean RT (msec) 690 (68,8) 612 (34,50) 596 (51,57) 603 (46,97) 2.79 ns
Mean RT after reversal  (msec) 679 (68,31) 621 (46,4) 583 (49,30) 589 (42,45) 1.83 ns
POMS
Depression 20,8 (3,64)A 20,78 (3,20) 25,8 (4,57) 17,0 (2,62) 2.94 <.05
Anger 20,9 (3,08)A 16,7 (2,33) 21,6 (3,14) 16,4 (2,41) 3.74 <.05
Fear 35,6 (4,19)B 31,0 (4,62) 36,1 (6,32)A 20,9 (2,65) 3.93 <.05
Vigor 30,4 (4,76)B 29,6 (4,82)B 35,9 (5,89)A 17,7 (2,75) 4.88 <.01
Tension 17,9 (2,36) 18,6 (2,51) 22,6 (3,66) 15,3 (2,37) 2.32 ns
A= p<.05 as indicated by separate drug-placebo contrasts
B= p<.01 as indicated by separate drug-placebo contrasts
C= p<.05 as indicated by separate drug contrasts compared to escitalopram
ns= non significant
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Table 3. Mean differences (confidence intervals), estimates of effects sizes and
observed power of significant drug-placebo contrasts
Drug placebo contrast
Escitalopram
Mean differnce (95% CI) Estimates of
effect  size
Observed Power
 VVLT
Total immediate recall ns - -
SMT
Localization error delay 0 (mm) ns - -
Localization error delay 2 (mm) ns - -
Localization error delay 4 (mm) ns - -
Intercept ns - -
POMS
Depression -6,36 (-12,09 – -0.69) 0,272 0,60
Anger -4,40 (-8,27 – -0,54) 0,282 0,62
Fear -11,62 (-18,50 – -4,75) 0,464 0,92
Vigor 12,66 (3,95 – 21,37) 0,390 0,83
Escitalopram + ketanserin
 VVLT
Total immediate recall ns - -
SMT
Localization error delay 0 (mm) 3,26 (1,06 – 5,46) 0,399 0,84
Localization error delay 2 (mm) 3,20 (0,17 – 6,24) 0,252 0,56
Localization error delay 4 (mm) 3,74 (0,60 – 6,89) 0,300 0,66
Intercept 3,07 (0,67 – 5,48) 0,330 0,72
POMS
Depression ns - -
Anger ns - -
Fear ns - -
Vigor 11,88 0,237 0,52
Escitalopram + pindolol
 VVLT
Total immediate recall -6,31 (-11,01 – -1,61) 0,353 0,76
SMT
Localization error delay 0 (mm) ns - -
Localization error delay 2 (mm) ns - -
Localization error delay 4 (mm) ns - -
Intercept ns - -
POMS
Depression ns - -
Anger ns - -
Fear -15,17 (-27,22 – -3,12) 0,324 0,71
Vigor 18,20 (6,13 – 30,27) 0,408 0,85
ns= non significant
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Figure 1 Mean (se) recall of words after 3 learning trials as performance measurement
in the Visual Verbal Learning Task
**= p<0.05 escitalopram + pindolol compared to placebo as indicated by separate drug-placebo
contrasts
# = p<0.05 escitalopram + pindolol compared to escitalopram as indicated by a separate drug
contrast
Spatial Memory Task (SMT)
A  significant  overall  effect  of  Treatment  was  found  on  localisation  error  in  each
response delay condition: i.e. after a response delay of 0 sec (delay 0) (F3,45=5.99,
p<.01), 2 sec (delay 2) (F3,45=3.03, p<.05) and 4 sec (delay 4) (F3,45=2.78, p=.05). Drug-
placebo contrasts showed an impairing effect of escitalopram + ketanserin in each
response delay condition; i.e. delay 0 (F1,15=9.94, p<.01), delay 2 (F1,15=5.06, p<.05) and
delay 4 (F1,15=6.44, p<.05). Drug-drug comparison showed that localisation error was
increased on delay 0 (F1,15=6.08, p<.05) and delay 2 (F1,15=4.98, p<.05) compared to
escitalopram. These results indicate that escitalopram + ketanserin increased
localization error independent of response delay. The latter notion was also evinced
by the fact that combined treatment of escitalopram + ketanserin affected the intercept
(F1,15=7.40, p<.05) compared to placebo and compared to escitalopram (F1,15=5.957,
p<.05), but not the slope of the regression equation determining localization error as a
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function of response delay. Reaction time was not affected by Treatment. Means (se)
localization error in every treatment condition is shown in Figure 2.
Figure 2 Mean (se) localization error of the Spatial Memory Task as a function of
response delay
*= p<0.01 escitalopram + ketanserin compared to placebo as indicated by separate drug-placebo
contrasts
**= p<0.05 escitalopram + ketanserin compared to placebo as indicated by separate drug-
placebo contrasts
# = p<0.05 escitalopram + ketanserin compared to escitalopram as indicated by a separate drug
contrast
Probabilistic Reversal Learning task (RVL)
No statistically significant Treatment effects were established on the RVL.
Subjective measurement
Overall effects of Treatment were found on feelings of depression (F3,45=2.94, p<.05),
anger (F3,45=3.74, p<.05), fatigue(F3,45=3.93, p<.05), and vigour (F3,45=4.88, p<.01). Drug-
placebo contrasts showed significantly increased feelings of depression after
escitalopram (F1,15=5.59, p<.05 ) and nearly significantly increased feelings of
depression after escitalopram + pindolol (F1,15=4.04, p=.06). Furthermore, escitalopram
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significantly increased feelings of anger (F1,15=5.89, p<.05) and escitalopram + pindolol
slightly increased feelings of anger although not significantly different from placebo
(F1,15=3.75, p=.07). Feelings of fatigue were significantly increased by escitalopram
(F1,15=12.96, p<.01) and escitalopram + pindolol (F1,15=7.20, p<.05) and nearly
significantly increased after escitalopram + ketanserin (F1,15=4.22, p=.06). Feelings of
vigour were significantly decreased by escitalopram (F1,15=9.60, p<.01), escitalopram +
ketanserin (F1,15=4.66, p<.05) and escitalopram + pindolol (F1,15=10.34, p<.01)
compared to placebo. No Significant correlations were found between the different
scales of the POMS and the cognitive measurements.
Discussion
 Escitalopram did not affect spatial memory and reversal learning, but tended to
impair immediate recall in a verbal learning task. Escitalopram furthermore produced
feelings of depression, anger and fear and decreased feelings of vigour. Additional
treatment with pindolol augmented the effects of escitalopram and caused significant
impairment of immediate verbal recall, elevated feelings of anger and fear and
deceased vigour. Additional treatment with ketanserin resulted in significant
impairment of spatial memory performance and less vigour. These findings suggest
that 5-HT1A and 5-HT2A receptors are distinctly involved in verbal memory and spatial
working memory processing respectively.
Verbal memory impairment approached statistical significance after treatment
with escitalopram but additional treatment with pindolol significantly augmented this
deficit compared to placebo as well as escitalopram alone. This combined effect of
escitalopram and pindolol was very selective and confined to verbal memory
performance only. The mechanism of escitalopram and pindolol on serotonin release
may be twofold. Firstly, pindolol binds at presynaptic 5-HT1A autoreceptors where it
disinhibits serotonin release and contributes to the general increase of serotonin
caused by escitalopram (Rasmussen et al., 2004). Secondly, pindolol binds at the post-
synaptic 5-HT1A receptor where it blocks signal transmission. The former might be the
main  mechanism  underlying  verbal  memory  impairment  as  pindolol  was  shown  to
preferentially bind at the presynaptic autoreceptors (Rabiner et al., 2004; Rabiner et al.,
2000).  Prior  studies  on the association between memory function and brain levels  of
serotonin have shown that  both elevated and reduced levels  of  serotonin have been
associated with impairment of immediate recall and delayed recall measures in verbal
memory tasks (Harrison et al., 2004; Riedel, Klaassen et al., 1999; Schmitt et al., 2000).
MEMORY IMPAIRMENT, 5-HT1A AND 5-HT2A RECEPTORS
95
It has been suggested that the association between serotonergic activity and cognition
can be described in  terms of  an inverted U-curve (Meeter  et  al.,  2006;  Schmitt  et  al.,
2006). That is, both understimulation as well as overstimulation of the serotonergic
system resulting from either serotonin depletion or serotonin suppletion may
imbalance the cortical network responsible for memory function and lead to
impairment  of  certain aspects  of  memory such as  learning and consolidation.  In  the
present study, pindolol would lead to a scenario of overstimulation by increasing the
overall availability of serotonin in the synaptic cleft.
Spatial working memory performance decreased after combined treatment
with escitalopram and ketanserin but not after treatment with escitalopram alone. As
before, the effect of this combined treatment was very selective and confined to spatial
working memory. The mechanisms underlying spatial working memory impairment
clearly must be related to blockade of post-synaptic 5-HT2A receptors by kentanserin
because memory impairment increased after combined escitalopram/ketanserin
treatment compared to escitalopram alone. The exact role of 5-HT2 receptors in
memory function however is rather unclear (Meneses, 2002). Indications are present
for 5-HT2 receptors  to  modulate  dopaminergic  activity.  Moreover,  5-HT2A receptors
and 5-HT2c receptors exert opposite effects on dopamine release (Esposito, 2006).
Evidence  has  been  provided  that  5-HT2c receptors inhibit dopamine pathways (Di
Matteo et al., 2001; Lucas & Spampinato, 2000) and that 5-HT2A receptors enhance
dopamine release (Bortolozzi et al., 2005; Lucas & Spampinato, 2000). Dopamine
enhancement occurs in the Ventral Tegmental Area (VTA) which gives rise to the
mesocortical dopamine system (Bortolozzi et al., 2005) and the mesocortical dopamine
system is regarded as an important modulator of cognition such as spatial working
memory (Ellis et al., 2005; Robbins, 2000). For example, dopaminergic  stimulation by
bromocriptine, a dopamine agonist has been demonstrated to improve spatial
working memory (Luciana et al., 1998) whereas decrements in dopamine levels after
tyrosine depletion has been shown to impair spatial working memory (Harmer et al.,
2001). The implication is that blockade of the 5-HT2A receptor by ketanserin in the
present study may have decreased dopamine release in the mesocortical pathway
which  in  turn  may  have  resulted  in  impairment  of  spatial  working  memory
performance.
It  is  noteworthy  that  the  impairing  effect  of  combined  escitalopram  and
ketanserin treatment on spatial working memory performance occurred independent
or  did  not  interact  with  variations  in  response  delay.  In  other  words,  combined
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treatment affected the intercept but not the slope of the regression lines describing
localization error as a function of response delay.  One could argue that spatial
memory impairments were caused by a general perceptual deficit following combined
treatment of escitalopram and ketanserin. However, the fact that impairment of
spatial memory was selective and specific to escitalopram/ketanserin and did not
appear in other tasks in which visual perception was also required, refutes this
argument. Furthermore, it is not expected that the effects caused by the differential
serotonergic manipulations were due to side effects caused by the drug treatments.
Participants  generally  reported  loss  of  vigour  and  increase  in  anger,  fatigue  and
drowsiness  to  similar  degrees  in  all  drug  conditions  which  cannot  account  for  the
specificity and selectivity of memory impairments that were observed in the present
study  under  different  drug  conditions.  In  addition,  no  correlations  were  found
between mood and cognition.
No significant effects of the serotonergic manipulations were found on
reversal  learning.  The  former  seems  in  line  with  a  number  of  previous  studies  that
failed to show any behavioural effects of acute tryptophan depletion on reversal
learning (Evers, Tillie et al., 2005; Evers, Cools et al., 2005; Gallagher et al., 2003;
Hughes, Gallagher et al., 2003; Murphy et al., 2002). Apart from the present study, no
other work on the effects of serotonin suppletion on reversal learning is available. The
overall conclusion thus seems to be that task performance in reversal learning tasks is
not strongly dependent on serotonergic mechanisms.
In the present  study,  pindolol,  a  5-HT1A partial agonist, impaired immediate
verbal memory and ketanserin, a 5-HT2A receptor antagonist, impaired spatial
memory, both in combination with the SSRI escitalopram. These results suggest that 5-
HT1A receptors and 5-HT2 receptor are distinctly involved in verbal and spatial
memory function.
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Chapter 7
The role of 5-HT1A and 5-HT2A receptors in attention
and motor control: a mechanistic study in healthy
volunteers
Abstract
Rationale: various studies have demonstrated a modulating role for serotonin in attention. Selective
serotonin inhibitors have repeatedly been shown to impair performance in sustained attention tasks.
Objectives: to assess the contribution of serotonin reuptake inhibition and specific blockade of the pre-
synaptic 5-HT1A receptor and the 5-HT2A receptor to deficits in attention. Methods: the study was conducted
according to a randomized, double-blind, placebo controlled, 4-way crossover design including 16 healthy
volunteers. Treatments consisted of oral administration of the SSRI escitalopram 20 mg + placebo,
escitalopram 20 mg + ketanserin (5-HT2A antagonist) 50 mg, escitalopram 20 mg + pindolol (5-HT1A
antagonist) 10 mg and placebo + placebo on 4 separate days. A range of performance tasks were conducted
to assess the subjects’ attention and motor functions. Results: escitalopram administered alone impaired
tracking performance in a divided attention task. The combination of escitalopram and pindolol as well as
escitalopram and ketanserin impaired divided attention as compared to placebo. In addition, escitalopram
and ketanserin impared sustained attention. Divided attention impairment observed after combined
treatments did not significantly differ from impairments after escitalopram alone. Sustained attention
impairment observed after combined escitalopram and ketanserin significantly differed from escitalopram
alone. Conclusions: 5-HT1A receptor blockade hardly affected SSRI effects on attention. Additional 5-HT2A
receptor blockade however produced impairments of sustained attention.
Wingen, M., Kuypers, K. P. C., & Ramaekers, J. G. (2007). The role of 5-HT1A and 5-
HT2A receptors in attention and motor control: a mechanistic study in healthy
volunteers. Psychopharmacology, 190, 391-400.
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Introduction
Suppletion of serotonin (5-HT) levels has been associated with a reduction in
sustained attention i.e. the capability to stay alert for a period of time, often called
vigilance. Enhancement of serotonin levels after acute and subchronic administration
of a range of selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine, paroxetine,
venlafaxine and citalopram, has been shown to reduce vigilance performance as
assessed  by  various  studies  in  healthy  volunteers  using  the  Mackworth  Clock
paradigm (O'Hanlon et al., 1998; Ramaekers et al., 1995; Riedel et al., 2005; Schmitt,
Ramaekers et al., 2002). The Mackworth Clock Task has been extensively used in
studies on human vigilance performance. The task last 45 minutes during which
subjects must sustain attention on the task, while waiting for an unpredictable event
(Mackworth, 1950).
The role of serotonin in vigilance performance has not been fully determined,
but may be indirectly related to dopaminergic neurotransmission. Stimulation of
dopamine transmission by amphetamine and methylphenidate has been shown to
improve vigilance performance (Koelega, 1993) and dopamine has been associated
with tonic internally-driven arousal and readiness to respond (Pribram &
McGuinness, 1975; Robbins, 1997). Serotonin exerts an inhibitory influence on
dopaminergic activity (Soubrie, 1986; Spoont, 1992) which in turn could lead to
vigilance impairment. The role of dopamine in SSRI induced vigilance impairment
was  previously  demonstrated  in  two  studies  assessing  the  effect  of  sertralin  on
vigilance (Riedel et al., 2005; Schmitt, Ramaekers et al., 2002). Both studies showed
that sertralin does not reduce vigilance, probably because the drug not only inhibits
serotonin transporters but dopamine transporters as well. This additional
dopaminergic stimulation is believed to attenuate the vigilance impairment following
indirect serotonin stimulation by sertralin (Schmitt, Ramaekers et al., 2002).
The aim of  the study was to  further  examine the association between serotonin and
attention and the contributing roles of specific serotonin receptors. Therefore, the
present study examined the role of 5-HT1A and 5-HT2A receptors in serotonin related
impairment of attention in subjects that were pre-treated with an SSRI. Pre-treatment
by the SSRI escitalopram, was expected to stimulate serotonergic functionby elevating
serotonin levels in the synaptic cleft by indirect activation of 5-HT1 and 5-HT2
receptors. Subsequently, blockade of 5-HT1A and 5-HT2A receptors  was  achieved  by
administration of pindolol and ketanserin respectively. Evidence exists that 5-HT2
receptors modulate dopaminergic activity (Esposito, 2006). It was expected that
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blocking the postsynaptic 5-HT2A receptor by ketanserin may decrease dopamine
release (Bortolozzi et al., 2005; Lucas & Spampinato, 2000). A decrease in dopamine
may lead to less activation of the mesocortical dopamine projections to the prefrontal
cortex (Robbins, 1997) which in turn may augment the impairing effect of the SSRI on
sustained  attention.  It  was  expected  that  blocking  the  5-HT1A receptor by pindolol
would  augment  the  effect  of  escitalopram  on  sustained  attention.  Pindolol  is  a  very
partial 5-HT1A agonist that blocks 5-HT1A receptors preferentially presynaptically
(Rabiner et al., 2004; Rabiner et al., 2000). The indirect inhibiting effect or feedback
mechanism  of  the  SSRI  on  serotonin  via  the  presynaptic  5-HT1A autoreceptor is
attenuated by pindolol which leads to increased serotonin levels (Rasmussen et al.,
2004). In addition to vigilance performance, other tasks measuring divided attention,
selective  attention,  motor  control  and  motor  impulse  control  were  included  in  the
present study to determine the effects of the abovementioned serotonergic
manipulations on these cognitive functions.
Methods
Subjects
Sixteen healthy volunteers (8?, 8?) mean age (se) 25,9 (1,73) were recruited. All
participants underwent a screening procedure consisting of a telephone interview,
health questionnaire, 12-lead electrocardiogram, laboratory testing (haematology and
blood  chemistry,  urinalysis,  drug-and  pregnancy  screening)  and  a  routine  medical
examination. Volunteers were included when they were 21 to 45 years of age, healthy
(i.e. absence of all exclusion criteria), had a normal static binocular acuity (corrected or
uncorrected),  a  body  mass  index  between  19  and  30,  and  were  willing  to  sign  an
informed consent. Excluded were those volunteers who suffered from, or had a
history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal,
haematological or psychiatric illness. Other exclusion criteria were excessive drinking
(>20 glasses of alcohol containing beverages a week), pregnancy or lactation,
menstrual disorder, use of medication other than oral contraceptives, smoking tobacco
or use of illicit drugs, and any sensory or motor deficits which could reasonably be
expected to affect test performance. Those volunteers who had a first-degree relative
with a psychiatric disorder or a history of a psychiatric disorder were also excluded.
Eventually,  3  out  of  8  women used oral  contraceptives.  The study was approved by
the standing medical ethics committee of Maastricht University and the Maastricht
Academic Hospital’s Board of Directors. It was carried out in accordance with the
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World Medical Association’s Declaration of Helsinki (Edinburgh, 2000). Written
informed consent was obtained from each volunteer prior to participation to the
study.
Design and treatment
The study was conducted according to a double-blind, placebo controlled, 4-way
crossover design. Complete balancing of the treatments yielded sixteen treatment
orders that were randomly assigned to 16 healthy human volunteers. Treatments
consisted  of  escitalopram  20  mg  +  placebo,  escitalopram  20  mg  +  ketanserin  50  mg,
escitalopram 20 mg + pindolol 10 mg and placebo + placebo administered at 4
different test days separated by a wash-out period of at least 7 days. Escitalopram,
ketanserin and pindolol oral dosages have a Cmax of 4 hours, 2 hours and 1 hour and
a half-life of 27-32 hours, 3-4 hours and 13-18 hours respectively (Aellig et al., 1981;
Hedner et al., 1983). An oral dose of 10 mg of pindolol was needed in healthy
volunteers  to  achieve  a  37  %  occupancy  of  the  5-HT1A autoreceptor (Rabiner et al.,
2001). A 50 mg single dose of Ketanserin was used based on a previous study (Liechti
et al., 2000).
Testing procedure
Participants underwent a training session of the performance test in order to minimize
learning effects. On test days, participants arrived at 9.00 a.m. at the test laboratory;
received a standard breakfast and completed a sleep quality questionnaire. They
received the first treatment capsule, containing either escitalopram or placebo at 9.30
a.m.  Participants  were  then  seated  for  the  next  4  hrs  in  a  secluded  waiting  room  in
order  to  wait  for  escitalopram  to  reach  Cmax.   At  12  hours  participants  received  a
standard lunch, followed by the second treatment capsule at 12.30 p.m. containing
pindolol, ketanserin or placebo. Mood assessment and cognitive assessments were
conducted at 13.30 p.m., i.e. at 1 hr after the second drug treatment. Participants were
not allowed to consume alcohol 24 hours prior to testing and caffeine-containing
beverages 4 hours prior to the start of the test day.
Performance tasks measuring attention
Sustained attention - Mackworth Clock Test
The Mackworth Clock Test measures vigilance or sustained attention (Mackworth,
1950). Participants were seated in front of a computer screen displaying a circular
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arrangement of 60 gray dots. The dots were briefly illuminated in clockwise rotation
at  a  rate  of  one per  500 milliseconds,  moving 6  degrees  from dot  to  dot.  Volunteers
were instructed that occasionally there would be a skip of illumination of one of the
dots (12 degrees move of the dots). At this signal volunteers were required to press a
button as fast as possible. A response within 3 seconds of the signal was registered as
a correct detection. A total of 30 signals were presented with 10 per 15 minute period
and  intervals  of  8  seconds  to  7.2  minutes.  Outcome  measures  were  total  correct
detections (hits) and corresponding reaction times.
Selective attention - Left-right task
The left-right task or choice reaction time task is a parametric version of the well-
known colour-word response conflict task (Stroop, 1935).The words ‘Left’ and ‘Right’
were displayed either at the left or the right side of a computer screen. Response
instructions  were  to  respond  quickly  (by  pressing  a  corresponding  button)  to  the
location of the word irrespective of its meaning. The outcome variables were correct
detections for compatible and incompatible words with the corresponding reaction
times. A compatible word stands for the word ‘left’ or ‘right’ presented at the
corresponding  side  of  the  computer  screen.  An  incompatible  word  means  that  the
word ‘left’ was presented at the right side of the computer screen or the word ‘right’
was presented at the left side of the computer screen.
Divided attention - Divided Attention Task
Divided Attention Task (DAT) (Moskowitz, 1973)measures the ability to divide
attention between two tasks performed simultaneously. Participants performed the
same tracking task as described below (CTT) but at a constant level of difficulty set at
50% of his/her maximum capacity. Tracking error is measured as the difference in
millimetre between the position of the cursor and the midpoint of the scale. While
tracking, the participant monitored 24 peripheral displays upon which single digits
change asynchronously at  5  seconds intervals.  The occurrence of  the digit  “2” was a
signal for the participant to remove the foot from a pedal as rapidly as possible.
Signals  occurred  twice  at  every  location,  in  random  order,  at  intervals  of  5  to  25
seconds. Average absolute tracking error, mean reaction time, hits and control losses
were taken as outcome variables.
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Performance tasks measuring motor control
Motor control - Critical Tracking Task
The Critical Tracking Task (CTT) (Jex et al., 1966)measures the participant’s ability to
control a displayed error signal in a first-order compensatory tracking task. Error was
displayed  as  an  increasing  horizontal  deviation  of  a  cursor  from  the  midpoint  on  a
horizontal, linear scale. Compensatory joystick movements nulled the error by
returning  the  cursor  to  the  midpoint.  The  frequency,  at  which  the  participant  lost
control, was the critical frequency or lambda c (lc ) in rad/s. The test included 5 trials
of which the lowest and the highest score were discarded the average of the remaining
scores was taken as the final score.
Motor inhibition - Stop signal task
This task requires participants to make quick key responses to visually presented go
signals  and  to  inhibit  any  response  when  a  visual  stop  signal  occurs  (Ramaekers  &
Kuypers,  2006).  The  go  signals  were  four  1.5  cm  letters  (ABCD)  presented  one  at  a
time in the centre of a computer screen. Participants were required to respond to each
letter as quickly as possible by pressing on one of two response buttons. One button
was pressed to indicate that “A” or “C” appeared and the other to indicate “B” or “D”.
Letters were displayed for 500 ms and the computer screen was blank for 1.5 s
interstimulus interval before the next letter was displayed. This provides a period of 2
sec in which the participant can respond to a letter.
 A  single  test  consisted  of  176  trials  in  which  each  of  the  4  letter  stimuli  were
presented  equally  often.  A  stop  signal  occurred  in  48  trials  during  a  test.  The  stop
signal consisted of visual cue, i.e. “*”, that appeared in one of the four corners of the
screen. Participants were required to withhold any response in case a stop-signal was
presented.  Stop  signal  were  presented  12  times  at  each  of  the  four  delays  after  the
onset of a letter: 50, 150, 250 and 350 ms. Trials always begin with a 500 ms
preparation  interval  in  which  a  fixation  point  appeared  on  the  centre  of  the  screen.
The task lasted about 10 minutes. Outcome measures were correct responses to the go
signals, successfully inhibited responses per delay (correct inhibitions), mean reaction
time of the go signals and an estimated time required to inhibit responses (stop signal
reaction time). The stop signal reaction time was calculated on the probability of
inhibiting responses to stop signals and the distribution of reaction times to go-signals
after excluding outliers (Logan, 1994).
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Subjective measurements
Each test day subjects filled out the Groninger Sleep Quality Scale (Mulder-Hajonides
van  der  Meulen,  1981)  to  assess  sleep  quality  during  the  preceding  night.  The  total
score  consisted  of  14  yes/no  questions  to  score  the  number  of  sleep  complaints
(ranging from good sleep (score 0) to worst possible sleep (score 14)). In addition,
specific questions about time needed to fall asleep, number of awakenings during the
night and sleep duration in hours were included. Bond and Lader Questionnaire was
assessed using different scales for Alertness, Contentedness and Calmness (Bond &
Lader, 1974).
Statistical analyses
Data were analyzed by means of a GLM repeated measures analysis (SPSS 11.5) with
Treatment (4 levels) as the main factor. Only when a significant overall effect of
Treatment  was  found  on  a  particular  performance  measure  (alpha  level  was  set  at
p=0.05), follow-up contrast analyses were conducted to test for differences between
treatments and placebo and between combined treatments and escitalopram. For
follow-up contrast analyses, alpha level was set at p=0.01 to correct for multiple (i.e. 5)
comparisons.
Results
Missing data
A total of 16 subjects completed the study. Due to technical failure data of one subject
on the Mackworth clock task in the escitalopram + ketanserin condition was not
recorded. These incomplete data were treated as missing values and replaced by the
mean score of the remaining 15 subjects in the escitalopram + ketanserin condition.
Cognitive assessments
Mean  (se)  of  the  cognitive  assessments  are  shown  in  Table  1.  Confidence  intervals,
estimates of effect size and observed power are presented in Table 2.
Cognitive outcome parameters measuring attention
Sustained attention - Mackworth Clock Test
Overall, Treatment significantly affected correct detections (F3,45=9.06, p<.001). In
addition  there  was  a  Time  on  task  effect  for  correct  detections  (F3,45=12.57, p<.001),
which indicates a vigilance decrement during the 45 minutes task performance, but no
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Treatment by Time on task interaction effect. Drug-placebo contrasts showed that
escitalopram + ketanserin (F1,15=37.59, p<.001) reduced the total number of correct
detections significantly, as compared to placebo. Drug-drug comparisons
demonstrated that escitalopram + ketanserin significantly impaired correct detections
(F1,15=8.065, p=.01) compared to escitalopram alone. Escitalopram alone or
escitalopram + pindolol did not affect the outcome measurements of the Mackworth
Clock Test. No Treatment effects or Time on task effects were found on the reaction
time.  Mean  (se)  number  of  correct  detections  in  every  treatment  condition  as  a
function of time on task is shown in Figure 1.
Table 1. Mean (se) outcome variables of cognitive tasks
Mean (standard error of mean)
Overall                             Treatment
Outcome measures
Escitalopram Escitalopram
+ ketanserin
Escitalopram
+ pindolol
Placebo
F, df=3,45 P
Mackworth Clock Task
Correct detections (hits) 21,4 (1,48) 15,2 (1,56)B,D 19,8 (1,50) 22,7 (1,04) 9.07 <.001
mean RT (msec) 797 (63,6) 905 (87,9) 788 (65,6) 770 (62,0) 2.47 ns
Choice Reaction TimeTask
Correct compatible 15,8 (0,10) 15,9 (0,06) 15,8 (0,14) 15,9 (0,09) 0.65 ns
Mean RT compatible (msec) 574 (19,6) 623 (29,2) 590 (23,9) 571 (24,7) 2.15 ns
Correct incompatible 15,5 (0,16) 15,5 (0,16) 15,4 (0,22) 15,4 (0,16) 0.09 ns
Mean RT incompatible (msec) 586 (20,1) 618 (24,7) 601 (22,0) 574 (15,9) 2.76 .053
Divided Attention Task
Average tracking error (mm) 19,0 (1,52)B 20,2 (1,62)B 19,2 (1,87)B 17,1 (1,47) 5.67 .002
Mean RT (msec) 1831 (66,0) 1955 (84,4) 1872 (96,7) 1759 (75,7) 2.45 ns
Hits 45,7 (0,70) 44,6 (0,89) 45,2 (1,28) 45,6 (0,73) 1.50 ns
Control losses 5,2 (1,73) 10,4 (4,13) 6,2 (2,20) 7,2 (3,27) 1.07 ns
Critical Tracking Task
lambda c (lc ) 3,7 (0,20) 3,8 (0,19) 3,9 (0,18) 3,8 (0,18) 0.69 ns
Stop Signal Task
Correct detections 116,8 (3,28) 115,7 (3,41) 118,4 (1,76) 118,7 (2,85) 0.59 ns
Correct inhibitions 350 3,6 (0,83) 4,5 (0,91) 4,0 (1,06) 3,8 (0,98) 0.88 ns
                                250 7,7 (0,95) 7,1 (1,03) 7,1 (1,08) 7,3 (1,01) 0.48 ns
                                150 9,8 (0,66) 9,2 (0,83) 9,4 (0,90) 9,1 (0,78) 0.54 ns
                                 50 10,8 (0,50) 10,2 (0,65) 10,5 (0,75) 10,6 (0,63) 1.10 ns
Mean RT hits (msec) 555 (29,0) 604 (37,0) 578 (45,3) 567 (40,9) 2.64 ns
Stop Signal RT (msec) 273 (12,0) 307 (19,4) 256 (13,7) 285 (11,3) 3.89 .028
B= p<.01 as indicated by separate drug-placebo contrasts
D= p=.01 as indicated by separate drug-drug comparisons compared to escitalopram
ns= not significant
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Table 2. Mean differences (confidence intervals), estimates of effects sizes and
observed power of significant drug-placebo contrasts
Drug placebo contrast
Escitalopram
Mean
Difference (95% CI)
Estimates of
Effect size
Observed
Power
 Mackworth Clock Task
Correct detections (hits) ns - -
mean RT (msec) ns - -
Choice Reaction TimeTtask
Correct compatible ns - -
Mean RT compatible (msec) ns - -
Correct incompatible ns - -
Mean RT incompatible (msec) ns - -
Divided Attention Task
Average tracking error (mm) 1,87 (0,70 – 3,05) 0,43 0,89
Mean RT (msec) ns - -
Hits ns - -
Control losses ns - -
Critical Tracking Task
lambda c (lc ) ns - -
Stop Signal Task
Correct detections ns - -
Correct inhibitions ns - -
Mean RT hits (msec) ns - -
Stop Signal RT (msec) ns - -
Escitalopram+ketanserin
 Mackworth Clock Task
Correct detections (hits) -7,51 (-10,1 – -4,90) 0,72 1,00
mean RT (msec) ns - -
Choice Reaction TimeTtask
Correct compatible ns - -
Mean RT compatible (msec) ns - -
Correct incompatible ns - -
Mean RT incompatible (msec) ns - -
Divided Attention Task
Average tracking error (mm) 3,05 (1,54 – 4,55) 0,55 0,98
Mean RT (msec) ns - -
Hits ns - -
Control losses ns - -
Critical Tracking Task
lambda c (lc ) ns - -
Stop Signal Task
Correct detections ns - -
Correct inhibitions ns - -
Mean RT hits (msec) ns - -
Stop Signal RT (msec) ns - -
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(Table 2 continued)
Drug placebo contrast
Escitalopram + pindolol
Mean
Difference (95% CI)
Estimates of
Effect size
Observed
Power
 Mackworth Clock Task
Correct detections (hits) ns - -
mean RT (msec) ns - -
Choice Reaction TimeTtask
Correct compatible ns - -
Mean RT compatible (msec) ns - -
Correct incompatible ns - -
Mean RT incompatible (msec) ns - -
Divided Attention Task
Average tracking error (mm) 2,07 (0,61 – 3,53) 0,38 0,81
Mean RT (msec) ns - -
Hits ns - -
Control losses ns - -
Critical Tracking Task
lambda c (lc ) ns - -
Stop Signal Task
Correct detections ns - -
Correct inhibitions ns - -
Mean RT hits (msec) ns - -
Stop Signal RT (msec) ns - -
ns= non significant
Selective attention - Left-right task
A  significant  overall  effect  of  Treatment  was  found  on  mean  reaction  time  in
incompatible trials (F3,45=2.76, p=05). Drug-placebo contrasts and drug-drug contrasts
did not reveal any differences. No effect was found on other outcome measurements
of the selective attention task.
Divided attention - Divided Attention Task
Treatment (F3,45=5.67, p<.01) significantly affected tracking performance in the divided
attention task. Escitalopram (F1,15=11.52, p<.01), escitalopram + pindolol (F1,15=9.13,
p<.01) and escitalopram + ketanserin (F1,15=18.64, p<.001) all increased tracking error
as  compared  placebo.  Mean  (se)  of  tracking  error  in  every  treatment  condition  is
shown in Figure 2. Drug-drug contrasts did not reveal any differences. No treatments
effects were found on other outcome measurements of the divided attention task.
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Figure 1 Mean  (se)  number  of  hits  as  performance  measurement  in  the  Mackworth
Clock Task
*= p<.01 escitalopram + ketanserin compared to placebo as indicated by separate drug-placebo
contrasts
# = p=.01 as indicated by separate drug-drug comparisons escitalopram + ketanserin compared
to escitalopram
Figure 2 Mean (se) tracking error of the Divided Attention Task
*= p<.01 compared to placebo as indicated by separate drug-placebo contrasts
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Cognitive outcome parameters measuring motor control
Motor control - Critical Tracking Task
No Treatment effects were found on the mean lambda score.
Motor inhibition - Stop signal task
A significant effect of Treatment was found on stop signal reaction time (F3,45=3.89,
p<.05). Drug-placebo and drug-drug contrasts did not reveal any significant
differences. No Treatment effects were found on correct detections, reaction times or
correct inhibitions per delay.
Subjective measurements
Subjective evaluations of sleep quality and mood are shown in Table 3.
Treatments did not affect the outcome measures of the Groninger Sleep Quality Scale
and the Contentedness and Calmness ratings but did affect the Alertness ratings
(F3,45=3,65, p<.05). Drug-placebo comparisons did not reveal any differences.
Subsequent analysis showed no significant correlations between the alertness ratings
and the significant attention performance measurements.
Table 3. Mean (se) outcome variables of subjective measurements
Mean (standard error of mean)
Overall                                  Treatment
Outcome measures
Escitalopram Escitalopram
+ ketanserin
Escitalopram
+ pindolol
Placebo
F, df=3,45 P
Groninger Sleep Quality Scale
Number of sleep complaints 2,6 (0,71) 1,4 (0,39) 2,2 (0,69) 0,88 (0,42) 2.42 ns
Time needed to fall asleep (min) 21,3 (6,20) 17,5 (3,39) 14,4 (3,49) 17,3 (3,93) 0.85 ns
Number of awakenings 1,4 (0,92) 0,3 (0,18) 0,6 (0,27) 0,5 (0,32) 1.01 ns
Sleep duration (h) 6,9 (0,31) 7,3 (0,23) 6,9 (0,31) 7,3 (0,21) 1.44 ns
Bond and Lader questionnaire
Alertness 66,2 (5,71) 67,6 (6,17) 63,0 (6,93) 80,4 (2,87) 3.65 .019
Contentedness 78,0 (4,39) 79,8 (3,54) 75,7 (4,42) 82,3 (2,97) 1.32 ns
Calmness 81,5 (2,99) 83,5 (2,76) 76,1 (4,34) 84,7 (2,46) 2.36 ns
ns= not significant
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Discussion
Data from the present study showed that escitalopram alone significantly impaired
tracking performance in a divided attention task. Combinations of pindolol +
escitalopram and ketanserin + escitalopram also impaired measures of divided
attention when compared to placebo. The combination of escitalopram + ketanserin
impaired sustained attention, even when compared to escitalopram alone. Subjective
mood scales showed an overall reduction in alertness. It is not expected that the effects
caused by the differential serotonergic manipulations were due to sedative properties,
because the drug effects on the performance measurements of the different tasks, were
very selective. If sedation was a causal factor, one would have expected more general
impairment on all laboratory tasks. In addition, no correlations were found between
degree of alertness and different measures of attention.
The lack of vigilance impairment after escitalopram alone is not in line with
previous studies showing impairing effects of various SSRIs on vigilance performance
using the same Mackworth Clock paradigm (Mackworth, 1950). This can probably be
explained by the relative small number of subjects that were employed in the present
study (n=16). SSRI induced vigilance decrements are usually very minor and
researchers  regularly  used  up  to  24  subjects  in  order  to  increase  statistical  power
(Riedel  et  al.,  2005).  In  the  present  study  the  number  of  correct  detections  after
escitalopram decreased by only 6%. When combined with pindolol the number of
correct detection decreased by 13%. The latter decrement did also not reach statistical
significance. There was no interaction between treatment and time on task, indicating
that the effect of the different treatments on vigilance decrement over time was
relatively equal. This is in accordance with the abovementioned previous studies on
serotonin and vigilance (Ramaekers et al., 1995; Schmitt, Ramaekers et al., 2002).
The combination of ketanserin + escitalopram decreased the number of
correct detections by 33%. This decrement not only differed from placebo but also
from escitalopram alone. This strongly suggests that postsynaptic 5-HT2A receptor
blockade plays a modulatory role in vigilance performance.  Various animal studies
indicate that 5-HT2 receptors modulate dopaminergic activity and that 5-HT2A
receptors and 5-HT2C receptors even exert opposite effects on dopamine release
(Esposito, 2006). Dopamine release is inhibited by 5-HT2C receptor stimulation (Di
Matteo et al., 2001; Lucas & Spampinato, 2000) and dopamine is enhanced by 5-HT2A
receptor activation (Bortolozzi et al., 2005; Lucas & Spampinato, 2000). Dopamine is
released in the Ventral Tegmental Area (VTA) which leads to the mesocortical
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dopamine system (Bortolozzi et al., 2005). The mesocortical dopamine system in turn
is  regarded  as  an  important  modulator  of  cognition  (Robbins,  2000).  In  the  current
study, 5-HT2A receptor blockade by ketanserin may have decreased dopamine release
which may have resulted in vigilance impairment.
There is more evidence that suggest a role for dopamine in attention. Simultaneous
depletion of serotonin and catecholamines in healthy volunteers produced vigilance
impairment independent of general drowsiness levels (Matrenza et al., 2004).
According to the authors, the impairment in sustained attention was more likely to be
caused by catecholamine reducement (norepinephrine and dopamine). However,
some studies failed to demonstrate changes in vigilance performance after tyrosine
depletion (Harmer et al., 2001; Harrison et al., 2004). Yet, dopamine suppletion
following stimulant drugs such as methylphenidate and amphetamines improved
sustained attention (Koelega, 1993; Nicholson & Pascoe, 1990). In addition, as
mentioned in the introduction, the SSRI sertraline did not impair vigilance
performance (Riedel et al., 2005; Schmitt, Ramaekers et al., 2002) probably because it
inhibits serotonergic as well as dopaminergic reuptake.
In  the  present  study  escitalopram  and  the  combinations  of  pindolol  +
escitalopram and ketanserin + escitalopram all decreased tracking performance in a
divided attention task. No effects of the specific serotonergic manipulations were
found on selective attention. Impairments seen on the divided attention task after both
combinations never differed from those observed after escitalopram alone, which
seems to indicate that blockade of 5-HT1A and 5-HT2A receptors did not significantly
contribute the impairments of divided attention. The impairment of tracking
performance was evident in the divided attention task but not in the critical tracking
task. The presence of impairment in the former task may be related tot the fact that
this  task  involves  performing  two  tasks  simultaneously  and  this  requires  more
attentional resources. Previous studies on the association between serotonin and
selective or divided attention have produced mixed results. Serotonin suppletion
following SSRI administration has usually not been associated with changes in
selective and divided attention (Schmitt, Ramaekers et al., 2002; Wingen et al., 2005).
Yet, tryptophan depletion generally improved performance in a Stroop task (Schmitt
et  al.,  2000)  and  reduced  motor  speed  on  incompatible  trials  in  a  reaction  time  task
(Coull et al., 1995).
With respect to the role of 5-HT1A and 5-HT2A receptors in attention, the
results of the present study suggest that the 5-HT2A receptor might be involved more
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in sustained attention as compared to divided or selective attention. As far as the 5-
HT1A receptor, it seems that this receptor does not have an additional effect next to a
possible effect of general increased serotonin levels. However, the present study used
10 mg pindolol to obtain a 37% binding of the 5-HT1A autoreceptor. Still there can be a
large variation in 5-HT1A binding between subjects (Rabiner et al., 2004) and it is
possible that not all subjects had an adequate 5-HT1A receptor blockade to cause
significant changes in serotonergic function. With less variation in binding, more
specific changes in serotonergic function could occur and different effects on attention
are possible. This is an important issue for future studies examining the role of
different serotonergic receptors in cognition.
Motor impulsivity as assessed in the stop signal task was not affected by the
specific serotonergic manipulations. Current notions on the role of serotonin in motor
impulse control show different results. Serotonin suppletion following a single dose of
3,4-Methylenedioxymethamphetamine (MDMA) has previously been shown to
decrease stop reaction time in a stop signal task (Ramaekers & Kuypers, 2006) and
motor impulse control decreases after central serotonin depletion (Harrison et al.,
1997). Results from animal studies however are mixed and demonstrate both
increments  and  decrements  in  motor  impulsivity  after  5-HT1A receptor stimulation
(Blokland et al., 2005; Carli & Samanin, 2000). Possibly, serotonin as well as dopamine
are  involved  in  motor  impulse  control.  It  has  been  shown  that  stimulation  of
dopamine release will improve motor impulse control in a stop signal paradigm (de
Wit  et  al.,  2000;  de  Wit  et  al.,  2002).  The  results  of  the  present  study  on  impulsivity
cannot support previous findings, but possibly with a bigger sample size more firm
statements can be given.
It is concluded that 5-HT1A blockade hardly affected SSRI effects on attention.
Combined 5-HT2A blockade however produced additional impairment of sustained
attention.
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Chapter 8
Sustained attention and serotonin: a pharmaco-
fMRI study
Abstract
Background: evidence suggests that stimulation of serotonergic function in healthy humans causes an
impairment of sustained attention. Aim: the present study assessed the influence of increased serotonin
levels on brain areas involved in sustained attention. Method: 10  healthy  volunteers  (5?,  5?)  received  the
selective serotonin reuptake inhibitor (SSRI) escitalopram (20mg) and placebo in a balanced, double blind,
2-way crossover design. Participants performed the Mackworth Clock Test to measure sustained attention
during functional MRI measurements at 3-Tesla. Subjective measurements after pharmacological
manipulation were conducted with the Bond & Lader Questionnaire. Results: independent of treatment,
brain areas associated with task performance on a sustained attention task were activated, including right
prefrontal and parietal areas. After escitalopram administration, less activation was shown in the caudate
nucleus, thalamus and frontal areas. No effect of escitalopram was shown on behavioral data although
subjective measurements showed decreased alertness after escitalopram. Conclusion: the results suggest that
serotonin stimulation impairs sustained attention through modulating activation of selective brain areas
including  the  thalamus  and  caudate  nucleus,  which  are  possibly  involved  in  a  subcortical  network  for
sustained attention.
Wingen, M., Kuypers, K. P. C.,Van de Ven, V., Formisano, E., & Ramaekers, J. G.
(2006). Sustained attention and serotonin: a pharmaco-fMRI study, submitted.
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Introduction
The neurotransmitter serotonin is involved in different psychiatric disorders,
including major depression. The majority of patients diagnosed with a depressive
disorder  have  a  malfunction  of  the  serotonergic  system  (Meltzer,  1989).  Depression
and also other psychiatric disorders are associated with cognitive dysfunction such as
impaired memory performance and attention or planning deficits (Austin et al., 2001;
Elliott, Baker et al., 1997; Landro et al., 2001). There is evidence that serotonin plays a
role in the etiology of depression and is associated with cognitive problems (reviewed
by (Schmitt et al., 2006)). Some studies in depressed patients showed that serotonin
stimulation by antidepressants such as fluoxetine, fluvoxamine and trazodone,
directly improves cognitive functions independent from elevation of depressive
symptoms (Doraiswamy et al., 2003; Koetsier et al., 2002; Riedel, Schoenmakers et al.,
1999). Studies in healthy volunteers have also provided evidence for a possible role of
serotonin in cognitive performance. Low serotonin levels following tryptophan
depletion and high serotonin levels following SSRI administration have both been
shown to reduce memory performance (Riedel, Klaassen et al., 1999; Riedel, Klaassen,
Griez et al., 2002; Wingen, Kuypers et al., 2006b). It has been suggested that the
relation between serotonin and memory reflects an inverted U-curve (Meeter et al.,
2006) which entails that both overstimulation and understimulation of serotonin levels
worsen memory performance. Other cognitive functions such as cognitive flexibility
and attention are possibly also modulated by serotonin (Schmitt et al., 2006).
Particularly, sustained attention, often called vigilance, is one aspect of the general
construct of attention that is associated with serotonergic functioning (Schmitt,
Ramaekers et al., 2002). Single and repeated doses of SSRIs have been shown to reduce
sustained attention in healthy volunteers in a number of studies using the Mackworth
Clock Test paradigm (O'Hanlon et al., 1998; Ramaekers et al., 1995; Riedel et al., 2005;
Schmitt, Ramaekers et al., 2002). While performing the Mackworth Clock Test,
participants have to sustain their attention for 45 minutes while monitoring a circular
arrangement of sequentially illuminating dots. A button press is required when a rare
event  occurs  (signal  detection)  (Mackworth,  1950).  As  time  passes,  it  becomes  more
difficult to sustain attention and more misses occur. This is called the vigilance
decrement (Teichner, 1974).
Antidepressants are suitable means for challenging the serotonergic system
while measuring cognitive functions. Moreover, combining (psycho)pharmacological
studies with functional magnetic resonance imaging (fMRI) might give more insight
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into the underlying neuroanatomical substrates of task performance  and changes in
functioning  of  these  brain  areas  associated  with  cognitive  performance.  Previous
pharmaco-fMRI studies for establishing the association between serotonin and
cognition  have  used  several  antidepressants.  For  instance,  one  study  used  the
noradrenergic and specific serotonergic antidepressant mirtazapine to examine the
effects of serotonin on behavioral inhibition in a parallel group design. The results
showed a modulatory role for serotonin of brain responses in a Go/No-Go and a
Reward/No-Reward task in various brain areas including orbitofrontal cortex and
parietal cortex (Vollm et al., 2006). Unfortunately, mirtazapine has additional
noradrenergic and histaminergic affinity, which can influence the results on the
behavior level as well as on the neuroanatomic level. Ideally, a more selective
serotonergic antidepressant is required. Another study used the selective serotonin
reuptake inhibitor (SSRI) citalopram in a within-subject fMRI design and
demonstrated  effects  of  serotonin  on  brain  areas  involved  in  several
neuropsychological tasks, despite little behavioral changes due to a ceiling effect (Del
Ben et al., 2005).  No prior pharmaco-fMRI studies have yet been undertaken to assess
the effects of serotonin on sustained attention.
The aim of the present study was to define the brain regions that are involved
in performance during the Mackworth Clock Test. In addition, the effects of increased
serotonin levels in healthy human volunteers were assessed on sustained attention
and on brain areas underlying sustained attention. Serotonin stimulation was
obtained by blocking serotonin reuptake through administration of the most selective
SSRI,  escitalopram.  It  was  expected  that  acutely  increased  serotonin  levels  would
impair sustained attention performance measured by the Mackworth Clock Test. In
addition, this impaired performance was expected to be reflected in activation
changes in the brain areas that underlie sustained attention. Previous studies using
sustained  attention  tasks  and  fMRI  showed  involvement  of  the  right  parietal  and
frontal brain areas (Coull et al., 1998; Lewin et al., 1996; O'Conner et al., 2004). It was
expected  that  the  same  brain  areas  would  be  involved  while  performing  the
Mackworth Clock Test.
Materials and Methods
Subjects
Ten healthy volunteers (5?, 5?), mean age (se) 26.3 (2.46) were recruited. All
participants underwent a screening procedure, which consisted of a telephone
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interview, health questionnaire, 12-lead electrocardiogram, laboratory testing
(hematology and blood chemistry, urinalysis, drug-and pregnancy screening) and a
routine medical examination. Volunteers were included when they were 21 to 45
years of age, healthy, had a normal static binocular acuity (corrected or uncorrected),
a body mass index between 19 and 30, and were willing to sign an informed consent.
Excluded were those volunteers who suffered from, or had a history of cardiac,
hepatic, renal, pulmonary, neurological, gastrointestinal, hematological or psychiatric
illness. Other exclusion criteria were excessive drinking (>20 glasses of alcohol
containing  beverages  a  week),  pregnancy  or  lactation,  menstrual  disorder,  use  of
medication other than oral contraceptives, smoking tobacco or use of illicit drugs, and
any sensory or motor deficits which could reasonably be expected to affect test
performance. Those volunteers who had a first-degree relative with a psychiatric
disorder  or  a  history  of  a  psychiatric  disorder  were  also  excluded.  The  study  was
approved by the standing medical ethics committee of Maastricht University and the
Maastricht Academic Hospital’s Board of Directors. It was carried out in accordance
with the World Medical Association’s Declaration of Helsinki (Edinburgh, 2000).
Written informed consent was obtained from each volunteer prior to participation to
the study.
Design and Treatment
The study was conducted according to a double-blind, placebo controlled, 2-way
crossover design. Complete balancing of the treatments led to two treatment orders
that were randomly assigned to the participants. Treatments consisted of
escitalopram (20 mg) and placebo administered at 2 different test days separated by a
wash-out period of at least 7 days.
Testing procedure
Participants underwent a short training session of the Mackworth Clock Test on the
day of  the medical  examination in  order  to  minimize learning effects.  On test  days,
participants  arrived  at  9.00  a.m.  at  the  laboratory,  filled  out  an  informed  consent
concerning scanning procedures, received a standard breakfast and completed a sleep
quality questionnaire. They received the treatment capsule containing either
escitalopram or placebo at 9.30 a.m. Participants were then seated for the next hours
in a secluded waiting room in order to wait for escitalopram to reach the maximum
concentration in blood (Cmax).  At noon participants received a standard light lunch.
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Mood  assessments  were  conducted  at  13.00  p.m.  followed  by  an  anatomical  scan.
Scanning  and  testing  took  place  at  13.30  p.m.,  i.e.  4  hrs  after  drug  intake,  till  14.15
p.m. Participants were not allowed to consume alcohol 24 hours prior to testing and
caffeine-containing beverages 4 hours prior to the start of the test day.
Subjective measurements
Subjects filled out the Groninger Sleep Quality Scale (Mulder-Hajonides van der
Meulen, 1981) on each test day to assess sleep quality during the preceding night. The
total score consisted of 14 yes/no questions to score the number of sleep complaints
(ranging  from  good  sleep  (score  0)  to  worst  possible  sleep  (score  14)).  In  addition,
specific questions on time needed to fall asleep, number of awakenings during the
night and sleep duration in hours were included. The Bond and Lader Questionnaire
was also assessed using different scales for Alertness, Contentedness and Calmness
(Bond & Lader, 1974).
FMRI Data acquisition
A 3T Siemens Allegra MR scanner, situated at the Faculty of Psychology (University
Maastricht, The Netherlands) was used for the anatomical and functional
measurements. A T1-weighted anatomical scan was acquired for each subject using a
3-D MDEFT (Modified Driven Equilibrium Fourier Transform) sequence with an
isotropic spatial resolution of 1 mm. During task performance 896 whole-brain
volumes of T2*-weighted functional measurements were acquired, each comprising
32 slices (slice thickness 3.5mm; no slice gap; flip angle 90o) using a blood
oxygenation level dependent (BOLD) measurement and echo planar image (EPI)
pulse sequence (TR: 2 sec; TE: 30 msec; resolution: 3.5 x 3.5 x 3.5 mm3, matrix size 64 x
64) and interleaved slice sampling. Stimulus presentation and scanning were
synchronized at the beginning of the task.
Sustained attention - Mackworth Clock Test
FMRI scans were obtained while subjects performed the Mackworth Clock Test for 30
minutes.  Participants  laid  supine  in  the  scanner  with  the  head  fixated  with  foam
pads. Head phone and earplugs were provided. Participants looked at the projection
of a computer screen displaying a circular arrangement of 60 gray dots, via a mirror
in the head volume coil. The dots were briefly illuminated in clockwise rotation at a
rate of one per 500 milliseconds, moving 6 degrees from dot to dot. Volunteers were
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instructed that occasionally the dot would move 12 degrees. This ‘skipping of one of
the dots’ was the signal participants had to detect throughout the task by pressing a
response button as fast as possible with the right index finger. A response within 3
seconds of the signal was registered as a correct detection. A total of 20 signals were
randomly  presented  with  10  per  15  minute  period.  Behavioral  measures  were  total
correct detections (hits) and corresponding reaction times. For objectives of a different
study  a  resting  condition  was  included  prior  to  as  well  as  proceeding  to  the  task
block. These additional time points were modeled as covariates in the current study.
Statistical analyses
Behavioral data were analyzed by means of a repeated measures general linear model
(GLM) analysis (SPSS 11.5) with Treatment (2 levels) and Time on task (2 levels) as the
main factors. The alpha criterion significance level was set at p = 0.05.
Preprocessing of the functional images was done using BrainVoyager QX
version 1.6 (www.brainvoyager.com), and contained slice scan correction, 3D motion
correction (trilinear interpolation) and linear trend removal and high pass temporal
filtering (cut-off = 5 cycles per time course). Individual anatomical datasets were
spatially normalized to a standardized 3-D space (Talairach & Tournoux, 1988).
Individual scans were realigned using the first scan as a reference and coregistered
and normalized to the anatomical data, and resampled to a voxel size of 3 x 3 x 3 mm3.
Analysis of the brain activations were performed using a whole-brain, fixed
effects  ANCOVA  that  included  12  predictors  based  on  the  task  design.  These
predictors included correct detections, misses, false alarms, fixation, task block, time
before correct detections and 6 motion correction preprocessing parameters. The
predictor correct responses (corresponding to 2 time scans) was used as a main
measure for sustained attention as previous studies showed an effect of increased
serotonin levels on this variable (O'Hanlon et al., 1998; Ramaekers et al., 1995; Riedel
et al., 2005; Schmitt, Ramaekers et al., 2002). The implication was that as a participant
responds to the event (signal detection), it is also sustaining attention.
Results were color-coded and superimposed onto a standardized template of
a single brain (courtesy of Montreal Neurological Institute (MNI)). Main task effects
of placebo were visualized using a p(bonf)<0.01 corrected, and a cluster threshold of
>100 voxels . The differential effect of escitalopram was analyzed using whole-brain
analyses within the placebo-escitalopram contrast on the correct responses of the task
using a q (FDR) < .001 (Genovese et al., 2002) (which corresponded to p<0.000008,
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uncorrected) and a cluster threshold of >50 voxels. Subsequent event-related
averaging of the cluster time courses corresponding to the correct response trials was
performed.
Results
Missing data
In total, 12 participants were included of which two ended their participation due to
claustrophobic reactions in the fMRI scanner. Ten participants completed the study,
there were no missing data. Escitalopram was well tolerated in all subjects.
Behavioural data
Means and standard errors (se) of the sustained attention task performance are shown
in Table 1.
Table 1 Mean (se) outcome variables of the Mackworth Clock Test and the Bond &
Lader questionnaire
 Treatment
N=10
Escitalopram Placebo
Mackworth Clock Test
Total correct responses 15.8 (1.25) 15.0 (1.69)
Total reaction time (msec) 629 (32.4) 662 (38.3)
Correct responses 0-15 min 8.4 (0.50) 7.9 (0.92)
Reaction time 0-15 min (msec) 589 (25.4) 635 (36.5)
Correct responses 15-30 min 7.4 (0.82) 7.1 (0.91)
Reaction time 15-30 min 664 (43.2) 680 (42.3)
Bond and Lader questionnaire
Alertness 67.0 (6.37)* 81.4 (3.96)
Contentedness 79.0 (4.41) 83.4 (4.05)
Calmness 79.3 (4.28) 80.7 (5.21)
* = p=.001
Treatment did not significantly affect correct detections or reaction time (F1,9=0.91,
p=.366). There was a trend for a Time on task effect for correct detections (F1,9=3.41,
p=.098) and a significant Time on task effect for reaction time (F1,9=9.61, p=.013),
which indicates an overall tendency for a vigilance decrement during the 30 minutes
performance. There was no Treatment by Time on task interaction effect.
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Subjective measurements
Mean (se) of subjective evaluations are shown in Table 1. The outcome measures of
the Groninger Sleep Quality Scale were not different for the two treatments.
Treatment did significantly affect the Alertness ratings (F1,9=21.5, p=.001) but not the
Contentedness or Calmness ratings. Escitalopram reduced alertness as compared to
placebo.
Functional MRI during task performance
Figure 1 shows significantly activated brain areas in the placebo condition during the
Mackworth  Clock  Test  performance.  The  main  effect  of  task  showed  increased
activation of motor areas including the left post central gyrus, the right precentral
gyrus, the middle cingulate gyrus, and the supplemental motor area. In addition there
was increased activation in brain areas associated with an attentional network
including the right inferior parietal gyrus, the right angular gyrus, the insula, the
thalamus and the caudate nucleus. Other areas which showed increased activation
were the middle frontal gyrus, the right middle temporal gyrus, the parietal-occipital
fissure, the precuneus and the vermis. Decreased activation was seen in the posterior
and anterior cingulate gyrus.
Figure 2 shows significantly activated brain areas after a contrast between
escitalopram and placebo two conditions with corresponding event-related plots.
Comparing escitalopram to placebo resulted in decreased activation of the left
supplementary motor area, parts of the thalamus, the left caudate nucleus, the left
precentral sulcus, the right middle frontal gyrus, the left inferior frontal gyrus and the
left superior frontal gyrus. In addition, after escitalopram administration there was
increased activation in the right superior temporal gyrus and the right lateral fissure.
The  event-related  plots  of  the  specific  brain  areas  in  the  contrast  between  the  two
conditions showed less or no response (BOLD signal) after escitalopram
administration. In table 2, significantly activated brain areas during Mackworth Clock
Test performance are presented in the placebo condition and after a contrast between
the two conditions (placebo-escitalopram) including mean t-value and number of
voxels.  Figure  3  shows  the  event  related  plot  of  the  primary  motor  cortex,  which
shows no difference between the two conditions.
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Table 2. Areas in which voxels were activated corresponding to correct detections of
the Mackworth Clock Test
Main effect (placebo)
Talairach coordinates
Region
Left/
Right X Y Z Numberof voxels
Mean
t-value
Postcentral gyrus/ Motor cortex + L -30 -30 50 945 7.725
Middle cingulate gyrus + L/R 1 3 36 1331 10.248
Supplementary motor area + L/R 2 12 51 1321 9.043
Inferior parietal gyrus + R 40 -47 42 1045 8.771
Precentral gyrus + R 41 -6 41 963 7.494
R 46 3 24 1274 7.946
Angular gyrus + R 49 -43 31 1211 9.330
Middle temporal gyrus + R 53 -43 9 1160 8.336
Insula + L/R 35 18 7 1331 11.139
Thalamus + L/R 9 -16 10 1070 8.015
Caudate nucleus + L/R 9 5 9 1133 7.247
Middle frontal gyrus + L/R 37 37 24 835 6.064
Parietal-occipital fissure + L/R 10 -70 28 735 6.349
Precuneus + L/R 1 -53 35 645 6.234
Vermis + L/R 2 -53 -19 1317 8.565
Posterior cingulate gyrus - L/R -3 -54 17 652 -6.055
Anterior cingulate gyrus - L/R -3 31 -7 157 -5.455
+ = increased activation
- = decreased activation
+ = significant increased activation compared to placebo
- = significant decreased activation compared to placebo
Different activation after escitalopram
administration
Talairach coordinates
Region
Left/
Right X Y Z Number
of voxels
Mean
t-value
Supplementary motor area - L -6 11 48 333 -4.972
Ventral nucleus left - L -8 -18 9 54 -4.649
Mediodorsal nucleus left - L -5 -7 9 209 -4.991
Mediodorsal nucleus right - R 7 -13 11 176 -4.847
Anterior nucleus - L/R 0 -5 7 372 -5.021
Caudate nucleus  - L -13 4 14 262 -4.796
Precentral sulcus - L -24 -8 51 299 -4.975
Middle frontal gyrus - R 32 16 43 79 -4.824
Inferior frontal gyrus - L -34 31 28 183 -5.072
Superior frontal gyrus - L -27 53 15 67 -4.731
Superior temporal gyrus + R 53 4 4 76 4.763
Lateral fissure + R 61 -19 15 77 4.856
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Figure 1 Main task effect of the Mackworth Clock Test (correct detections) in the
placebo condition, increased and decreased activations are both presented at a
p(bonf)<0.01 and a cluster threshold of >100 voxels
Figure 2 Decreased activation after the placebo-escitalopram contrast at q (FDR) <
.001 and a cluster threshold of >50 voxels
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Figure 3 Event related plot in the primary motor cortex which shows no difference
between escitalopram and placebo administration
Discussion
The present study examined the effects of increased serotonin levels on sustained
attention and underlying brain activation. Similar to previous studies that measured
sustained attention (Coull et al., 1998; Lewin et al., 1996; O'Conner et al., 2004) the
current study showed activation of right dorsal and prefrontal areas. The brain areas
of the present study involved in sustained attention show some remarkable overlap
with brain areas associated with visual attention (Corbetta et al., 2002). In addition,
escitalopram and consequently the neurotransmitter serotonin modulated activity of
several brain areas including the thalamus and prefrontal areas during a sustained
attention task, although no effect was found on behavioral measurements of
sustained attention.
Performance of  the Mackworth Clock Test  in  the placebo condition showed
increased activation in  the right  inferior  parietal  gyrus,  the  right  angular  gyrus,  the
right precentral gyrus, the insula bilateral, the thalamus bilateral, and the bilateral
middle frontal gyrus. These areas and particularly right parietal and prefrontal areas
have been associated with sustained attention in previous research with fMRI
(Cabeza & Nyberg, 2000; Sturm & Willmes, 2001) and PET (Positron Emission
Tomography) (Mottaghy et al., 2006). Using the rapid visual information (RIVP) task
to assess networks of sustained attention, Lawrence et al. (2003) demonstrated a
network comprising frontal and parietal cortical areas and the thalamus and caudate
nucleus, which is very comparable to the set of active brain areas found in the present
study (Lawrence et al., 2003). Coull (1998) suggests that two different networks are
= placebo
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involved in attention and arousal and interact with each other: a cortical network
including the right frontal and inferior parietal cortex, which is associated with
attention and a subcortical network including the thalamus, striatum and the anterior
cingulate, which is associated with arousal (Coull, 1998). Adequate levels of both
arousal and attention are necessary to achieve good sustained attention performance
(Coull,  1998).  Other  areas  with increased activation in  the present  study were areas
associated  with  the  response  by  a  button  press  including  the  left  postcentral
gyrus/motor  cortex  and  the  supplemental  motor  area.  Activation  of  the  parietal-
occipital fissure is probably related to the seeing of the signal in the Mackworth Clock
Test, as this area has been previously associated with perception of visual motion
(Richer et al., 1991).
After escitalopram administration, differences in activation were seen in
several brain areas. Decreased activation was seen in parts of the basal ganglia,
including the ventral lateral nucleus of the left thalamus, the mediodorsal nucleus of
thalamus bilateral and the left caudate nucleus. In addition, the left superior
precentral sulcus, the left superior frontal gyrus and the right middle frontal gyrus
also showed decreased activation after acutely elevated serotonin levels.  The event-
related plots of these areas also showed lower amplitude of activity and/or a post-
event dip in activation for the escitalopram administration condition in the
abovementioned areas. These decreased activations did not appear in the motor
cortex, there were no differences between the two conditions in the primary motor
cortex and also the event-related plot  of  the primary motor  cortex showed an equal
BOLD  response  after  escitalopram  and  placebo.  This  suggests  that  the  observed
effects may be related to cognitive effects, possibly sustained attention.
Several nuclei of the thalamus including the ventrolateral and mediodorsal nuclei, in
which decreased activity is found after escitalopram administration in the present
study, are involved in mediating the interaction between attention and arousal in
humans  (Portas  et  al.,  1998).  The  findings  of  the  present  study  suggest  that
increments in serotonin levels impair sustained attention through influencing the
interaction between the cortical and subcortical network involved in arousal and
attention, described previously by Coull et al (1998). A candidate mechanism of the
influence  of  serotonin  on  selective  changes  in  brain  activity  may  be  through  a
serotonin-dopamine interaction mechanism. The basal ganglia (including the
thalamus and the caudate nucleus) are often associated with the neurotransmitter
dopamine  (Garnett  et  al.,  1983)  and  it  has  previously  been  proposed  that  serotonin
SUSTAINED ATTENTION, SEROTONIN AND FMRI
125
has a general inhibitory effect on dopamine release (Soubrie, 1986; Spoont, 1992).
Particularly serotonin projections from the raphe nucleus have an inhibitory influence
over  the  mesocortical  dopamine  system  and  forebrain,  which  are  involved  in
cognition (Kapur & Remington, 1996). It could be suggested that serotonin impairs
sustained attention through inhibiting dopamine in the thalamus and the caudate
nucleus and consequently a decrease in dopamine may lead to less activation of the
mesocortical dopamine projections to the prefrontal cortex (Robbins, 1997). The
results from the present study support this statement by showing decreased activity
in the thalamus as well as in (pre)frontal areas after serotonin stimulation. In humans
and in primates, connections between the mediodorsal nuclei of the thalamus and the
prefrontal cortex are well demonstrated (Behrens et al., 2003; Siwek & Pandya, 1991)
and these connections are involved in top-down modulation of attention (La Berge,
1995).
The present study did not show an effect of increased serotonin stimulation
on  behavioral  measurements  of  attention.  However,  other  studies  did  find  an
impairing  effect  of  serotonin  on  sustained  attention  measured  by  the  Mackworth
Clock Test (O'Hanlon et al., 1998; Ramaekers et al., 1995; Riedel et al., 2005; Schmitt,
Ramaekers et al., 2002). The differences between the previous studies and the present
study are probably due to a small sample size and a small effect size. In addition, in
the present fMRI study, the task only lasted 30 minutes whereas it lasted 45 minutes
in  performance  studies.  Possibly,  the  task  duration  was  too  short  to  pick  up  any
significant differences between the treatment conditions, which is supported by our
finding of a non-significant trend of a vigilance decrement. Escitalopram did decrease
alertness subjectively but this was not reflected in behavioral measures of sustained
attention. In addition, the entire procedure of conducting the task in the scanner may
have influenced performance in that both treatments affect sustained attention in a
comparable way. The number of correct detections after 30 minutes in the placebo
condition in other (not-fMRI) studies is around 17.4 (se +/-2.0) (Ramaekers et al.,
1995; Wingen, Kuypers et al., 2007). In the present study the number of correct
detections in the placebo condition is certainly lower, 15.0 (se+/- 1.8).
An important issue is the influence of drug administration on general blood
flow. In fMRI, activations measured are an indirect reflection of neural activity but a
direct reflection of the difference between the magnetic properties of oxygenated and
deoxygenated hemoglobin or BOLD response. Theoretically, it is possible that
serotonin  influenced  blood  flow  or  BOLD  changes  in  the  present  study.  However,
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activations seen in the current study are task dependent and specific. This is in line
with a  previous study using intravenous administration of  the SSRI  citalopram that
demonstrated  that  citalopram  is  a  good  tool  to  use  in  pharmacoMRI  studies  to
manipulate the serotonergic system (McKie et al., 2005). Furthermore, the present
study showed increased activations as well as decreased activations of BOLD
response after increased serotonin levels in the same task manipulation. Activations
in opposite direction are not possible in the context of a general effect on blood flow.
Finally, SSRIs in general have few cerebrovascular effects (Ramasubbu, 2004) and
particularly 20 mg of the parent compound of escitalopram (citalopram) did not alter
heart rate in healthy males (Seifritz et al., 1996). Therefore, it is unlikely that general
effects on the BOLD response caused by escitalopram influenced the results.
For future studies it would be very interesting to use a data-driven method
such as independent component analysis (ICA) (McKeown & Sejnowski, 1998) to
indicate different components or functional networks related to sustained attention.
The decreased activity demonstrated in the anterior and posterior cingulate cortex in
the present study is a remarkable finding to further examine with ICA as these areas
seem  to  be  involved  in  a  certain  network  concerning  resting  and  are  shown  to
decrease when the cognitive demand of a certain task increases (Raichle et al., 2001).
Furthermore, the use of this method would allow us to better attribute the influence
of increased serotonin on sustained attention to a certain neural network.
To conclude, it could be suggested that serotonin stimulation may impair
sustained attention through modulation of selective brain areas including (pre)frontal
areas and parts of the basal ganglia, which are possibly involved in a subcortical
network for sustained attention.
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Depression and the use of  antidepressants  are  an important  concern for  the patient
and the society. Research in the present thesis examined antidepressant effects on
cognitive functions and driving performance in healthy volunteers as well as in
depressed patients. Furthermore, the hypothesis that the neurotransmitter serotonin
is involved in different aspects of behaviour (including mood) and cognition was
investigated. The involvement of serotonin in cognition (specifically memory and
attention) was investigated by manipulating serotonin availability and measuring its
effects on specific brain mechanisms and comparing between drugs affecting
different 5-HT receptors. In this last chapter, it is attempted to relate the outcomes
from  the  different  chapters,  to  give  an  overview  and  to  discuss  the  findings  in  a
broader perspective. First, the main results of the different chapters will be
considered  in  the  light  of  the  aim  of  the  thesis.  Next,  it  will  be  discussed  how  the
results of this thesis contribute to previous research on depression, antidepressants,
serotonin and cognition. Furthermore, methodological issues in experimental
psychopharmacological studies will be discussed and implications will be given for
future psychopharmacological research. Finally some concluding remarks will close
this chapter.
Main results
The present thesis contains two types of experimental psychopharmacological
studies: applied studies and fundamental studies. The aim was firstly to give more
information on side effects of antidepressants. The two applied studies, described in
Chapter 3 and 4, assessed the side effects of antidepressants on cognition and driving
performance, in healthy volunteers and in depressed patients. In healthy volunteers,
the SSRI escitalopram did not influence psychomotor function or driving
performance, but the noradrenergic and serotonergic antidepressant mirtazapine
impaired actual driving performance (increase in Standard Deviation of Lateral
Position or SDLP), produced an increase in tracking error on a divided attention task
and caused decreased subjective alertness. Both antidepressants were administered in
the evening and mirtazapine’s detrimental effects were only seen after the initial
dose. Subchronic use did not influence psychomotor function or driving
performance. Impairing effects of mirtazapine can be attributed to histaminergic H1
receptor binding, which causes drowsiness or sedation. In depressed patients, after
long-term use of commonly administered antidepressants such as SSRIs and the SNRI
venlafaxine driving performance was impaired (increased SDLP and Time to Speed
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Adaptation) compared to healthy volunteers. The use of these antidepressants had no
effects on laboratory tests of cognition in the depressed patients. Driving impairment
after long-term SSRI and SNRI use by depressed patients is somehow unexpected
given that SSRIs are generally known to produce no or little effects on psychomotor
function  and  cognition  in  healthy  volunteers  compared  to  sedative  antidepressants
(Ramaekers, 2003) as also was demonstrated in Chapter 3. In addition, it is known
that depressed patients receiving antidepressant treatment will experience difficulties
in  performance  particularly  at  the  beginning  of  the  treatment  before  the  onset  of
therapeutic response, based on the side effects of the medication and the depressive
symptoms.  After a few weeks, when the treatment provides an alleviation of
depressive symptoms, there will be a balance between side effects and beneficial
effects of the treatment (Lane & O'Hanlon, 1999). Consequently, it is unlikely that side
effects of the antidepressants influenced driving performance in our study and
therefore most likely the impairing effects are caused by residual depressive
symptoms  which  were  still  present.  However,  other  studies  are  necessary  to  draw
firm conclusions.
The second aim of  the present  thesis  was to  explore  the role  of  serotonin in
cognition.  The fundamental  studies  of  this  thesis  described in  Chapter  5,  6,  7  and 8
were  preceded  by  a  review  discussing  previous  knowledge  on  serotonin  and
cognition. There is a role for serotonin in several cognitive functions, particular in
human episodic memory, attention and cognitive flexibility. Evidence can be found
mainly in challenge studies which use acute tryptophan depletion or SSRIs but there
are inconsistencies concerning the direction of experimentally induced serotonin
decrease and increase and its association with either cognitive enhancement or
impairment. Regarding (elderly) depressed patients, serotonin seems to have
beneficial effects on memory (Butters et al., 2000) and studies in depressed patients
but  also  in  aging  would  provide  further  insight  in  these  issues.  In  Chapter  5,  the
effects  of  acute  and  subchronic  administration  of  the  SSRI  escitalopram  and  the  3rd
generation antidepressant mirtazapine were examined on verbal memory. In fact, this
chapter describes the effects of two different antidepressants on verbal memory
(applied research) on the one hand but provides more information on serotonin and
memory (fundamental research) on the other hand. The results of this study showed
a slight impairing effect of mirtazapine on verbal memory probably due to its H1
receptor blocking properties. No effects of acute and subchronic administration of
escitalopram and consequently of serotonin on verbal memory were demonstrated.
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Unfortunately, there was no measurement of the earliest action of escitalopram
because the antidepressants were administered in the evening. Conversely, the
following chapters described the effects of acutely manipulated serotonin levels on
different aspects of cognition. Escitalopram tended to impair immediate verbal recall
and further increased serotonin levels by means of combining an SSRI and a 5-HT1A
autoreceptor antagonist significantly impaired immediate verbal memory. Together
with previous work (Meeter et al., 2006), the present results support an association
between serotonin and memory that describes an inverted U-curve. This effect is
specific for verbal memory because additional increased serotonin levels through 5-
HT1A receptor blockade did not impair spatial memory and hardly affected different
aspects of attention. The 5-HT2A receptor appears to be involved in spatial memory,
as blockade of this receptor in combination with escitalopram, impairs performance
on a spatial memory task. Furthermore, sustained attention is also modulated by the
5-HT2A receptor and probably a link between the 5-HT2A receptor and dopamine
release  is  responsible  for  these  effects  on  cognition  (Bortolozzi  et  al.,  2005).  More
information on an interaction between serotonin and dopamine associated with
sustained  attention  comes  from  the  fMRI  study  in  this  thesis,  in  which  increased
serotonin  levels  on  brain  mechanisms  involved  in  the  Mackworth  Clock  Task  were
explored.  After  increased  serotonin  levels,  less  activation  was  found  in  the  caudate
nucleus, thalamus and (pre)frontal areas. This suggests that serotonin modulates
sustained attention via a subcortical network including the thalamus from which
dopaminergic pathways leading to (pre)frontal areas are also influenced.
Side effects of antidepressants on cognition and driving performance
Side effects of antidepressants as sedation, blurred vision or dizziness, interact with
daily life and may impair cognition and driving performance. Sedative
antidepressants including tricyclic antidepressant impair driving performance in
healthy volunteers, but SSRIs cause less impairing effects (Ramaekers, 2003).
Epidemiological research shows that TCAs increase the risk of becoming involved in
a traffic accident (Leveille et al., 1994) (Ray et al., 1992) but SSRIs do not (Barbone et
al., 1998). Recently, a clinical study in depressed patients using a computerized
testsystem assessing driving skills confirmed these results (Brunnauer et al., 2006).
Preferably, severe major depression should be treated with effective antidepressants
with few side effects.
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One novel finding described in this thesis is that escitalopram of which is said that it
is currently the most selective SSRI (Owens et al., 2001) had no influence on actual
driving performance and psychomotor function after an evening dose. In addition, a
nocturnal dose (30 mg) of the sedative antidepressant mirtazapine did impair driving
performance and psychomotor function the day after initial treatment, in spite of the
fact that previous studies suggested that the considerably impairing acute sedative
effect of daytime-administered mirtazapine (15 mg) might much be alleviated by
noctural administration (Ramaekers et al., 1998) . This information may be valuable
for  medical  practice  as  mirtazapine  is  often  prescribed  at  a  start  dosage  of  30  mg.
Considering the effects of antidepressant use in depressed patients, various studies
show impairing effects on measurements related to driving behaviour (Gerhard &
Hobi, 1984) (Grabe et al., 1998) and also on actual driving performance (Ramaekers et
al., 1997). In other words, antidepressant treatment of maximally 6 weeks did not
normalize performance in depressed patients. This thesis adds to this that even after
long-term  antidepressant  treatment  (SSRIs  and  SNRI),  i.e.  6  till  52  weeks,  driving
performance in depressed patients is still impaired compared to healthy persons.
An important issue is the correspondence of cognition and driving
performance in terms of information processing demands. Driving behaviour
contains aspects varying from automatic (fast and inflexible) processing to effortful
(slow and flexible) processing. The actual driving tasks used in the research of this
thesis measured driving performance on the more automatic operational level
(weaving) and on the manoeuvring level (car-following) (Lamers & Ramaekers,
2001). Other aspects of driving behaviour including planning, understanding and
applying  traffic  rules  occur  at  the  strategic  level  and  are  not  measured  with  the
driving tests used in the present thesis. Laboratory tasks are supposed to measure
different aspects of driving related behaviour. More specific, the divided attention
task, a double task containing a signal detection subtask and a tracking subtask,
seems to be closely related to the Road Tracking Test, for example the tracking
component is very similar to keeping a car on the road. Nevertheless, results of the
tracking task correlate only modestly with SDLP measurements and other
psychomotor tests do not correlate with these results of driving performance (mean r
of 0.23 – 0.45) (Ramaekers, 2003). Another inconsistency is that SSRIs impair
sustained attention or vigilance in the Mackworth Clock Test, but SSRIs have few
effects on driving performance as the Road Tracking Test, although both tasks may be
seen as vigilance tasks. A possible explanation is that the Mackworth Clock Test
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measures only sustained attention by signal detection and reaction time but the Road
Tracking Test measures various variables including Standard Deviation of Lateral
Position  and  speed  variation.  The  Mackworth  Clock  Test  is  designed  to  mainly
measure vigilance while the road tracking task also measures other aspects of driving
performance. Importantly, an actual driving test also includes selfmonitoring of
arousal and performance which can be seen as an executive function. While driving
in a real car there is the knowledge of the possibility of getting involved in an
accident. This component is not or to a lesser extent existing in laboratory tasks and
this may account for different results. Obviously the two types of tasks are not
directly comparable and possibly different processes are measured on different
levels.  Apparently,  the  character  of  the  task  in  terms  of  its  cognitive  demands  is  of
great importance to assess psychopharmacological effects. From this point of view,
actual driving tasks are of important additional value as cognitive tasks are limited in
predicting the effects of drugs on daily life.
Role of serotonin in cognition
Animal research previously showed that serotonin receptors in the brain are situated
in structures associated with memory function such as the hippocampus. Moreover,
memory is influenced by 5-HT agonists or antagonists that act on different
serotonergic receptors (Buhot et al., 2000) (Meneses, 1999). Evidence exists that 5-
HT1A and 5-HT2 receptors are involved in memory.  The present thesis showed for the
first time that human 5-HT1A and 5-HT2A receptors are distinctly involved in verbal
memory and spatial memory respectively. Furthermore, the results are consistent
with the notion that 5-HT2A receptors modulate dopaminergic activity (Bortolozzi et
al., 2005) and thereby influence aspects of cognition as spatial memory and sustained
attention.  This  is  in  line  with  findings  reported  in  a  very  recent  review  on  the
mechanisms of serotonin in regulating dopamine neurotransmission (Alex & Pehek,
2006). Evidence is available that activation of the 5-HT2A receptor increases
dopaminergic activity in all three dopaminergic pathways, i.e. nigrostriatal,
mesolimbic and mesocortical pathway. Furthermore, selective antagonism of 5-HT2A
receptors diminishes dopamine release (Alex & Pehek, 2006). Consequently, this
suggests that a decrease in dopamine activity by blockade of the 5-HT2A receptor may
lead to cognitive impairment as was shown in the present thesis. Since the present
thesis manipulated serotonin, no direct conclusions can be drawn on dopamine or an
interaction between dopamine and serotonin and therefore future research is needed.
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In addition, the present thesis for the first time provides more evidence for a role of
serotonin in sustained attention by showing less activity in brain areas including
thalamus, caudate nucleus and prefrontal areas while performing the Mackworth
Clock  Test  after  SSRI  administration.  Two  different  networks,  one  subcortical  for
arousal  and one cortical  for  attention,  are  involved in  sustained attention and these
networks interact with each other (Coull, 1998). Particularly the thalamus is involved
in mediating the interaction between attention and arousal in humans (Portas et al.,
1998). The results of the present thesis suggest, together with previous research, that
an SSRI impairs sustained attention by affecting the interaction between the
subcortical and cortical network in the thalamus.
Altogether, the relation between serotonin and cognition is complex and not
only  mediated  by  serotonin  levels  but  also  by  receptor  mechanisms  and  the
interaction  with  other  neurotransmitters.  Previous  research  showed  a  role  for
serotonin in cognitive flexibility (Murphy et al., 2002), motor impulse control
(Ramaekers & Kuypers, 2006) and selective attention (Coull et al., 1995; Schmitt et al.,
2000) and also impulsivity (Chamberlain et al., 2006).The fundamental studies in this
thesis cannot confirm these findings and future studies could examine the role of
different serotonin receptors in other aspects of cognition. In addition, other 5-HT
receptors may also be involved in cognition including learning and memory given
the number and diversity of serotonin receptors found in brain areas associated with
learning and memory (Buhot et al., 2000; Meneses, 1999). Recent evidence from
animal studies suggest even cognition enhancing effects after 5-HT4 or 5-HT6 receptor
manipulations (Micale et al., 2006; Schreiber et al., 2006).
Methodological issues in psychopharmacology and recommendations for future
research
In  the  applied  studies,  a  typical  design  to  assess  the  effects  of  antidepressant  on
driving performance is a placebo-controlled within subjects design. However, the
study conducted in  depressed patients  in  this  thesis  deviates  from this  by studying
driving  performance  in  a  between  subject  design.  The  SDLP  of  different  groups
(depressed patients using antidepressants vs healthy controls) were compared
whereas it is challenging to compare driving behaviour of different persons. By
matching the groups on several variables including age, gender and driving
experience and by only allowing participants with a driving license for at least three
years and driving experience of at least 5000 km/years, differences between groups
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are minimized and this may be a good design for studying between-subject driving
performance. However, there will be other variables influencing driving performance
except from age, gender and driving experience, for example personality or risk
taking behaviour. For this reason, a within subject-design will be better when there is
the possibility to use this study design.
Furthermore, after examining the effect of antidepressant treatment on driving
performance of depressed patients, the question remains if antidepressant treatment
may attenuate even more severe driving impairment after untreated depression.
Additional analysis in the present thesis suggests that there may be a small beneficial
effect  of  treatment  on  driving  performance.  This  is  in  line  with  recent  results  of  a
study in which crash-involved drivers filled out a questionnaire on health and use of
medication.  The  chance  to  be  involved  in  a  traffic  accident  was  greater  for  persons
with depressed feelings than for persons who take antidepressant drugs (Sagberg,
2006). The development of driving performance of depressed patients without and
with antidepressant treatment over time is an important topic for further
investigation in an experimental within-subject design. In addition, applied studies
measuring the effects of antidepressants on driving performance could be more
elaborated by measuring more aspects of driving behaviour than currently is
conducted. By measuring driving behaviour on different levels and also on the
strategic level, which includes the reaction of a participant to traffic signs, in
experimental research, it should be possible to draw even more conclusions on
accident risk and participating in traffic in daily life.
In the studies described in this thesis, relatively new methods are applied in
humans. This thesis contains the first ever publication of a human study in which
cognition was examined while different specific serotonergic drugs were
administered in combination, with the aim to elevate synaptic 5-HT availability while
also blocking specific (post-)synaptic 5-HT receptors. The present thesis showed that
these  are  promising  methods  in  psychopharmacology  but  it  has  to  be  emphasized
that the use of selective agents with no other side effects is very important to provide
information on the role of specific receptors in cognition. In addition, manipulation of
the serotonergic system in depressed patients may lead to further insight in the role
of serotonin in cognition as this can give additional information to studies in healthy
volunteers. For example, more room is available for improvement of cognitive
functions after serotonergic stimulation in depressed patients. Another main issue
when studying the role of serotonin in patients is if cognitive improvement is directly
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due  to  enhanced  serotonin  levels  or  if  the  improvement  of  cognition  is  due  to
alleviation of depressive illness. Studies that compare cognitive performance of
healthy volunteers and depressed patients after administration of a selective agonist
or  antagonist  can  give  more  insight  in  these  issues.  For  example,  in  a  previously
conducted study (Riedel et al., 2002) ipsapirone, a 5-HT1A agonist, tended to improve
short-term memory in depressed patients but impaired short-term memory in healthy
volunteers, independent of mood changes. These results suggest a role for serotonin
in memory but differently between patients and healthy volunteers. Future studies
may  investigate  the  role  of  serotonin  in  cognition  at  the  receptor  level  in  healthy
volunteers as well as in depressed patients.
Furthermore,  the  use  of  fMRI  in  psychopharmacological  research  is  also  a
relative new method. Functional imaging methods in psychopharmacology will help
identifying neural circuits involved in drug effects on cognition and performance.
However, knowledge obtained in pharmaco-fMRI studies provides only indirect
clues about how drugs may modify cognitive task related BOLD activation.
Pharmaco-fMRI’s best value therefore may be to close the gap between prior
knowledge obtained at the neurotransmitter level, i.e. about cellular mechanisms of
drugs and obtained at the behavioural level such as changes in cognitive performance
induced by these drugs. More information on the role of different serotonin receptors
in cognition could be obtained by methods as PET and SPECT in which specific
receptors can be anatomically mapped. Brain imaging in general together with the
use  of  selective  agents  to  get  more  insight  in  underlying  brain  mechanisms  is  an
appealing method to use in healthy volunteers as well as patients which will receive
more publicity in the future.
Concluding remarks
Taking into account the results described in the present thesis, some conclusions and
implications can be given. Firstly, the adverse side effects of antidepressants due to
additional mechanisms next to their therapeutic action may have an impact on the life
and performance of patients. Therefore it is important to test these drugs on negative
cognitive effects. This may of course be done in a laboratory with computerized tasks,
although to predict performance in daily life as much as possible, actual driving tests
should be included and more experimental studies in patients should be conducted.
Secondly, the core therapeutic action of antidepressants relies on serotonin. Using
selective antidepressants in fundamental research to manipulate serotonin can
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provide more insight in negative or positive effects on cognitive functions.
Furthermore, selectively manipulating 5-HT receptors and also using pharmaco-fMRI
in human studies may give even more information on the underlying mechanisms of
serotonin in cognition. The present thesis is the first to show that the 5-HT1A receptor
is involved in verbal memory and that the 5-HT2A receptor is an important receptor
involved in spatial memory and sustained attention. Furthermore, the impairing
effect of SSRIs on sustained attention is visualized in the brain. These findings have
opened new doors for future experimental research that concerns neurotransmitters
and cognition.
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Summary
The  central  theme  in  the  present  thesis  is  the  behavioral  toxicity  of  antidepressant
drugs. It is hypothesized that the net action of antidepressants on serotonin
neurotransmission has specific effects on cognition, including memory improvement
and attention impairment, whereas other pharmacological mechanisms encountered
in antidepressants, such as anticholinergic-, anti-adrenergic and antihistaminergic
mechanisms may have a negative impact on performance.
The first part of the thesis concerns antidepressants that exert adverse effects
on cognition and driving performance. The effects of specific antidepressant
treatments on cognition and driving performance are investigated in healthy
volunteers and depressed patients. The second part of the thesis concerns the role of
serotonin in cognition. The neurotransmitter serotonin was manipulated by an
antidepressant (particularly a selective serotonin reuptake inhibitor (SSRI)) in
combination with 5-HT receptor agents and cognitive performance was assessed.
In Chapter 1 the aims of the present thesis are described. Research in animals as well
as in humans demonstrates that serotonin is involved in different aspects of cognition
including attention and memory. The question arises which pharmacological
mechanisms mediate these effects of serotonin on memory and attention.
Furthermore,  serotonergic  dysfunctioning  is  assumed  to  be  part  of  the  etiology  of
major depressive disorder and next to the more commonly recognised features as
sadness and diminished energy, depression is often accompanied by a decline in
cognitive and psychomotor functioning. Antidepressants are among the most
prescribed  psychoactive  drugs  nowadays  of  which  SSRIs  are  the  most  common.
Depending on the mechanism of action, antidepressant drugs exert different side
effects, physically as well as cognitively. The aim of the present thesis was to assess
the  side  effects  of  commonly  used  antidepressants  on  cognition  and  actual  driving
performance in healthy volunteers as well as in depressed patients. Expected was that
treated depressed patients did not differ in cognitive function or driving performance
compared to healthy volunteers because treatment with common prescribed
antidepressants alleviates the depression with little adverse effect. In addition, the
question was what the role of increased serotonin levels in memory and attention in
humans is in different brain and receptor mechanisms. Manipulation of the 5-HT1A
and 5-HT2A receptors was expected to augment the effects of pre-treated serotonin
levels and by this means influencing memory and attention. Sustained attention
impairment after SSRI treatment was expected to be observed in brain regions
involved in sustained attention investigated in an fMRI study.
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In Chapter 2 an overview is given on experimental studies involving healthy human
volunteers and selected (clinical) patients which revealed that manipulations of the
central serotonin system can produce quite specific changes in cognitive functioning,
independent of overt mood changes. Reduced serotonin turnover is consistently
associated with impaired long-term memory functioning. Low serotonin function
may also impair cognitive flexibility and improve focused attention. On the other
hand, stimulation of central serotonin has repeatedly been found to impair
performance in a true vigilance task. Currently, there is little evidence for mirrored
cognitive changes due to opposite serotonin manipulations in healthy volunteers.
Given the mounting evidence for a role of serotonin in human cognition, reduced
serotonin function could be directly linked to cognitive disturbances in certain
conditions,  such  as  in  depression  and  Alzheimer’s  Disease  (AD).  There  is  evidence
that stimulating (i.e. normalizing) serotonin activity in depression may have specific
beneficial effects on cognition, independent of a general relief of depressive
symptoms, but this premise needs to be confirmed by larger-scale clinical studies.
Recently, a potential role of serotonin in the cognitive symptoms in AD has been
identified, but there is insufficient data to evaluate the effects of serotonin stimulation
on cognitive symptoms in AD. It is concluded that serotonin is a potential target for
pharmacological cognition enhancement, particularly for restoration of impaired
cognitive performance due to serotonin dysfunction. Further differentiation of the
role  of  serotonin in  normal  and disturbed cognition and evaluation of  the effects  of
serotonin manipulations in various populations is required to establish the full
potential of serotonin drugs as cognition enhancers.
In Chapter 3 the effects of escitalopram 10-20 mg per day and mirtazapine 30-45 mg
per day on actual  driving and psychomotor  performance of  18  healthy subjects  in  a
randomised, double-blind, placebo-controlled, multiple-dose, 3-way crossover trial
are  determined.  The  effects  of  ecitalopram  on  psychomotor  and  actual  driving
performance had not been investigated. Mirtazapine previously impaired
psychomotor  function  and  driving  performance  and  in  the  present  study  it  was
included as an active control. It was expected that escitalopram had no effect but that
mirtazapine would impair driving performance and psychomotor function. Each
treatment  period  lasted  for  15  days  and  was  separated  from  the  next  period  by  a
washout period of at least 13 days. Subjects received an evening dose of escitalopram
10mg, mirtazapine 30mg, or placebo from Days 1-7 and an evening dose of
escitalopram 20mg, mirtazapine 45mg, or placebo from Days 8-15. On Days 2, 9, and
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16,  reflecting  acute  period,  dose  increase,  and  steady  state,  respectively,  the  Road
Tracking test was performed. The main parameter was Standard Deviation of Lateral
Position.  Psychomotor  performance  was  also  assessed  on  Days  2,  9,  and  16  by
laboratory computer tasks. Subjective sleep quality and mood were measured by
visual analogue scales. Treatment differences were apparent during the acute
treatment  period,  in  which  subjects  treated  with  mirtazapine  30mg  performed  less
well in the driving test as compared to placebo. The Divided Attention Task results
also revealed a significant increase in tracking error after a single dose of mirtazapine
30mg as compared with placebo. Mirtazapine decreased feelings of alertness and
contentedness.  Escitalopram  did  not  affect  driving,  psychomotor  performance  or
subjective mood throughout treatment. In conclusion, driving performance, as well as
psychomotor functioning, were not affected by escitalopram treatment in healthy
subjects. Driving performance was significantly impaired after ingestion of
mirtazapine 30 mg during the acute treatment period.
In Chapter 4 actual driving performance and cognition of depressed patients
receiving long-term antidepressant treatment is assessed. It is generally known that
SSRIs  have less  impairing effects  on driving performance than TCAs.  Expected was
that driving performance and cognition of depressed patients receiving long-term
SSRI  or  SNRI  treatment  was  comparable  to  that  of  healthy  volunteers,  due  to
alleviated depressive symptoms. Performance was assessed in 24 depressed patients
receiving SSRI (Selective Serotonin Reuptake inhibitor) or SNRI (Serotonin and
Noradrenalin Reuptake Inhibitor) treatment for 6-52 weeks and in 24 matched,
healthy controls by means of two standardized on-the-road driving tests and
laboratory tests  of  cognition.  Data  showed poorer  driving performance as  indicated
by a higher Standard Deviation of Lateral Position (SDLP) or ‘weaving motion’ in
medicated patients relative to controls. Time to speed adaptation and Critical Flicker
Fusion Threshold were also impaired in medicated patients. Hamilton Depression
Rating Scale scores in medicated patients were significantly higher as compared to
controls. No other significant results between the two groups were demonstrated on
the variables of the driving tests and laboratory tests of cognition. Depressed patients
receiving  long-term  treatment  with  SSRI  and  SNRI  type  antidepressants  show
impaired driving performance. This impairment in driving performance can probably
be attributed to residual depressive symptoms instead the of antidepressant
treatment.
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In Chapter 5 the effects of escitalopram 10-20 mg per day and mirtazapine 30-45 mg
per day on verbal memory of 18 healthy participants are assessed in a randomized,
double-blind, placebo-controlled, 3-way crossover trial. It was expected that
escitalopram may enhance verbal memory due to its serotonergic action and that
mirtazapine would impair verbal memory due to its histaminergic affinity. Each
treatment  period  lasted  for  15  days  and  was  separated  from  the  next  period  by  a
washout  period  of  at  least  13  days.  Participants  received  an  evening  dose  of
escitalopram 10mg, mirtazapine 30mg, or placebo from days 1-7 and an evening dose
of escitalopram 20mg, mirtazapine 45mg, or placebo from days 8-15. On days 2, 9,
and 16 a visual verbal memory task was performed measusing drug effects during the
acute phase, after dose increase and at steady state. Escitalopram did not affect
immediate or delayed verbal memory score throughout treatment. During
mirtazapine treatment, participants performed less well in the overall immediate
recall score compared to placebo. This impairment was most pronounced in the final
trial of the visual verbal learning task. Verbal memory was not affected by acute and
subchronic escitalopram treatment in healthy participants. Overall immediate verbal
memory was slightly but significantly impaired throughout mirtazapine treatment,
probably due to a general reduction in overall arousal caused by H1 receptor
blockade.
In Chapter 6 a study conducted according to a randomized, double-blind, placebo
controlled, 4-way crossover design including 16 healthy volunteers, is described.
Assessed was whether the 5-HT1A and 5-HT2A receptors  are  involved  in  the
association  between  serotonin  and  memory.  The  treatment  consisted  of  oral
administration of escitalopram 20 mg + placebo, escitalopram 20 mg + ketanserin 50
mg (5-HT2A antagonist), escitalopram 20 mg + pindolol 10 mg (5-HT1A partial agonist)
and placebo on 4 separate days with a wash-out period of minimum 7 days. It was
expected that  pindolol  and ketanserin would augment  the effect  of  escitalopram on
memory.  Different memory tasks were performed including task measuring verbal
memory, spatial working memory and reversal learning. Escitalopram showed an
impairing effect on immediate verbal recall which nearly reached statistical
significance. No effects of escitalopram were found on other types of memory. In
combination with pindolol, immediate verbal recall was significantly impaired.
Escitalopram in combination with ketanserin impaired spatial working memory
significantly. No effects were found on reversal learning. To conclude, selective
impairment of immediate verbal recall after a 5-HT1A partial agonist and selective
impairment of spatial working memory performance after 5-HT2A receptor
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antagonist, both in combination with a selective serotonergic reuptake inhibitor
(escitalopram), suggests that 5-HT1A and 5-HT2A receptors are distinctly involved in
verbal and spatial memory.
In Chapter  7 the contribution of serotonin reuptake inhibition and specific blockade
of the pre-synaptic 5-HT1A receptor and the 5-HT2A receptor to deficits in attention is
assessed according to a randomized, double-blind, placebo controlled, 4-way
crossover study design including 16 healthy volunteers. Treatments consisted of oral
administration of the SSRI escitalopram 20 mg + placebo, escitalopram 20 mg +
ketanserin (5-HT2A antagonist) 50 mg, escitalopram 20 mg + pindolol (5-HT1A
antagonist)  10  mg  and  placebo  +  placebo  on  4  separate  days.  It  was  expected  that
pindolol and ketanserin would augment the impairing effect of escitalopram on
sustained attention by acutely elevating serotonin levels and by decreasing dopamine
release respectively. A range of performance tasks were conducted to assess the
subjects’ attention and motor functions. Escitalopram administered alone impaired
tracking performance in a divided attention task. The combination of escitalopram
and pindolol as well as escitalopram and ketanserin impaired divided attention as
compared to placebo. In addition, escitalopram and ketanserin impared sustained
attention. Divided attention impairment observed after combined treatments did not
significantly differ from impairments after escitalopram alone. In conclusion,
sustained attention impairment observed after combined escitalopram and ketanserin
significantly differed from escitalopram alone. 5-HT1A receptor blockade hardly
affected SSRI effects on attention. Additional 5-HT2A receptor blockade however
produced impairments of sustained attention.
SSRIs  were  previously  shown  to  impair  sustained  attention  as  measured  with  the
Mackworth Clock Test. In Chapter 8 the influence of presumably increased serotonin
levels  on brain regions involved in  sustained attention is  examined by means of  an
fMRI study. Expected was that escitalopram administration would impair sustained
attention observed in brain regions involved in sustained attention. Ten healthy
volunteers (5?, 5?) received the selective serotonin reuptake inhibitor (SSRI)
escitalopram (20mg) and placebo in a balanced, double blind, 2-way crossover
design.  Participants  performed  the  Mackworth  Clock  Test  to  measure  sustained
attention during functional MRI measurements at 3-Tesla. Subjective measurements
after  pharmacological  manipulation  were  conducted  with  the  Bond  &  Lader
Questionnaire. Independent of treatment, brain areas associated with task
performance on a sustained attention task were activated, including right prefrontal
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and parietal areas. After escitalopram administration, less activation was shown in
the caudate nucleus, thalamus and frontal areas. No effect of escitalopram was shown
on behavioral data although subjective measurements showed decreased alertness
after escitalopram. The results suggest that serotonin stimulation impairs sustained
attention through modulating activation of selective brain areas including the
thalamus and caudate nucleus, which are possibly involved in a subcortical network
for sustained attention.
In Chapter 9 the results of this thesis are discussed in a broader perspective.  Overall,
antidepressants with anticholinergic, anti-adrenergic or antihistaminergic
mechanisms may impair cognition and driving performance in healthy subjects. It is
very important to take into account any residual depressive symptoms by considering
the effects of antidepressants on cognition and specifically driving performance in
depressed patients. The research in this thesis gives additional evidence for an
association between serotonin and memory because after administration of an SSRI in
combination with a 5-HT1A partial agonist presumably increased serotonin levels
impair verbal memory. Furthermore, it is also demonstrated that the 5-HT2A receptor
is an important receptor in modulating specific effects of serotonin on spatial memory
and sustained attention. In addition, the effect of serotonin on an attentional network
including the thalamus is possibly responsible for sustained attention performance. In
this thesis, several relative new methods in human studies are introduced including
the use of brain imaging and examining brain mechanisms at the receptor level. These
methods  could  be  further  elaborated  in  future  studies  to  acquire  knew  knowledge
relating to neurotransmitter mechanisms, behaviour and the development of
pharmacological treatment.
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Samenvatting
Het centrale thema van dit proefschrift is gedragstoxicologie van antidepressiva. De
hypothese is dat de netto werking van antidepressiva op serotonine tot specifieke
effecten leidt op cognitie, waaronder geheugen verbetering en aandacht
verslechtering, en dat andere farmacologische mechanismen van antidepressiva
waaronder anticholinerge, anti-adrenerge  en antihistaminerge effecten een negatieve
impact hebben op prestatie.
Het  eerste  gedeelte  van  dit  proefschrift  handelt  over  de  bijwerkingen  van
antidepressiva op cognitie en rijvaardigheid. The effecten van bepaalde
antidepressiva op cognitie en rijvaardigheid zijn gemeten bij gezonde vrijwilligers en
depressieve patiënten. Het tweede gedeelte van het proefschrift handelt over de rol
van serotonine in cognitieve prestaties. De neurotransmitter serotonine werd
gemanipuleerd door de toediening van een selectief antidepressivum (in het
bijzonder een selectieve serotonine heropname remmer (SSRI) al of niet in combinatie
met middelen die op 5-HT receptoren werken terwijl cognitieve prestaties werden
gemeten.
In hoofdstuk 1 worden de doelen van het huidige proefschrift besproken. Zowel
dieronderzoek als humaanonderzoek laat zien dat serotonine betrokken is bij
verschillende cognitieve aspecten waaronder aandacht en geheugen. De vraag is
welke farmacologische mechanismen aan deze effecten van serotonine op geheugen
en aandacht ten grondslag liggen. Daarbij wordt het disfunctioneren van serotonine
gezien als een van de mogelijke oorzaken van een depressie en naast meer algemeen
herkenbare kenmerken van depressie zoals neerslachtigheid en verlies van energie,
gaat een depressie vaak gepaard met een afname van cognitief en psychomotorisch
functioneren. Antidepressiva vallen momenteel onder de meest voorgeschreven
psychoactieve medicatie en daarvan worden SSRIs het meest voorgeschreven.
Antidepressiva verschillen in fysieke en cognitieve bijwerkingen, afhankelijk van het
werkingsmechanisme. Het doel van het huidige proefschrift was het vaststellen van
de bijwerkingen van vaak gebruikte antidepressiva op cognitie en rijvaardigheid bij
zowel gezonde vrijwilligers als depressieve patiënten. Verwacht werd dat
behandelde depressieve patiënten niet verschilden van gezonde vrijwilligers wat
betreft cognitieve prestaties en rijvaardigheid omdat behandeling met veel
voorgeschreven antidepressiva de depressie verlicht met weinig bijwerkingen. De
vraag is ook wat de rol is van verhoogde serotonine niveaus in geheugen en aandacht
bij mensen in verschillende hersen- en receptor mechanismen. Manipulatie van de 5-
HT1A en 5-HT2A receptor werd verwacht de effecten van voorverhoogde serotonine
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niveaus te verergeren en daarbij geheugen en aandacht te beïnvloeden. Het werd
verwacht dat verslechtering van volgehouden aandacht na SSRI toediening waar te
nemen is in hersengebieden die betrokken zijn bij volgehouden aandacht, onderzocht
in een fMRI onderzoek.
In hoofdstuk 2 wordt een overzicht gegeven van experimenteel onderzoek bij
gezonde menselijke vrijwilligers en geselecteerde (klinische) patiënten waarin wordt
besproken dat manipulaties van het serotonerge systeem specifieke veranderingen
teweeg brengen in cognitief functioneren, onafhankelijk van zichtbare veranderingen
in stemming. Verlaagde serotonine verwerking wordt herhaaldelijk geassocieerd met
verslechterd lange termijn geheugen. Aan de andere kant is meerdere malen gebleken
dat stimulatie van centrale sertonine de prestatie op een vigilantietaak verslechterd.
Tot nu toe is er weinig bewijs voor gespiegelde cognitieve veranderingen door
tegenovergestelde serotonine manipulaties bij gezonde vrijwilligers. Verlaagd
serotonerg functioneren kan direct worden verbonden met cognitieve stoornissen bij
bepaalde condities zoals depressie en de ziekte van Alzheimer (AD), gezien het
groeiende bewijs voor een rol voor serotnine in menselijke cognitieve functies. Bewijs
is geleverd dat stimulatie (oftewel normalisatie) van serotonerge activiteit bij
depressie voordelige effecten kan hebben op cognitie, onafhankelijk van verlichting
van de depressieve symptomen, alhoewel dit nog bevestigd moet worden door
grootschalige klinische onderzoeken. Recent is er een potentiële rol voor serotonine in
cognitieve symptomen bij AD vastgesteld, maar er zijn onvoldoende gegevens om de
effecten van serotonine stimulatie op cognitieve symptomen bij AD te evalueren.
Geconcludeerd kan worden dat serotonine een potentieel doel is voor
farmacologische cognitieverbetering na serotonerg disfunctioneren. Verder
onderscheid tussen de rol van serotonine in normaal en verstoord cognitief
functioneren en evaluatie van de effecten van serotonerge manipulaties in
verschillende populaties is vereist om de volwaardige rol van serotoninerge
medicatie in cognitieverbetering vast te leggen.
In hoofdstuk 3 werden de effecten van escitalopram 10-20 mg per dag en mirtazapine
30-45 mg per dag onderzocht op rijvaardigheid en psychomotorisch functioneren bij
18 gezonde vrijwilligers in een gerandomiseerde, dubbelblinde, placebo
gecontroleerde, 3 wegs onderzoeksprocedure. The effecten van escitalopram op
psychomotorisch functioneren en rijvaardigheid waren nog niet eerder onderzocht.
Eerder werd aangetoond dat mirtazapine psychomotorisch functioneren en
rijvaardigheid verslechterd en in het huidige onderzoek werd het meegenomen als
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actief controlemiddel. Er werd verwacht dat escitalopram geen effect zou hebben
maar dat mirtazapine rijvaardigheid en psychomotorisch functioneren negatief zou
beïnvloeden. Iedere behandelingsperiode duurde 15 dagen en werd onderscheidden
van de volgende periode door een uitwerkperiode van minimaal 13 dagen.
Proefpersonen ontvingen een avonddosering escitalopram 10 mg, mirtazapine 30 mg
of placebo van dag 1 t/m 7 en een avonddosering escitalopram 20 mg, mirtazapine 45
mg of placebo van dag 8 t/m 15. Op dag 2, 9 en 16 dat wil zeggen in de acute periode,
na  verhoging  van  de  dosering  en  in  de  stabiele  staat  werd  de  Road  Tracking  Test
uitgevoerd. De hoofd parameter was de Standaard Deviatie van de Laterale Positie.
Psychomotorisch functioneren werd ook gemeten op dag 2, 9 en 16. Subjectieve
slaapkwaliteit en stemming werden door visuele analoge schalen gemeten.
Verschillen tussen de medicatie werden zichtbaar in de acute periode waarin
proefpersonen na mirtazapine 30 mg slechter presteerden op rijvaardigheid
vergeleken met placebo. De resultaten van de Divided Attention Task lieten en
significante toename in tracking error zien na een enkele dosering van mirtazapine 30
mg vergeleken met placebo. Mirtazapine verminderde ook de alertheid en de
tevredenheid. Escitalopram had geen effect op rijvaardigheid, psychomotorisch
functioneren of subjectieve stemming tijdens de hele periode. Ter conclusie, zowel
rijvaardigheid en psychomotorisch functioneren bij gezonde vrijwilligers werd niet
beïnvloedt door escitalopram. Rijvaardigheid was significant slechter na inname van
mirtazapine 30 mg tijdens de acute behandelingsperiode.
In hoofdstuk 4 werden rijvaardigheid en cognitie van depressieve patiënten tijdens
lange termijn behandeling met antidepressiva onderzocht. Het is bekend dat SSRIs in
mindere mate een negatieve invloed hebben op rijvaardigheid dan TCAs. In het
huidige onderzoek werd verwacht dat rijvaardigheid en cognitie van depressieve
patiënten behandeld met SSRIs en een SNRI voor een langere termijn te vergelijken is
met de rijvaardigheid en de cognitie van gezonde vrijwilligers, door de verlichting
van depressieve symptomen. De prestatie van 24 depressieve patiënten behandeld
met een SSRI of SNRI voor 6-52 weken, werd vergeleken met 24 gezonde vrijwilligers
door middel van 2 gestandaardiseerde rijtesten en gedragstaken die cognitie meten.
De resultaten lieten een slechtere rijvaardigheid zien ( grotere Standaard Deviatie van
de Laterale Positie oftewel slingering) bij behandelde patiënten relatief ten opzichte
van gezonden. De benodigde tijd om de snelheid aan te passen en de Critical Flicker
Fusion drempelwaarde waren ook verslechterd bij behandelde patiënten. De scores
op de Hamilton Depression Rating Scale waren bij behandelde patiënten significant
hoger vergeleken met gezonden. Geen andere verschillen werden gemeten op het
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gebeid van rijvaardigheid en cognitie tussen de twee groepen. Geconcludeerd kan
worden dat depressieve patiënten die voor een langere tijd behandeld worden met
SSRIs of SNRIs een verslechterde rijvaardigheid laten zien. Deze verslechtering van
rijvaardigheid is waarschijnlijk te wijten aan de nog steeds aanwezige depressieve
symptomen en niet aan de behandeling met de genoemde antidepressiva.
In hoofdstuk 5 werden de effecten van escitalopram 10-20 mg per dag en mirtazapine
30-45 mg per dag onderzocht op verbaal geheugen bij 18 gezonde vrijwilligers in een
gerandomiseerde, dubbelblinde, placebo gecontroleerde, 3 wegs
onderzoeksprocedure. Er werd verwacht dat escitalopram verbaal geheugen
verbeterd door de serotonerge werking en dat mirtazapine verbaal geheugen
verslechterd door de histaminerge affiniteit. Proefpersonen ontvingen een
avonddosering escitalopram 10 mg, mirtazapine 30 mg of placebo van dag 1 t/m 7 en
een avonddosering escitalopram 20 mg, mirtazapine 45 mg of placebo van dag 8 t/m
15. Op dag 2, 9 en 16 werd een verbale geheugen taak uitgevoerd, de effecten van de
medicatie werden dus gemeten in de acute periode, na verhoging van de dosering en
in de stabiele staat. Escitalopram had geen effect op direct of lange termijn verbaal
geheugen tijdens de behandelingsperiode. Tijdens behandeling met mirtazapine
presteerden de proefpersonen minder goed op de totale directe herhaling vergeleken
met placebo. Deze verslechtering kwam het meeste naar voren in de laatste poging
van de visuele verbale geheugen taak. Ter conclusie, verbaal geheugen werd niet
beïnvloedt door acute en subchronische behandeling van escitalopram bij gezonde
vrijwilligers. Totaal direct verbaal geheugen was enigszins maar significant
verslechterd tijdens behandeling met mirtazapine en dit is waarschijnlijk te wijten
aan afname van algemene alertheid veroorzaakt door H1 receptor blokkade.
Hoofdstuk 6 handelt over een gerandomiseerde, dubbelblinde, placebo
gecontroleerde, 4-wegs studie met 16 gezonde vrijwilligers. Onderzocht werd of de 5-
HT1A en de 5-HT2A receptor betrokken zijn in de associatie tussen serotonine en
geheugen. De behandeling bestond uit de toediening van een capsule escitalopram 20
mg + placebo, escitalopram 20 mg + ketanserine 50 mg (5-HT2A antagonist),
escitalopram 20 mg + pindolol 10 mg (5-HT1A partiële agonist) en placebo op 4 aparte
dagen met een tussentijdse uitwerkperiode van minimaal 7 dagen. Verwacht werd
dat pindolol en ketanserine het effect van escitalopram op geheugen zouden
versterken. Verschillende geheugentaken werden uitgevoerd waaronder taken voor
verbaal geheugen, ruimtelijk geheugen en reversal learning. Na escitalopram
toediening was direct verbaal geheugen enigszins verslechterd, geen effecten van
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escitalopram werden gevonden op andere geheugentaken. In combinatie met
pindolol was direct verbaal geheugen significant verslechterd. Escitalopram in
combinatie met ketanserine verslechterde ruimtelijk werkgeheugen significant. Geen
effecten werden gevonden op reversal learning. Selectieve verslechtering van direct
verbaal geheugen na een 5-HT1A receptor partial agonist en selectieve verslechtering
van ruimtelijk werkgeheugen na een 5-HT2A receptor antagonist, beide in combinatie
met een SSRI (escitalopram) suggereert dat 5-HT1A en 5-HT2A receptors afzonderlijk
betrokken zijn bij verbaal en ruimtelijk geheugen.
In hoofdstuk 7 werd de bijdrage van serotonine heropname inhibitie en specifieke
blokkade van pre-synaptische 5-HT1A receptors  en  de  5-HT2A receptors aan
stoornissen in aandacht onderzocht door middel van een gerandomiseerde,
dubbelblinde, placebo gecontroleerde, 4-wegs studie met 16 gezonde vrijwilligers. De
behandeling bestond uit de toediening van een capsule escitalopram 20 mg +
placebo, escitalopram 20 mg + ketanserine 50 mg (5-HT2A antagonist), escitalopram
20 mg + pindolol 10 mg (5-HT1A partial  agonist)  en placebo op 4  aparte  dagen met
een tussentijdse uitwerkperiode van minimaal 7 dagen. Verwacht werd dat pindolol
en ketanserine het verslechterende effect van escitalopram op volgehouden aandacht
verergerden door respectievelijk acute verhoging van de serotonine niveaus en
verlaging van dopamine afgifte. Om de aandachts en motorische functies van de
proefpersonen te onderzoeken werd een reeks taken afgenomen. Na toediening van
alleen escitalopram was tracking prestatie veslechterd in een verdeelde aandachtstaak.
De combinatie escitalopram en pindolol en ook escitalopram en ketanserine
verslechterden verdeelde aandacht. Daarbij verslechterde de combinatie escitalopram
en ketanserine ook volgehouden aandacht. De verslechtering van verdeelde aandacht
na de combinaties verschilden niet significant van escitalopram alleen.
Geconcludeerd kan worden dat verlechtering van volgehouden aandacht na de
combinatie escitalopram en ketanserine significant verschilt van alleen escitalopram
toediening. Blokkade van de 5-HT1A receptor beïnvloedde nauwelijks de effecten van
een SSRI op aandacht. Blokkade van de 5-HT2A receptor veroorzaakte echter wel
verslechtering van volgehouden aandacht.
In eerder onderzoek werd aangetoond dat SSRIs volgehouden aandacht verslechteren
gemeten met de Mackworth Clock Taak. In hoofdstuk 8 werd de invloed van
vermoedelijk toegenomen serotonine niveaus onderzocht in hersengebieden
betrokken bij volgehouden aandacht door middel van een fMRI onderzoek. Verwacht
werd dat toediening van escitalopram volgehouden aandacht verslechterd en dat dit
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waarneembaar zou zijn in hersengebieden betrokken bij volgehouden aandacht. Tien
gezonde vrijwilligers (5?, 5?) kregen de SSRI escitalopram (20 mg) toegediend en
placebo in een gebalanceerde, dubbelblinde, 2-wegs studie. De Mackworth Clock
Taak werd uitgevoerd in een 3-Tesla functionele MRI meting om volgehouden
aandacht te meten. De Bond & Lader vragenlijst werd afgenomen om subjectief de
stemming te meten. Hersengebieden die geassocieerd zijn met taakprestatie op een
volgehouden aandachtstaak waren geactiveerd, waaronder de rechter prefrontaal en
pariëtale gebieden, onafhankelijk van medicatie. Na toediening van escitalopram was
er een verminderde activiteit waarneembaar in de caudate nucleus en de thalamus en
in frontale gebieden. De gedragsdata lieten geen effect van escitalopram zien hoewel
subjectieve metingen lieten zien dat er een afname was van alertheid na escitalopram.
Deze resultaten suggereren dat vermoedelijke serotonine stimulatie, volgehouden
aandacht verslechterd door de activatie van specifieke hersengebieden te moduleren
waaronder de thalamus en de caudate nucleus. Deze gebieden zijn mogelijk
betrokken in een subcorticaal netwerk voor volgehouden aandacht.
In hoofdstuk 9 zijn de resultaten van dit proefschrift bediscussieerd in een breder
perspectief. Over het algemeen hebben antidepressiva met anticholinerge, anti-
adrenerge of antihistamninerge mechanismen een negatief effect op cognitie en
rijvaardigheid bij gezonde vrijwilligers. Als de effecten van antidepressiva op
cognitie en rijvaardigheid bij depressieve patiënten worden beschouwd, is het
belangrijk om rekening te houden met resterende depressieve symptomen na een
behandeling. Het onderzoek in dit proefschrift geeft aanvullend bewijs voor een
associatie tussen serotonine en geheugen door aan te tonen dat na toediening van een
SSRI in combinatie met een 5-HT1A partiële agonist verbaal geheugen verslechterd
door vermoedelijk verhoogde serotonine niveaus. Bovendien is er ook aangetoond
dat de 5-HT2A receptor een belangrijke receptor is bij het moduleren van specifieke
effecten van serotonine op ruimtelijk geheugen en volgehouden aandacht. Het effect
van serotonine op een aandachtsnetwerk met daarin de thalamus is mogelijk
verantwoordelijk voor de volgehouden aandachtsprestatie. In dit proefschrift zijn
enkele relatief nieuwe methoden geïntroduceerd waaronder het gebruik van brain
imaging en het onderzoeken van hersenmechanismen op receptor niveau. Deze
methoden kunnen verder worden uitgebreid in toekomstig onderzoek om nieuwe
kennis te verwerven over neurotransmitter mechanismen, gedrag en de ontwikkeling
van medicijnen.
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